{"Environment": ["We anticipate that the volume of cold chain storage and shipping may increase due to the COVID-19 pandemic, as we assist with the strategic national stockpile as well as possible distribution of COVID-19 vaccines.", "The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims,  that  we  failed  to  provide  effective  controls  and  procedures  to  guard  against  the  diversion  of  controlled  substances,  acted  negligently  by  distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations.", "Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict.", "Other Risks We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business.", "A sustained or prolonged outbreak could exacerbate the adverse impact of such events, and the impact of COVID-19 may also exacerbate other risks discussed in Item 1A to our Form 10-K, any of which could have a material adverse effect on us.", "Further, the long-term effects of climate change on general economic", "conditions  and  the  pharmaceutical  distribution  industry  in  particular  are  unclear,  and  changes  in  the  supply,  demand,  or  available  sources  of  energy  and  the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses.", "We anticipate that the volume of cold chain storage and shipping may increase due to the COVID-19 pandemic, as we assist with the strategic national stockpile as well as possible distribution of COVID-19 vaccines.", "The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims,  that  we  failed  to  provide  effective  controls  and  procedures  to  guard  against  the  diversion  of  controlled  substances,  acted  negligently  by  distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations.", "Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict.", "Other Risks We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business.", "A sustained or prolonged outbreak could exacerbate the adverse impact of such events, and the impact of COVID-19 may also exacerbate other risks discussed in Item 1A to our Form 10-K, any of which could have a material adverse effect on us.", "Further, the long-term effects of climate change on general economic", "conditions  and  the  pharmaceutical  distribution  industry  in  particular  are  unclear,  and  changes  in  the  supply,  demand,  or  available  sources  of  energy  and  the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses.", "We anticipate that the volume of cold chain storage and shipping may increase due to the COVID-19 pandemic, as we assist with the strategic national stockpile as well as possible distribution of COVID-19 vaccines.", "The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims,  that  we  failed  to  provide  effective  controls  and  procedures  to  guard  against  the  diversion  of  controlled  substances,  acted  negligently  by  distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations.", "Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict.", "Other Risks We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business.", "A sustained or prolonged outbreak could exacerbate the adverse impact of such events, and the impact of COVID-19 may also exacerbate other risks discussed in Item 1A to our Form 10-K, any of which could have a material adverse effect on us.", "Further, the long-term effects of climate change on general economic", "conditions  and  the  pharmaceutical  distribution  industry  in  particular  are  unclear,  and  changes  in  the  supply,  demand,  or  available  sources  of  energy  and  the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses.", "We anticipate that the volume of cold chain storage and shipping may increase due to the COVID-19 pandemic, as we assist with the strategic national stockpile as well as possible distribution of COVID-19 vaccines.", "The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims,  that  we  failed  to  provide  effective  controls  and  procedures  to  guard  against  the  diversion  of  controlled  substances,  acted  negligently  by  distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations.", "Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict.", "Other Risks We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business.", "A sustained or prolonged outbreak could exacerbate the adverse impact of such events, and the impact of COVID-19 may also exacerbate other risks discussed in Item 1A to our Form 10-K, any of which could have a material adverse effect on us.", "Further, the long-term effects of climate change on general economic", "conditions  and  the  pharmaceutical  distribution  industry  in  particular  are  unclear,  and  changes  in  the  supply,  demand,  or  available  sources  of  energy  and  the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses.", "We anticipate that the volume of cold chain storage and shipping may increase due to the COVID-19 pandemic, as we assist with the strategic national stockpile as well as possible distribution of COVID-19 vaccines.", "The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims,  that  we  failed  to  provide  effective  controls  and  procedures  to  guard  against  the  diversion  of  controlled  substances,  acted  negligently  by  distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations.", "Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict.", "Other Risks We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business.", "A sustained or prolonged outbreak could exacerbate the adverse impact of such events, and the impact of COVID-19 may also exacerbate other risks discussed in Item 1A to our Form 10-K, any of which could have a material adverse effect on us.", "Further, the long-term effects of climate change on general economic", "conditions  and  the  pharmaceutical  distribution  industry  in  particular  are  unclear,  and  changes  in  the  supply,  demand,  or  available  sources  of  energy  and  the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses.", "We anticipate that the volume of cold chain storage and shipping may increase due to the COVID-19 pandemic, as we assist with the strategic national stockpile as well as possible distribution of COVID-19 vaccines.", "The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims,  that  we  failed  to  provide  effective  controls  and  procedures  to  guard  against  the  diversion  of  controlled  substances,  acted  negligently  by  distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations.", "Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict.", "Other Risks We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business.", "A sustained or prolonged outbreak could exacerbate the adverse impact of such events, and the impact of COVID-19 may also exacerbate other risks discussed in Item 1A to our Form 10-K, any of which could have a material adverse effect on us.", "Further, the long-term effects of climate change on general economic", "conditions  and  the  pharmaceutical  distribution  industry  in  particular  are  unclear,  and  changes  in  the  supply,  demand,  or  available  sources  of  energy  and  the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses."], "Social": ["Yes \u00fe No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.", "While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays.", "A number of patents for widely used brand-name pharmaceutical products will continue to expire during the", "In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that", "increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs.", "Subsequent legislation and rules promulgated by government agencies have made additional changes to federal drug payment policies.", "These  policies  and  other  legislative  developments  (including  potential  revisions  to  or  repeal  of  any  portions  of  the  health  reform  legislation)  may  affect  our businesses directly and/or indirectly (see Government Regulation on page 6 and the risk factor titled Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates on page 12 for further details).", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and  cash  flows.  These  items  include,  but  are  not  limited  to,  the  financial  condition  of  our  customers  and  the  realization  of  accounts  receivable,  decreased availability and demand for our products and services, and delays related to current and future projects.", "While our operational and financial performance may be significantly impacted by COVID-19, it is not possible for us to predict the duration or magnitude of the outbreak and whether it could have a material adverse impact on the Company's financial position, results of operations, or cash flows (see Risk Factor - We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business).", "Our provider solutions include: our Good Neighbor Pharmacy\u00ae program, which enables independent community pharmacies to compete more effectively through  pharmaceutical  benefit  and  merchandising  programs;  Elevate  Provider  Network\u00ae,  our  managed  care  network,  which  connects  our  retail pharmacy customers to payor plans throughout the country and is one of the largest in the United States; generic product purchasing and private label services;  hospital  pharmacy  consulting  designed  to  improve  operational  efficiencies;  and  packaging  solutions  for  institutional  and  retail  healthcare providers.", "We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs.", "We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies.", "If those contracts are not renewed or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.", "We seek patent protection for our proprietary intellectual property from time to time as appropriate.", "third parties may assert infringement claims against us from time to time.", "The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.", "There can be no assurance that we are fully compliant with the DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our operations into compliance.", "These and other requirements will continue to increase the cost of our operations.", "The  regulation  of  public  and  private  health  insurance  and  benefit  programs  can  also  affect  our  business  and  scrutiny  of  the  healthcare  delivery  and reimbursement systems in the United States can be expected to continue at both the state and federal levels.", "In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate certain of our distribution centers, which may have a material adverse effect on our financial condition and results of operations.", "We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.", "We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act.", "requirements could have a significant impact on our results of operations and financial condition.", "that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.", "Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations.", "Our operations, depending on their location, may also be subject  to  state  or  foreign  regulations  affecting  personal  data  protection  and  the  manner  in  which  information  services  or  products  are  provided.  Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws.", "We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.", "Personally identifiable information is also highly regulated in many other countries in which we operate.", "As such regulations continue to evolve, we must comply with applicable privacy and security requirements of these countries, including but not limited to those in the European Union.", "We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with the applicable privacy laws and regulations.", "There can be no assurances that compliance with these requirements will not impose new costs on our business.", "For  more  information  about  us,  visit  our  website  at www.amerisourcebergen.com.  The  contents  of  the  website  are  not  part  of  this  Form  10-K.  Our", "We expect these trends to continue in fiscal 2021, which could have an adverse effect on our results of operations.", "Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products generally use wholesale acquisition cost (\"WAC\") as the reference price.", "We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price.", "If manufacturers change their pricing policies or practices with regard to WAC or if prices charged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our results of operations could be adversely affected.", "we have entered into with brand and generic pharmaceutical manufacturers have a price appreciation component to them.", "As a result, our gross profit from brand- name and generic pharmaceuticals  continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control.", "If the frequency or rate of brand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected.", "If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations will be greater.", "Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.", "Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured.", "Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers.", "The COVID-19 pandemic has increased volatility of the capital and credit markets and has led to a general worsening of economic conditions, which has put financial pressure on many of our customers and may threaten certain customers\u2019 ability to maintain liquidity sufficient to repay their obligations to us as they become due.", "The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on  our  operating  revenue  and  results  of  operations.  As  of  September  30,  2020,  our  two  largest  trade  receivable  balances  due  from  customers  represented approximately 47% and 7% of accounts receivable, net.", "The pharmaceutical products that we purchase are also subject to price inflation and deflation.", "Most of our customers buy pharmaceuticals and other products and services from us on credit.", "Credit is made available to customers based upon our", "Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.", "returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers.", "Volatility of the capital and credit markets, general economic  conditions,  pending  litigation,  and  regulatory  changes  may  adversely  affect  the  solvency  or  creditworthiness  of  our  suppliers.  The  bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.", "Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.", "downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit.", "Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.", "Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings.", "Actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.", "economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability.", "Negative trends in the general economy, including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products.", "Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flow from operations.", "Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced.", "Declining economic conditions may also increase our costs.", "Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.", "We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract.", "A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these  customers  or  GPO  relationships  if  we  are  unable  to  extend,  renew,  renegotiate  or  replace  the  contracts.  The  loss  of  any  significant  customer  or  GPO relationship could adversely affect our revenue, results of operations, and cash flows.", "Additionally, from time to time, significant contracts may be renewed or modified prior to their expiration date in furtherance of our strategic objectives.", "If those contracts are renewed or modified at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.", "Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities.", "WBA accounted for approximately 33% of our revenue in the fiscal year ended September 30, 2020.", "Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the terms under which we extended the duration of the distribution agreement and generics purchasing services agreement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; changes in the economic  terms  under  which  we  distribute  pharmaceuticals  to  WBA,  including  changes  necessitated  by  changing  market  conditions  or  other  unforeseen developments that may arise during the term of the distribution agreement, to the extent that any such changes are not offset by other financial benefits that we are able to obtain through collaboration in other aspects of our strategic relationship with WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the anticipated strategic and financial benefits of the relationship.", "18, 2013 to make certain additional investments in our common stock.", "WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholder Agreement.", "Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock.", "We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration we anticipate pursuing with WBA.", "If we are unable to achieve any of our objectives, the expected future benefits may not be realized fully or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.", "we may have an obligation to pay or credit WBA for failure to supply products.", "We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations.", "At any particular time, we may be in various stages of", "or more acquisitions, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions.", "The impact of a divestiture on our results of operations could also be greater than anticipated.", "Our results of operations and our financial condition may be adversely affected by our global operations.", "Changes or uncertainty in U.S. or foreign policy, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase.", "Any of these factors could adversely affect our business, financial position, and results of operations.", "We are subject to operational and logistical risks that might not be covered by insurance.", "Although we seek to maintain adequate insurance coverage, coverage on acceptable terms might be unavailable, or coverage might not cover our losses or may require large deductibles.", "Uninsured losses or operational losses that result in large deductible payments in order to receive insurance coverage might have an adverse impact on our business operations and our financial position or results of operations.", "Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies.", "There have been increasing efforts by Congress and state", "regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance.", "Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs and could have an adverse impact on our financial position or results of operations.", "Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.", "Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at the federal or state level, could adversely affect our operations. reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute.", "Given the scope of the changes made by the ACA and continuing implementation controversies, we cannot predict the impact of every aspect of the law on our operations.", "Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.", "Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs.", "The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs.", "Any reduction in the Medicaid reimbursement  rates  to  our  customers  may  indirectly  impact  the  prices  that  we  can  charge  our  customers  for  multiple  source  pharmaceuticals  and  cause corresponding declines in our profitability.", "There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business.", "Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.", "There can be no assurance that recent or future rules established by CMS will not have an adverse impact on our business.", "Our customers include covered entities and organizations with significant participation as contract pharmacies, and the unavailability of 340B discounts through contract pharmacy arrangements may adversely affect such customers and, therefore, could adversely affect our business.", "Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers.", "At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have a material adverse effect on our business.", "as Medicare and Medicaid, which may adversely affect our business.", "There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.", "If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.", "continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs.", "Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs.", "Many states have enacted similar statutes which are not necessarily limited to items and services for  which  payment  is  made  by  federal  healthcare  programs.  While  we  believe  that  we  are  in  compliance  with  applicable  laws  and  regulations,  many  of  the regulations applicable to us, including those", "We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse.", "They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations.", "If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal and state healthcare programs.", "Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.", "Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future and lawsuits could be brought against the Company by other plaintiffs under other theories related to opioid abuse.", "We are deeply committed to diversion control efforts, have sophisticated systems in place to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in significant due diligence and ongoing monitoring of customers.", "While we are vigorously defending ourselves in these lawsuits, the allegations may negatively affect our business in various ways, including through increased costs and harm to our reputation.", "We are currently engaged in advanced discussions, which are ongoing, with the objective of reaching potential terms (which would include monetary payments and certain changes to our anti-diversion programs) for a global resolution of the multi-district opioid litigation involving certain state and local governmental entities and other related state court litigation described in Note 14 of the Notes to Consolidated Financial Statements.", "We have recorded a charge of $6.6 billion in the fourth quarter of the fiscal year ended September 30, 2020 related to the global settlement and other related opioid litigation.", "Until such time as a plaintiff participates in a global settlement or otherwise resolves its lawsuit, we will continue to litigate and prepare for trial in the cases pending in the multi-district opioid litigation, those remanded from the multi-district opioid litigation to federal district courts, as well as  in  state  courts  where  lawsuits  have  been  filed,  and  we  intend  to  continue  to  vigorously  defend  ourselves  in  all  such  cases.  Since  these  matters  are  still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief, including changes to our anti-diversion programs, that may affect how we operate our business.", "Further, any final settlement amongst parties may differ materially from our advanced  discussions  related  to  global  resolution  of  the  multi-district  opioid  litigation.  The  inability  to  reach  a  global  settlement  of  the  multi-district  opioid litigation and adverse resolution of any of these lawsuits or investigations could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders.", "If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company's results of operations, cash flows, or financial condition.", "Our business, results of operations, and cash flows could be adversely affected by legal proceedings.", "Each of our businesses may cause us to become involved in legal disputes or proceedings.", "The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations  and  financial  condition.  Violations  of  various  federal  and  state  laws,  including  with  respect  to  the  marketing,  sale,  purchase,  and  dispensing  of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs.", "Any settlement, judgment or fine could materially adversely affect our results of operations.", "Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations  and damages arising from resultant  false  claims,  if the litigation  proceeds whether or not government  authorities  decide  to intervene  in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.", "In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement with the Office of Inspector General of the U.S.", "Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.", "Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.", "There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives.", "We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent.", "In addition, U.S. federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations.  There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.", "Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the 2017 Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties  regarding  the  geographic  mix  of  earnings  in  any  particular  period,  and  other  factors,  material  adjustments  to  our  tax  estimates  may  impact  our provision for income taxes and our earnings per share, as well as our cash flows, in the period in which any such adjustments would be made.", "Further, we cannot predict the impact of any efforts to change or repeal the 2017 Tax Act or enact alternative legislation by the incoming presidential administration or the next Congress.", "Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market.", "The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls.", "If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses.", "From time to time, we may face audits or investigations by one or", "As such, we are subject to tax laws and regulations of the U.S.", "The qui tam provisions of the federal and various state civil False", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.", "We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations.", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties.", "That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.", "Any extended disruption in our ability to service our customers could have a material adverse effect on our revenue, results of operations, and cash flows.", "An economic slowdown or recession related to COVID-19 may affect our customers' ability to obtain credit to finance their business on acceptable terms, which could result in reduced spending on our products and services.", "For example, the continued spread of COVID-19 has led to disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets.", "Certain of our employees have contracted COVID-19 which", "Since April 2020, COVID-19 has adversely  impacted  and may continue  to adversely  impact  our revenue,  results of operations,  and cash flows.", "Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.", "In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.", "Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value.", "goodwill, indefinite-lived intangible assets, or long-lived assets is determined.", "Any such charge could have a material adverse impact on our results of operations.", "Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.", "U.S. generally accepted accounting principles (\"GAAP\") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual", "The Company anticipates that it will continue to pay quarterly cash dividends in the future.", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and cash flows (refer to our COVID-19 risk factor in Item 1A.", "\u2022 Distribution, selling, and administrative expenses increased 3.9% from the prior fiscal year primarily due to an increase in operating costs to support our revenue growth;", "We are currently in advanced discussions, which are ongoing, with the states and various plaintiffs\u2019 representatives that would be necessary to reach a global settlement of the Multidistrict Litigation (\"MDL\") and other related state-court litigation brought by certain state and local governmental entities to be paid over 18 years in which our payment would be $6.5 billion assuming all parties participate.", "While a global settlement remains subject to contingencies that could impact  whether  the  parties  ultimately  decide  to  move  forward,  we  believe  a  global  settlement  is  probable  and  our  loss  related  thereto  can  be reasonably estimated as of September 30, 2020;", "\u2022 Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2020 was higher than the U.S. statutory rate due to our operating loss, the tax benefits associated with our decision to permanently exit the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.  Our  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of PharMEDium's assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international  income.  The  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  also  impacted  by  a  $37.0  million  decrease  to  the Company's transition tax related to the U.S.", "If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "Changes to any of the above factors may have a material impact to our annual LIFO provision.", "In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018.", "District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018.", "In September 2020, the United States Court of Appeals for the Second Circuit reversed the District Court\u2019s decision, and, as a result, we accrued $14.8 million in the fourth quarter of the fiscal year ended September 30, 2020 as we revised our estimated liability for the 2017 and 2018 calendar years.", "Gross profit in the current fiscal year was favorably impacted by increases in", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $9.1 million and $145.9 million during the fiscal years", "Consolidated Financial Statements) and $115.4 million of litigation costs that related to legal fees in connection with opioid lawsuits and investigations, $34.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, $38.0 million related to our business transformation efforts, and $12.6 million of acquisition-related deal and integration costs and other restructuring initiatives.", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "Prior to October 1, 2019, we recognized interest expense associated with financing obligations in connection with lease construction assets (see Note 1 of the Notes to Consolidated Financial Statements).", "Upon adoption of the new lease standard as of October 1, 2019, we began recognizing  rent  expense  related  to  these  leases  in  Distribution,  Selling,  and  Administrative  expenses  in  our  Consolidated  Statements  of  Operations.  Interest income was lower in the current fiscal year as a result of a decline in investment interest rates, which was offset in part by a $1.0 billion increase in average invested cash balances compared to the prior fiscal year.", "borrowing facilities, and strategic decisions to deploy our invested cash.", "Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September  30,  2020  was  higher  than  the  U.S.  statutory  rate  due  to  our  operating  loss,  the  tax  benefits  associated  with  our  decision  to  permanently  exit  the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.", "Our effective tax rate in the fiscal year ended September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of  PharMEDium's  assets  (see  Note  1  of  the  Notes  to  Consolidated  Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $145.9 million and $35.9 million during the fiscal years", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D.", "We  recorded  a  $570.0  million  impairment  of  PharMEDium's  long-lived  assets  in  the  fiscal  year  ended  September  30,  2019  (see  Note  1  of  the  Notes  to Consolidated Financial Statements).", "increase in operating expenses.     We recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the fiscal year ended September 30, 2019.", "We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in the fiscal year September 30, 2018 in connection with our", "We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the fiscal year ended", "to an increase in interest income due to a $752 million increase in our average invested cash balance during the fiscal year ended September 30, 2019 and an increase in investment interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D.", "specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019.", "Our effective tax rates were 11.7% and (37.2)% in the fiscal years ended September 30, 2019 and 2018, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2019 was primarily impacted by the $570.0 million impairment of PharMEDium assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "The effective tax rate in the fiscal year ended September 30, 2019 was  also  impacted  by  a  $37.0  million  decrease  to  the  Company's  transition  tax  related  to  the  2017  Tax  Act.  Our  effective  tax  rate  in  the  fiscal  year  ended September 30, 2018 was primarily impacted by the effect of 2017 Tax Act.", "Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act.", "Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018.", "Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were also favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.", "Actual results may differ from these estimates due to uncertainties inherent in such estimates.", "Below are those policies applied in preparing our financial statements that management believes are the most dependent upon the application of estimates and assumptions.", "Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit.", "trends, and our customers' financial strength, credit standing, payment and default history, and macroeconomic conditions.", "Changes in the aforementioned factors, among others, may lead to adjustments in our allowance for doubtful accounts.", "The calculation of the required allowance requires judgment by our management as to the impact of these and other factors on the ultimate realization of our trade receivables.", "For the fiscal year ended September 30, 2018, we recorded a $42.3 million loss in connection with the January 2018 consolidations of Profarma and the", "We write off balances against the reserves when collectability is deemed remote.", "The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments.", "We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed.  Such  valuations  require  management  to  make  significant  judgments,  estimates,  and  assumptions,  especially  with  respect  to  intangible  assets.", "Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.", "For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite- lived intangible assets, respectively.", "If we conclude based on our qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative analysis.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2020, with the exception of our testing of goodwill and indefinite-lived intangibles in the MWI and the Profarma reporting units.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of our testing  in  the  Profarma  reporting  unit.  In  the  fourth  quarter  of  fiscal  2018,  we  elected  to  bypass  performing  the  qualitative  assessment  and  went  directly  to performing our annual quantitative assessments of goodwill and indefinite-lived intangible assets.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium.", "Schedule II of this Form 10-K sets forth a rollforward of allowances for returns and doubtful accounts.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction.", "The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan.", "While we use  the  best  available  information  to  prepare  our  cash  flows  and  discount  rate  assumptions,  actual  future  cash  flows  and/or  market  conditions  could  differ significantly resulting in future impairment charges related to recorded goodwill balances.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "We estimate the fair value of our indefinite- lived intangibles using the relief from royalty method.", "We believe the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "We recorded a goodwill impairment of $59.7 million in our Profarma reporting unit in connection with our fiscal 2018 annual  impairment  test.  No  goodwill  impairments  were  recorded  in  the  fiscal  years  ended  September  30,  2020  and  2019.  No  indefinite-lived  intangible impairments were recorded in the fiscal years ended September 30, 2020, 2019, and 2018.", "we performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value.", "We believed that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represents a Level 3 nonrecurring fair value measurement.", "We allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.", "regulatory matters, ongoing operational challenges, and lower-than-expected operating results, we updated our recoverability assessment of PharMEDium\u2019s long- lived assets as of December 31, 2019.", "Using forecasted undiscounted cash flows that were based on the weighted average of multiple strategic alternatives, we concluded that the carrying value of the PharMEDium long-lived asset group was not recoverable as of December 31, 2019.", "The forecasted undiscounted cash flows as of December 31, 2019 were lower than the forecasted undiscounted cash flows as of September 30, 2019 due to a change in weighting of multiple strategic alternatives and lower  operating  results  in  the  three  months  ended  December  31,  2019  compared  to  expectations.  We  then  performed  an  impairment  test  by  comparing  the PharMEDium asset group's fair value of $145 million to its carrying value, which resulted in a $138.0 million impairment loss in the three months ended December 31, 2019.", "We perform a recoverability assessment of our long-lived assets when impairment indicators are present.", "that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represented a Level 3 nonrecurring fair value measurement.", "We allocated $123.2 million of the impairment to finite-lived intangibles, $11.6 million of the impairment to property and equipment, and $3.2 million to ROU assets.", "After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.", "In the normal course of business, our tax returns are subject to examination by various taxing authorities.", "Such examinations may result in future tax and interest assessments by these taxing authorities.", "Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations.", "We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.", "If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $52.9 million in the fiscal year ended September 30, 2020.", "respectively,  has  been  determined  using  the  LIFO  method.  If  we  had  used  the  first-in,  first-out  method  of  inventory  valuation,  which  approximates  current replacement cost, inventories would have been approximately $1,519.2 million and $1,511.8 million higher than the amounts reported as of September 30, 2020 and 2019, respectively.", "We recorded LIFO expenses of $7.4 million and $67.3 million in the fiscal years ended September 30, 2020 and 2018, respectively.", "We recorded a LIFO credit of $22.5 million in the fiscal year ended September 30, 2019.", "Changes to any of the above factors can have a material impact to our annual LIFO provision.", "We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain.", "The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year.", "We record a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency and whether a reasonable estimate of the loss or the range of the loss can made in the footnotes to our financial statements.", "We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made.", "Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 14 of the Notes to Consolidated Financial Statements.", "provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock.", "purchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities.", "Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that are expected to be made over 18 years (see below).", "distribution of prescription opioid pain medications, we recorded a $6.6 billion ($5.5 billion, net of an income tax benefit) charge.", "We are in advanced discussions, which are ongoing, to reach a global settlement of the MDL and related state-court litigation brought by certain state and local governmental entities in which our payment would be over 18 years to resolve cases currently filed and that could be filed by states, counties, municipalities, and other government entities.", "aforementioned litigation accrual has not and is not expected to have an impact on our compliance with our debt covenants or our ability to pay dividends.", "We have the ability to repatriate the majority of our cash and cash equivalents held by our foreign subsidiaries without incurring significant additional taxes upon repatriation.", "require the use of our credit facilities to fund short-term capital needs.", "Our cash balance in the fiscal years ended September 30, 2020 and 2019 needed to be supplemented  by  intra-period  credit  facility  borrowings  to  cover  short-term  working  capital  needs.  The  largest  amount  of  intra-period  borrowings  under  our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 2020 and 2019 was $39.6 million and $240.6 million, respectively.", "We had $117.4 million, $606.0 million, and $25,115.3 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2020, 2019, and 2018, respectively.", "We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D.", "Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon our debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2020) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable.", "We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based upon our debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2020).", "We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time.", "The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of September 30, 2020.", "The maturities on the notes will vary, but may not  exceed  365  days  from  the  date  of  issuance.  The  notes  will  bear  interest,  if  interest  bearing,  or  will  be  sold  at  a  discount  from  their  face  amounts.  The commercial  paper  program  does  not  increase  our  borrowing  capacity  as  it  is  fully  backed  by  our  Multi-Currency  Revolving  Credit  Facility.  There  were  no borrowings outstanding under our commercial paper program as of September 30, 2020 and 2019.", "have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters.", "Interest rates are based upon prevailing market rates for short-term commercial paper or  LIBOR  plus  a  program  fee.  We  pay  a  customary  unused  fee  at  prevailing  market  rates,  annually,  to  maintain  the  availability  under  the  Receivables Securitization Facility.", "The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "As of September 30, 2020 and 2019, our cash and cash equivalents held by foreign subsidiaries were $675.9 million and $826.8 million, respectively, and", "We used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a", "We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion", "In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.", "We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources.", "Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice.", "The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "During the fiscal year ended September 30, 2018, we purchased $663.1 million of our common stock under this program, which included $24.0 million of September 2018 purchases that cash settled in October 2018.", "During the fiscal year ended September 30, 2019, we purchased $125.8  million  of  our  common  stock  under  this  program,  which  excluded  $24.0  million  of  September  2018  purchases  that  cash  settled  in  October  2018,  to complete our authorization under this program.", "In October 2018, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions.", "During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019.", "During the fiscal year ended September 30, 2020, we purchased $405.6 million of our common stock, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019.", "As of September 30, 2020, we had $55.5 million of availability remaining under this program.", "In October 2020, we repaid the $400 million October 2018 Term Loan that became due.", "In addition to the 2027 Notes, the 2030 Notes, and the 2047 Notes, we have $500 million of 3.40% senior notes due May 15, 2024, $500 million of 3.25%", "In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion in shares of our common", "The 2017 Tax Act required a one-time transition tax to be recognized on historical foreign earnings and profits.", "We currently estimate that our liability related to the  transition  tax  is  $182.6  million,  net  of  overpayments  and  tax  credits,  as  of  September  30,  2020,  which  is  payable  in  installments  over  a  six-year  period commencing in January 2021.", "As of September 30, 2020, a settlement has not been reached, and, therefore, we applied significant judgment in estimating the ultimate amount of the opioid litigation settlement that would be deductible for U.S. federal and state purposes.", "In estimating the amount that would ultimately be deductible, we considered prior U.S. tax case law, the amount and character of the damages sought in the opioid litigation, the inherent uncertainty related to litigation of this nature and magnitude, and other relevant factors.", "While we believe that our estimate of the uncertain tax position appropriately reflects these considerations, it is reasonably possible that the uncertain tax position recognized as of September 30, 2020 may be revised in future periods as the settlement with the various plaintiffs is finalized.", "The remaining amount of the liability represents an estimate of tax positions that we have taken in our tax returns or expect to take in future tax returns which may ultimately not be sustained upon examination by taxing authorities.", "Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers.", "In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms.", "Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.", "Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations.", "Our  liability  for  uncertain  tax  positions  was  $498.3  million  (including  interest  and  penalties)  as  of  September  30,  2020.  Included  in  this  balance  is", "Our  cash  flows  from  operating  activities  can  vary  significantly  from  period  to  period  based  upon  fluctuations  in  our  period  end  working  capital.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "In the fiscal year ended September 30, 2018, we acquired H.D.", "In addition, we made incremental investments in Brazil totaling $78.1 million.", "and $343.6 million in cash dividends paid on our common stock.", "and $339.0 million in cash dividends paid on our common stock.", "senior notes, $639.2 million in purchases of our common stock, and $333.0 million in cash dividends paid on our common stock, offset in part by the issuance of $750.0 million of 3.45% senior notes and $500 million of 4.3% senior notes.", "discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.", "The amount of variable-rate debt fluctuates during the year based on our working capital requirements.", "We had $0.8 billion of variable-rate debt outstanding as of September 30, 2020.", "We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates.", "However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us.", "The unfavorable impact of a hypothetical decrease in", "We currently  expect  to spend approximately  $400 million  for capital  expenditures  during fiscal 2021.", "Net cash used in financing activities in the fiscal year ended September 30, 2020 principally related to $420.4 million in purchases of our common stock,", "Net cash used in financing activities in the fiscal year ended September 30, 2019 principally related to $674.0 million in purchases of our common stock", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "We have market risk exposure to interest rate fluctuations relating to our debt.", "We manage interest rate risk by using a combination of fixed-rate and", "We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents.", "interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt.", "For every $100 million of cash invested that is in excess of variable-rate debt, a 10-basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.", "Revenue from our foreign operations is approximately two percent of our consolidated revenue.", "We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates.", "We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes.", "We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations.", "Our largest exposure to foreign exchange rates exists", "These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.", "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2020, in conformity with U.S. generally accepted accounting principles.", "Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We  conducted  our  audits  in  accordance  with  the  standards  of  the  PCAOB.  Those  standards  require  that  we  plan  and  perform  the  audit  to  obtain  reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of the opioid litigation liability and related uncertain tax position.", "For example, we inspected management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of the opioid litigation liability and the related financial statement footnote disclosures.", "To  test  the  Company\u2019s  opioid  litigation  liability,  our  substantive  audit  procedures  included,  among  others,  testing  the completeness  of  the  opioid  litigation  contingencies  subject  to  evaluation  by  the  Company  and  evaluating  the  Company\u2019s analysis of its assessment of the probability of outcome by considering the progress of settlement discussions involving the opioid litigation and communications with plaintiffs, as well as the experience of other similar entities when evaluating the Company\u2019s  conclusions.  We  inspected  responses  to  inquiry  letters  sent  to  both  internal  and  external  legal  counsel,  held discussions with internal and external legal counsel to confirm our understanding of the settlement discussions, and obtained written representations from executives of the Company.", "We also compared the Company\u2019s assessment with its relevant history of  similar  legal  contingencies  that  have  been  settled  or  otherwise  resolved  to  evaluate  the  consistency  of  the  Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "In addition, we also evaluated the adequacy of the Company\u2019s financial statement disclosures.", "We involved our tax subject matter professionals  in assessing the technical  merits and measurement  of the Company\u2019s tax position related to the opioid litigation liability.", "We examined the Company\u2019s analysis and evaluated the underlying facts upon which  the  tax  position  was  based.  We  used  our  knowledge  of  historical  settlement  activity  to  evaluate  the  Company\u2019s measurement  of the uncertain tax position associated  with the opioid litigation.  This included evaluating third-party  advice obtained by the Company and performing inquiries of the Company\u2019s external income tax advisers.", "We also evaluated the adequacy  of  the  Company\u2019s  financial  statement  disclosures  and  obtained  written  representations  from  executives  of  the Company related to this income tax matter.", "We have served as the Company's auditor since 1985.", "This included testing controls related to the Company\u2019s process for  identification,  recognition,  measurement  and  disclosure  of  legal  contingencies.  For  example,  we  tested  controls  over management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures.", "We also tested controls over management\u2019s assessment of the likelihood of the resolution of the matters through settlement or litigation.", "To test the Company\u2019s legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company\u2019s analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal and external legal counsel to confirm our understanding of the allegations,  and  obtaining  written  representations  from  executives  of  the  Company.  We  also  compared  the  Company\u2019s assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, and for those legal contingencies for which the Company has determined that a loss is either probable or reasonably possible, but the Company is unable to estimate the range of loss, and is therefore required to be disclosed, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies.", "We assessed the Company\u2019s  estimate  of  the  amount  of  the  loss,  for  both  contingencies  that  are  probable  and  reasonably  possible,  through inspection of responses to inquiry letters sent to both internal and external legal counsel, direct discussions with internal and external  legal  counsel,  inspection  of  court  rulings,  and  inspection  of  settlement  agreements.  We  also  obtained  written representations from executives of the Company.", "All intercompany accounts and transactions have been eliminated in consolidation.", "ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.", "performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.", "The Company did not elect the hindsight practical expedient in determining the lease term.", "The adoption of ASC 842 did not and will not have a material impact on the Company's results of operations or cash flows.", "An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances.", "The Company does not expect the adoption of this new accounting guidance to have a material impact on its financial position, results of operations, or cash flows.", "ASU 2019-12 removes certain exceptions to the general principles in ASC 740 in order to reduce the cost and complexity of its application.", "The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.", "The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "The Company's trade accounts receivables are exposed to credit risk.", "Deposits held with banks may exceed the amount of insurance", "Gain Contingencies: The Company records gain contingencies when they are realized.", "Gains from antitrust litigation settlements are realized upon the", "If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method.", "The Company believes the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "recoverability assessment of its long-lived assets when impairment indicators are present.", "This represents a Level 3 nonrecurring fair value measurement.", "This represented a Level 3 nonrecurring fair value measurement.", "Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.", "Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.", "contains a lease based on the facts and circumstances present.", "The Company does not recognize on the balance sheet leases with terms of one year or less.", "The Company's leases do not contain residual value guarantees.", "further obligation to provide services related to such products.", "Service revenue is recognized over the period that services are provided to the customer.", "The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company\u2019s common stock.", "Share-based  compensation  expense  is  recognized  over  the  requisite  service  period  within  Distribution,  Selling,  and  Administrative  in  the  Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees.", "Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.", "The ultimate outcome of any outstanding claim may be different than the Company's estimate.", "The purchase price exceeded the fair value of the net tangible and intangible assets acquired by", "The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively.", "Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.", "The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "These represent Level 2 nonrecurring fair value measurements.", "The Company is not obligated to provide future financial support to Profarma.", "A  reconciliation  of  the  statutory  U.S.  federal  income  tax  rate  to  the  Company's  consolidated  effective  income  tax  rate  is  as  follows  for  the  periods", "The estimated tax benefit is higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction can now be carried back to years with higher statutory tax rates.", "resulting from the recognition of the above discrete tax benefits.", "A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income.", "To phase in the tax rate increase, the canton of Bern has granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years.", "It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.", "During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $13.9 million.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to have an impact on the Company's compliance with its debt covenants.", "The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility.", "Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "An additional covenant requires compliance with a financial leverage ratio test.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to impact the Company's ability to pay dividends.", "employees at a price not less than the fair market value of the common stock on the date the option is granted.", "This unfunded plan, under which 2.96 million shares of", "The risk-free rates during the terms of such options are based upon the U.S.", "Performance  stock  units  are  granted  to  certain  executive  employees  under  the  Plan  and  represent  common  stock  potentially  issuable  in  the  future.", "The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "uncertainty  remains  with  regard  to  whether  such  matters  will  proceed  to  trial,  whether  settlements  will  be  reached,  and  the  amount  and  terms  of  any  such settlements.", "If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.", "While a global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move forward, the Company believes a global settlement is probable and its loss related thereto can be reasonably estimated as of September 30, 2020.", "Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events.", "The Company will regularly review these opioid litigation matters to determine whether its accrual is adequate.", "The amount of ultimate loss may differ materially from the $6.6 billion accrual.", "Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations.", "The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.", "The Company cannot predict how these matters would be affected by a global settlement.", "The Company's responses often require time and effort and can result in considerable costs being incurred.", "None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds", "approximate fair value based upon the relatively short-term nature of these financial instruments.", "The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.", "The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.", "AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.", "effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.", "that could have a material effect on the financial statements.", "We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated November 19, 2020 expressed an unqualified opinion thereon.", "Our responsibility is to express an opinion on the Company\u2019s internal control over financial reporting based on our audit.", "We are a public accounting firm registered with the PCAOB and are required  to  be  independent  with  respect  to  the  Company  in  accordance  with  the  U.S.  federal  securities  laws  and  the  applicable  rules  and  regulations  of  the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "We will file the 2021 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.", "Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.", "of our reports dated November 19, 2020, with respect to the consolidated financial statements and schedule of AmerisourceBergen Corporation and subsidiaries and the effectiveness of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries included in this Annual Report (Form 10-K) of AmerisourceBergen Corporation and subsidiaries for the year ended September 30, 2020.", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Yes \u00fe No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.", "While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays.", "A number of patents for widely used brand-name pharmaceutical products will continue to expire during the", "In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that", "increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs.", "Subsequent legislation and rules promulgated by government agencies have made additional changes to federal drug payment policies.", "These  policies  and  other  legislative  developments  (including  potential  revisions  to  or  repeal  of  any  portions  of  the  health  reform  legislation)  may  affect  our businesses directly and/or indirectly (see Government Regulation on page 6 and the risk factor titled Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates on page 12 for further details).", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and  cash  flows.  These  items  include,  but  are  not  limited  to,  the  financial  condition  of  our  customers  and  the  realization  of  accounts  receivable,  decreased availability and demand for our products and services, and delays related to current and future projects.", "While our operational and financial performance may be significantly impacted by COVID-19, it is not possible for us to predict the duration or magnitude of the outbreak and whether it could have a material adverse impact on the Company's financial position, results of operations, or cash flows (see Risk Factor - We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business).", "Our provider solutions include: our Good Neighbor Pharmacy\u00ae program, which enables independent community pharmacies to compete more effectively through  pharmaceutical  benefit  and  merchandising  programs;  Elevate  Provider  Network\u00ae,  our  managed  care  network,  which  connects  our  retail pharmacy customers to payor plans throughout the country and is one of the largest in the United States; generic product purchasing and private label services;  hospital  pharmacy  consulting  designed  to  improve  operational  efficiencies;  and  packaging  solutions  for  institutional  and  retail  healthcare providers.", "We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs.", "We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies.", "If those contracts are not renewed or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.", "We seek patent protection for our proprietary intellectual property from time to time as appropriate.", "third parties may assert infringement claims against us from time to time.", "The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.", "There can be no assurance that we are fully compliant with the DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our operations into compliance.", "These and other requirements will continue to increase the cost of our operations.", "The  regulation  of  public  and  private  health  insurance  and  benefit  programs  can  also  affect  our  business  and  scrutiny  of  the  healthcare  delivery  and reimbursement systems in the United States can be expected to continue at both the state and federal levels.", "In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate certain of our distribution centers, which may have a material adverse effect on our financial condition and results of operations.", "We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.", "We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act.", "requirements could have a significant impact on our results of operations and financial condition.", "that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.", "Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations.", "Our operations, depending on their location, may also be subject  to  state  or  foreign  regulations  affecting  personal  data  protection  and  the  manner  in  which  information  services  or  products  are  provided.  Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws.", "We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.", "Personally identifiable information is also highly regulated in many other countries in which we operate.", "As such regulations continue to evolve, we must comply with applicable privacy and security requirements of these countries, including but not limited to those in the European Union.", "We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with the applicable privacy laws and regulations.", "There can be no assurances that compliance with these requirements will not impose new costs on our business.", "For  more  information  about  us,  visit  our  website  at www.amerisourcebergen.com.  The  contents  of  the  website  are  not  part  of  this  Form  10-K.  Our", "We expect these trends to continue in fiscal 2021, which could have an adverse effect on our results of operations.", "Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products generally use wholesale acquisition cost (\"WAC\") as the reference price.", "We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price.", "If manufacturers change their pricing policies or practices with regard to WAC or if prices charged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our results of operations could be adversely affected.", "we have entered into with brand and generic pharmaceutical manufacturers have a price appreciation component to them.", "As a result, our gross profit from brand- name and generic pharmaceuticals  continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control.", "If the frequency or rate of brand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected.", "If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations will be greater.", "Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.", "Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured.", "Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers.", "The COVID-19 pandemic has increased volatility of the capital and credit markets and has led to a general worsening of economic conditions, which has put financial pressure on many of our customers and may threaten certain customers\u2019 ability to maintain liquidity sufficient to repay their obligations to us as they become due.", "The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on  our  operating  revenue  and  results  of  operations.  As  of  September  30,  2020,  our  two  largest  trade  receivable  balances  due  from  customers  represented approximately 47% and 7% of accounts receivable, net.", "The pharmaceutical products that we purchase are also subject to price inflation and deflation.", "Most of our customers buy pharmaceuticals and other products and services from us on credit.", "Credit is made available to customers based upon our", "Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.", "returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers.", "Volatility of the capital and credit markets, general economic  conditions,  pending  litigation,  and  regulatory  changes  may  adversely  affect  the  solvency  or  creditworthiness  of  our  suppliers.  The  bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.", "Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.", "downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit.", "Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.", "Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings.", "Actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.", "economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability.", "Negative trends in the general economy, including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products.", "Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flow from operations.", "Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced.", "Declining economic conditions may also increase our costs.", "Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.", "We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract.", "A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these  customers  or  GPO  relationships  if  we  are  unable  to  extend,  renew,  renegotiate  or  replace  the  contracts.  The  loss  of  any  significant  customer  or  GPO relationship could adversely affect our revenue, results of operations, and cash flows.", "Additionally, from time to time, significant contracts may be renewed or modified prior to their expiration date in furtherance of our strategic objectives.", "If those contracts are renewed or modified at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.", "Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities.", "WBA accounted for approximately 33% of our revenue in the fiscal year ended September 30, 2020.", "Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the terms under which we extended the duration of the distribution agreement and generics purchasing services agreement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; changes in the economic  terms  under  which  we  distribute  pharmaceuticals  to  WBA,  including  changes  necessitated  by  changing  market  conditions  or  other  unforeseen developments that may arise during the term of the distribution agreement, to the extent that any such changes are not offset by other financial benefits that we are able to obtain through collaboration in other aspects of our strategic relationship with WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the anticipated strategic and financial benefits of the relationship.", "18, 2013 to make certain additional investments in our common stock.", "WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholder Agreement.", "Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock.", "We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration we anticipate pursuing with WBA.", "If we are unable to achieve any of our objectives, the expected future benefits may not be realized fully or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.", "we may have an obligation to pay or credit WBA for failure to supply products.", "We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations.", "At any particular time, we may be in various stages of", "or more acquisitions, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions.", "The impact of a divestiture on our results of operations could also be greater than anticipated.", "Our results of operations and our financial condition may be adversely affected by our global operations.", "Changes or uncertainty in U.S. or foreign policy, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase.", "Any of these factors could adversely affect our business, financial position, and results of operations.", "We are subject to operational and logistical risks that might not be covered by insurance.", "Although we seek to maintain adequate insurance coverage, coverage on acceptable terms might be unavailable, or coverage might not cover our losses or may require large deductibles.", "Uninsured losses or operational losses that result in large deductible payments in order to receive insurance coverage might have an adverse impact on our business operations and our financial position or results of operations.", "Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies.", "There have been increasing efforts by Congress and state", "regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance.", "Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs and could have an adverse impact on our financial position or results of operations.", "Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.", "Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at the federal or state level, could adversely affect our operations. reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute.", "Given the scope of the changes made by the ACA and continuing implementation controversies, we cannot predict the impact of every aspect of the law on our operations.", "Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.", "Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs.", "The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs.", "Any reduction in the Medicaid reimbursement  rates  to  our  customers  may  indirectly  impact  the  prices  that  we  can  charge  our  customers  for  multiple  source  pharmaceuticals  and  cause corresponding declines in our profitability.", "There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business.", "Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.", "There can be no assurance that recent or future rules established by CMS will not have an adverse impact on our business.", "Our customers include covered entities and organizations with significant participation as contract pharmacies, and the unavailability of 340B discounts through contract pharmacy arrangements may adversely affect such customers and, therefore, could adversely affect our business.", "Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers.", "At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have a material adverse effect on our business.", "as Medicare and Medicaid, which may adversely affect our business.", "There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.", "If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.", "continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs.", "Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs.", "Many states have enacted similar statutes which are not necessarily limited to items and services for  which  payment  is  made  by  federal  healthcare  programs.  While  we  believe  that  we  are  in  compliance  with  applicable  laws  and  regulations,  many  of  the regulations applicable to us, including those", "We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse.", "They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations.", "If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal and state healthcare programs.", "Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.", "Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future and lawsuits could be brought against the Company by other plaintiffs under other theories related to opioid abuse.", "We are deeply committed to diversion control efforts, have sophisticated systems in place to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in significant due diligence and ongoing monitoring of customers.", "While we are vigorously defending ourselves in these lawsuits, the allegations may negatively affect our business in various ways, including through increased costs and harm to our reputation.", "We are currently engaged in advanced discussions, which are ongoing, with the objective of reaching potential terms (which would include monetary payments and certain changes to our anti-diversion programs) for a global resolution of the multi-district opioid litigation involving certain state and local governmental entities and other related state court litigation described in Note 14 of the Notes to Consolidated Financial Statements.", "We have recorded a charge of $6.6 billion in the fourth quarter of the fiscal year ended September 30, 2020 related to the global settlement and other related opioid litigation.", "Until such time as a plaintiff participates in a global settlement or otherwise resolves its lawsuit, we will continue to litigate and prepare for trial in the cases pending in the multi-district opioid litigation, those remanded from the multi-district opioid litigation to federal district courts, as well as  in  state  courts  where  lawsuits  have  been  filed,  and  we  intend  to  continue  to  vigorously  defend  ourselves  in  all  such  cases.  Since  these  matters  are  still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief, including changes to our anti-diversion programs, that may affect how we operate our business.", "Further, any final settlement amongst parties may differ materially from our advanced  discussions  related  to  global  resolution  of  the  multi-district  opioid  litigation.  The  inability  to  reach  a  global  settlement  of  the  multi-district  opioid litigation and adverse resolution of any of these lawsuits or investigations could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders.", "If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company's results of operations, cash flows, or financial condition.", "Our business, results of operations, and cash flows could be adversely affected by legal proceedings.", "Each of our businesses may cause us to become involved in legal disputes or proceedings.", "The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations  and  financial  condition.  Violations  of  various  federal  and  state  laws,  including  with  respect  to  the  marketing,  sale,  purchase,  and  dispensing  of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs.", "Any settlement, judgment or fine could materially adversely affect our results of operations.", "Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations  and damages arising from resultant  false  claims,  if the litigation  proceeds whether or not government  authorities  decide  to intervene  in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.", "In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement with the Office of Inspector General of the U.S.", "Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.", "Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.", "There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives.", "We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent.", "In addition, U.S. federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations.  There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.", "Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the 2017 Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties  regarding  the  geographic  mix  of  earnings  in  any  particular  period,  and  other  factors,  material  adjustments  to  our  tax  estimates  may  impact  our provision for income taxes and our earnings per share, as well as our cash flows, in the period in which any such adjustments would be made.", "Further, we cannot predict the impact of any efforts to change or repeal the 2017 Tax Act or enact alternative legislation by the incoming presidential administration or the next Congress.", "Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market.", "The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls.", "If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses.", "From time to time, we may face audits or investigations by one or", "As such, we are subject to tax laws and regulations of the U.S.", "The qui tam provisions of the federal and various state civil False", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.", "We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations.", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties.", "That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.", "Any extended disruption in our ability to service our customers could have a material adverse effect on our revenue, results of operations, and cash flows.", "An economic slowdown or recession related to COVID-19 may affect our customers' ability to obtain credit to finance their business on acceptable terms, which could result in reduced spending on our products and services.", "For example, the continued spread of COVID-19 has led to disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets.", "Certain of our employees have contracted COVID-19 which", "Since April 2020, COVID-19 has adversely  impacted  and may continue  to adversely  impact  our revenue,  results of operations,  and cash flows.", "Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.", "In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.", "Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value.", "goodwill, indefinite-lived intangible assets, or long-lived assets is determined.", "Any such charge could have a material adverse impact on our results of operations.", "Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.", "U.S. generally accepted accounting principles (\"GAAP\") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual", "The Company anticipates that it will continue to pay quarterly cash dividends in the future.", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and cash flows (refer to our COVID-19 risk factor in Item 1A.", "\u2022 Distribution, selling, and administrative expenses increased 3.9% from the prior fiscal year primarily due to an increase in operating costs to support our revenue growth;", "We are currently in advanced discussions, which are ongoing, with the states and various plaintiffs\u2019 representatives that would be necessary to reach a global settlement of the Multidistrict Litigation (\"MDL\") and other related state-court litigation brought by certain state and local governmental entities to be paid over 18 years in which our payment would be $6.5 billion assuming all parties participate.", "While a global settlement remains subject to contingencies that could impact  whether  the  parties  ultimately  decide  to  move  forward,  we  believe  a  global  settlement  is  probable  and  our  loss  related  thereto  can  be reasonably estimated as of September 30, 2020;", "\u2022 Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2020 was higher than the U.S. statutory rate due to our operating loss, the tax benefits associated with our decision to permanently exit the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.  Our  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of PharMEDium's assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international  income.  The  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  also  impacted  by  a  $37.0  million  decrease  to  the Company's transition tax related to the U.S.", "If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "Changes to any of the above factors may have a material impact to our annual LIFO provision.", "In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018.", "District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018.", "In September 2020, the United States Court of Appeals for the Second Circuit reversed the District Court\u2019s decision, and, as a result, we accrued $14.8 million in the fourth quarter of the fiscal year ended September 30, 2020 as we revised our estimated liability for the 2017 and 2018 calendar years.", "Gross profit in the current fiscal year was favorably impacted by increases in", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $9.1 million and $145.9 million during the fiscal years", "Consolidated Financial Statements) and $115.4 million of litigation costs that related to legal fees in connection with opioid lawsuits and investigations, $34.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, $38.0 million related to our business transformation efforts, and $12.6 million of acquisition-related deal and integration costs and other restructuring initiatives.", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "Prior to October 1, 2019, we recognized interest expense associated with financing obligations in connection with lease construction assets (see Note 1 of the Notes to Consolidated Financial Statements).", "Upon adoption of the new lease standard as of October 1, 2019, we began recognizing  rent  expense  related  to  these  leases  in  Distribution,  Selling,  and  Administrative  expenses  in  our  Consolidated  Statements  of  Operations.  Interest income was lower in the current fiscal year as a result of a decline in investment interest rates, which was offset in part by a $1.0 billion increase in average invested cash balances compared to the prior fiscal year.", "borrowing facilities, and strategic decisions to deploy our invested cash.", "Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September  30,  2020  was  higher  than  the  U.S.  statutory  rate  due  to  our  operating  loss,  the  tax  benefits  associated  with  our  decision  to  permanently  exit  the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.", "Our effective tax rate in the fiscal year ended September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of  PharMEDium's  assets  (see  Note  1  of  the  Notes  to  Consolidated  Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $145.9 million and $35.9 million during the fiscal years", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D.", "We  recorded  a  $570.0  million  impairment  of  PharMEDium's  long-lived  assets  in  the  fiscal  year  ended  September  30,  2019  (see  Note  1  of  the  Notes  to Consolidated Financial Statements).", "increase in operating expenses.     We recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the fiscal year ended September 30, 2019.", "We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in the fiscal year September 30, 2018 in connection with our", "We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the fiscal year ended", "to an increase in interest income due to a $752 million increase in our average invested cash balance during the fiscal year ended September 30, 2019 and an increase in investment interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D.", "specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019.", "Our effective tax rates were 11.7% and (37.2)% in the fiscal years ended September 30, 2019 and 2018, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2019 was primarily impacted by the $570.0 million impairment of PharMEDium assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "The effective tax rate in the fiscal year ended September 30, 2019 was  also  impacted  by  a  $37.0  million  decrease  to  the  Company's  transition  tax  related  to  the  2017  Tax  Act.  Our  effective  tax  rate  in  the  fiscal  year  ended September 30, 2018 was primarily impacted by the effect of 2017 Tax Act.", "Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act.", "Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018.", "Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were also favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.", "Actual results may differ from these estimates due to uncertainties inherent in such estimates.", "Below are those policies applied in preparing our financial statements that management believes are the most dependent upon the application of estimates and assumptions.", "Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit.", "trends, and our customers' financial strength, credit standing, payment and default history, and macroeconomic conditions.", "Changes in the aforementioned factors, among others, may lead to adjustments in our allowance for doubtful accounts.", "The calculation of the required allowance requires judgment by our management as to the impact of these and other factors on the ultimate realization of our trade receivables.", "For the fiscal year ended September 30, 2018, we recorded a $42.3 million loss in connection with the January 2018 consolidations of Profarma and the", "We write off balances against the reserves when collectability is deemed remote.", "The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments.", "We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed.  Such  valuations  require  management  to  make  significant  judgments,  estimates,  and  assumptions,  especially  with  respect  to  intangible  assets.", "Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.", "For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite- lived intangible assets, respectively.", "If we conclude based on our qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative analysis.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2020, with the exception of our testing of goodwill and indefinite-lived intangibles in the MWI and the Profarma reporting units.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of our testing  in  the  Profarma  reporting  unit.  In  the  fourth  quarter  of  fiscal  2018,  we  elected  to  bypass  performing  the  qualitative  assessment  and  went  directly  to performing our annual quantitative assessments of goodwill and indefinite-lived intangible assets.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium.", "Schedule II of this Form 10-K sets forth a rollforward of allowances for returns and doubtful accounts.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction.", "The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan.", "While we use  the  best  available  information  to  prepare  our  cash  flows  and  discount  rate  assumptions,  actual  future  cash  flows  and/or  market  conditions  could  differ significantly resulting in future impairment charges related to recorded goodwill balances.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "We estimate the fair value of our indefinite- lived intangibles using the relief from royalty method.", "We believe the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "We recorded a goodwill impairment of $59.7 million in our Profarma reporting unit in connection with our fiscal 2018 annual  impairment  test.  No  goodwill  impairments  were  recorded  in  the  fiscal  years  ended  September  30,  2020  and  2019.  No  indefinite-lived  intangible impairments were recorded in the fiscal years ended September 30, 2020, 2019, and 2018.", "we performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value.", "We believed that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represents a Level 3 nonrecurring fair value measurement.", "We allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.", "regulatory matters, ongoing operational challenges, and lower-than-expected operating results, we updated our recoverability assessment of PharMEDium\u2019s long- lived assets as of December 31, 2019.", "Using forecasted undiscounted cash flows that were based on the weighted average of multiple strategic alternatives, we concluded that the carrying value of the PharMEDium long-lived asset group was not recoverable as of December 31, 2019.", "The forecasted undiscounted cash flows as of December 31, 2019 were lower than the forecasted undiscounted cash flows as of September 30, 2019 due to a change in weighting of multiple strategic alternatives and lower  operating  results  in  the  three  months  ended  December  31,  2019  compared  to  expectations.  We  then  performed  an  impairment  test  by  comparing  the PharMEDium asset group's fair value of $145 million to its carrying value, which resulted in a $138.0 million impairment loss in the three months ended December 31, 2019.", "We perform a recoverability assessment of our long-lived assets when impairment indicators are present.", "that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represented a Level 3 nonrecurring fair value measurement.", "We allocated $123.2 million of the impairment to finite-lived intangibles, $11.6 million of the impairment to property and equipment, and $3.2 million to ROU assets.", "After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.", "In the normal course of business, our tax returns are subject to examination by various taxing authorities.", "Such examinations may result in future tax and interest assessments by these taxing authorities.", "Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations.", "We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.", "If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $52.9 million in the fiscal year ended September 30, 2020.", "respectively,  has  been  determined  using  the  LIFO  method.  If  we  had  used  the  first-in,  first-out  method  of  inventory  valuation,  which  approximates  current replacement cost, inventories would have been approximately $1,519.2 million and $1,511.8 million higher than the amounts reported as of September 30, 2020 and 2019, respectively.", "We recorded LIFO expenses of $7.4 million and $67.3 million in the fiscal years ended September 30, 2020 and 2018, respectively.", "We recorded a LIFO credit of $22.5 million in the fiscal year ended September 30, 2019.", "Changes to any of the above factors can have a material impact to our annual LIFO provision.", "We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain.", "The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year.", "We record a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency and whether a reasonable estimate of the loss or the range of the loss can made in the footnotes to our financial statements.", "We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made.", "Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 14 of the Notes to Consolidated Financial Statements.", "provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock.", "purchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities.", "Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that are expected to be made over 18 years (see below).", "distribution of prescription opioid pain medications, we recorded a $6.6 billion ($5.5 billion, net of an income tax benefit) charge.", "We are in advanced discussions, which are ongoing, to reach a global settlement of the MDL and related state-court litigation brought by certain state and local governmental entities in which our payment would be over 18 years to resolve cases currently filed and that could be filed by states, counties, municipalities, and other government entities.", "aforementioned litigation accrual has not and is not expected to have an impact on our compliance with our debt covenants or our ability to pay dividends.", "We have the ability to repatriate the majority of our cash and cash equivalents held by our foreign subsidiaries without incurring significant additional taxes upon repatriation.", "require the use of our credit facilities to fund short-term capital needs.", "Our cash balance in the fiscal years ended September 30, 2020 and 2019 needed to be supplemented  by  intra-period  credit  facility  borrowings  to  cover  short-term  working  capital  needs.  The  largest  amount  of  intra-period  borrowings  under  our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 2020 and 2019 was $39.6 million and $240.6 million, respectively.", "We had $117.4 million, $606.0 million, and $25,115.3 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2020, 2019, and 2018, respectively.", "We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D.", "Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon our debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2020) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable.", "We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based upon our debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2020).", "We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time.", "The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of September 30, 2020.", "The maturities on the notes will vary, but may not  exceed  365  days  from  the  date  of  issuance.  The  notes  will  bear  interest,  if  interest  bearing,  or  will  be  sold  at  a  discount  from  their  face  amounts.  The commercial  paper  program  does  not  increase  our  borrowing  capacity  as  it  is  fully  backed  by  our  Multi-Currency  Revolving  Credit  Facility.  There  were  no borrowings outstanding under our commercial paper program as of September 30, 2020 and 2019.", "have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters.", "Interest rates are based upon prevailing market rates for short-term commercial paper or  LIBOR  plus  a  program  fee.  We  pay  a  customary  unused  fee  at  prevailing  market  rates,  annually,  to  maintain  the  availability  under  the  Receivables Securitization Facility.", "The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "As of September 30, 2020 and 2019, our cash and cash equivalents held by foreign subsidiaries were $675.9 million and $826.8 million, respectively, and", "We used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a", "We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion", "In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.", "We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources.", "Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice.", "The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "During the fiscal year ended September 30, 2018, we purchased $663.1 million of our common stock under this program, which included $24.0 million of September 2018 purchases that cash settled in October 2018.", "During the fiscal year ended September 30, 2019, we purchased $125.8  million  of  our  common  stock  under  this  program,  which  excluded  $24.0  million  of  September  2018  purchases  that  cash  settled  in  October  2018,  to complete our authorization under this program.", "In October 2018, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions.", "During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019.", "During the fiscal year ended September 30, 2020, we purchased $405.6 million of our common stock, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019.", "As of September 30, 2020, we had $55.5 million of availability remaining under this program.", "In October 2020, we repaid the $400 million October 2018 Term Loan that became due.", "In addition to the 2027 Notes, the 2030 Notes, and the 2047 Notes, we have $500 million of 3.40% senior notes due May 15, 2024, $500 million of 3.25%", "In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion in shares of our common", "The 2017 Tax Act required a one-time transition tax to be recognized on historical foreign earnings and profits.", "We currently estimate that our liability related to the  transition  tax  is  $182.6  million,  net  of  overpayments  and  tax  credits,  as  of  September  30,  2020,  which  is  payable  in  installments  over  a  six-year  period commencing in January 2021.", "As of September 30, 2020, a settlement has not been reached, and, therefore, we applied significant judgment in estimating the ultimate amount of the opioid litigation settlement that would be deductible for U.S. federal and state purposes.", "In estimating the amount that would ultimately be deductible, we considered prior U.S. tax case law, the amount and character of the damages sought in the opioid litigation, the inherent uncertainty related to litigation of this nature and magnitude, and other relevant factors.", "While we believe that our estimate of the uncertain tax position appropriately reflects these considerations, it is reasonably possible that the uncertain tax position recognized as of September 30, 2020 may be revised in future periods as the settlement with the various plaintiffs is finalized.", "The remaining amount of the liability represents an estimate of tax positions that we have taken in our tax returns or expect to take in future tax returns which may ultimately not be sustained upon examination by taxing authorities.", "Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers.", "In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms.", "Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.", "Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations.", "Our  liability  for  uncertain  tax  positions  was  $498.3  million  (including  interest  and  penalties)  as  of  September  30,  2020.  Included  in  this  balance  is", "Our  cash  flows  from  operating  activities  can  vary  significantly  from  period  to  period  based  upon  fluctuations  in  our  period  end  working  capital.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "In the fiscal year ended September 30, 2018, we acquired H.D.", "In addition, we made incremental investments in Brazil totaling $78.1 million.", "and $343.6 million in cash dividends paid on our common stock.", "and $339.0 million in cash dividends paid on our common stock.", "senior notes, $639.2 million in purchases of our common stock, and $333.0 million in cash dividends paid on our common stock, offset in part by the issuance of $750.0 million of 3.45% senior notes and $500 million of 4.3% senior notes.", "discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.", "The amount of variable-rate debt fluctuates during the year based on our working capital requirements.", "We had $0.8 billion of variable-rate debt outstanding as of September 30, 2020.", "We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates.", "However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us.", "The unfavorable impact of a hypothetical decrease in", "We currently  expect  to spend approximately  $400 million  for capital  expenditures  during fiscal 2021.", "Net cash used in financing activities in the fiscal year ended September 30, 2020 principally related to $420.4 million in purchases of our common stock,", "Net cash used in financing activities in the fiscal year ended September 30, 2019 principally related to $674.0 million in purchases of our common stock", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "We have market risk exposure to interest rate fluctuations relating to our debt.", "We manage interest rate risk by using a combination of fixed-rate and", "We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents.", "interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt.", "For every $100 million of cash invested that is in excess of variable-rate debt, a 10-basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.", "Revenue from our foreign operations is approximately two percent of our consolidated revenue.", "We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates.", "We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes.", "We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations.", "Our largest exposure to foreign exchange rates exists", "These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.", "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2020, in conformity with U.S. generally accepted accounting principles.", "Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We  conducted  our  audits  in  accordance  with  the  standards  of  the  PCAOB.  Those  standards  require  that  we  plan  and  perform  the  audit  to  obtain  reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of the opioid litigation liability and related uncertain tax position.", "For example, we inspected management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of the opioid litigation liability and the related financial statement footnote disclosures.", "To  test  the  Company\u2019s  opioid  litigation  liability,  our  substantive  audit  procedures  included,  among  others,  testing  the completeness  of  the  opioid  litigation  contingencies  subject  to  evaluation  by  the  Company  and  evaluating  the  Company\u2019s analysis of its assessment of the probability of outcome by considering the progress of settlement discussions involving the opioid litigation and communications with plaintiffs, as well as the experience of other similar entities when evaluating the Company\u2019s  conclusions.  We  inspected  responses  to  inquiry  letters  sent  to  both  internal  and  external  legal  counsel,  held discussions with internal and external legal counsel to confirm our understanding of the settlement discussions, and obtained written representations from executives of the Company.", "We also compared the Company\u2019s assessment with its relevant history of  similar  legal  contingencies  that  have  been  settled  or  otherwise  resolved  to  evaluate  the  consistency  of  the  Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "In addition, we also evaluated the adequacy of the Company\u2019s financial statement disclosures.", "We involved our tax subject matter professionals  in assessing the technical  merits and measurement  of the Company\u2019s tax position related to the opioid litigation liability.", "We examined the Company\u2019s analysis and evaluated the underlying facts upon which  the  tax  position  was  based.  We  used  our  knowledge  of  historical  settlement  activity  to  evaluate  the  Company\u2019s measurement  of the uncertain tax position associated  with the opioid litigation.  This included evaluating third-party  advice obtained by the Company and performing inquiries of the Company\u2019s external income tax advisers.", "We also evaluated the adequacy  of  the  Company\u2019s  financial  statement  disclosures  and  obtained  written  representations  from  executives  of  the Company related to this income tax matter.", "We have served as the Company's auditor since 1985.", "This included testing controls related to the Company\u2019s process for  identification,  recognition,  measurement  and  disclosure  of  legal  contingencies.  For  example,  we  tested  controls  over management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures.", "We also tested controls over management\u2019s assessment of the likelihood of the resolution of the matters through settlement or litigation.", "To test the Company\u2019s legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company\u2019s analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal and external legal counsel to confirm our understanding of the allegations,  and  obtaining  written  representations  from  executives  of  the  Company.  We  also  compared  the  Company\u2019s assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, and for those legal contingencies for which the Company has determined that a loss is either probable or reasonably possible, but the Company is unable to estimate the range of loss, and is therefore required to be disclosed, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies.", "We assessed the Company\u2019s  estimate  of  the  amount  of  the  loss,  for  both  contingencies  that  are  probable  and  reasonably  possible,  through inspection of responses to inquiry letters sent to both internal and external legal counsel, direct discussions with internal and external  legal  counsel,  inspection  of  court  rulings,  and  inspection  of  settlement  agreements.  We  also  obtained  written representations from executives of the Company.", "All intercompany accounts and transactions have been eliminated in consolidation.", "ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.", "performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.", "The Company did not elect the hindsight practical expedient in determining the lease term.", "The adoption of ASC 842 did not and will not have a material impact on the Company's results of operations or cash flows.", "An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances.", "The Company does not expect the adoption of this new accounting guidance to have a material impact on its financial position, results of operations, or cash flows.", "ASU 2019-12 removes certain exceptions to the general principles in ASC 740 in order to reduce the cost and complexity of its application.", "The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.", "The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "The Company's trade accounts receivables are exposed to credit risk.", "Deposits held with banks may exceed the amount of insurance", "Gain Contingencies: The Company records gain contingencies when they are realized.", "Gains from antitrust litigation settlements are realized upon the", "If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method.", "The Company believes the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "recoverability assessment of its long-lived assets when impairment indicators are present.", "This represents a Level 3 nonrecurring fair value measurement.", "This represented a Level 3 nonrecurring fair value measurement.", "Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.", "Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.", "contains a lease based on the facts and circumstances present.", "The Company does not recognize on the balance sheet leases with terms of one year or less.", "The Company's leases do not contain residual value guarantees.", "further obligation to provide services related to such products.", "Service revenue is recognized over the period that services are provided to the customer.", "The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company\u2019s common stock.", "Share-based  compensation  expense  is  recognized  over  the  requisite  service  period  within  Distribution,  Selling,  and  Administrative  in  the  Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees.", "Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.", "The ultimate outcome of any outstanding claim may be different than the Company's estimate.", "The purchase price exceeded the fair value of the net tangible and intangible assets acquired by", "The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively.", "Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.", "The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "These represent Level 2 nonrecurring fair value measurements.", "The Company is not obligated to provide future financial support to Profarma.", "A  reconciliation  of  the  statutory  U.S.  federal  income  tax  rate  to  the  Company's  consolidated  effective  income  tax  rate  is  as  follows  for  the  periods", "The estimated tax benefit is higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction can now be carried back to years with higher statutory tax rates.", "resulting from the recognition of the above discrete tax benefits.", "A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income.", "To phase in the tax rate increase, the canton of Bern has granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years.", "It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.", "During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $13.9 million.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to have an impact on the Company's compliance with its debt covenants.", "The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility.", "Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "An additional covenant requires compliance with a financial leverage ratio test.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to impact the Company's ability to pay dividends.", "employees at a price not less than the fair market value of the common stock on the date the option is granted.", "This unfunded plan, under which 2.96 million shares of", "The risk-free rates during the terms of such options are based upon the U.S.", "Performance  stock  units  are  granted  to  certain  executive  employees  under  the  Plan  and  represent  common  stock  potentially  issuable  in  the  future.", "The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "uncertainty  remains  with  regard  to  whether  such  matters  will  proceed  to  trial,  whether  settlements  will  be  reached,  and  the  amount  and  terms  of  any  such settlements.", "If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.", "While a global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move forward, the Company believes a global settlement is probable and its loss related thereto can be reasonably estimated as of September 30, 2020.", "Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events.", "The Company will regularly review these opioid litigation matters to determine whether its accrual is adequate.", "The amount of ultimate loss may differ materially from the $6.6 billion accrual.", "Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations.", "The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.", "The Company cannot predict how these matters would be affected by a global settlement.", "The Company's responses often require time and effort and can result in considerable costs being incurred.", "None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds", "approximate fair value based upon the relatively short-term nature of these financial instruments.", "The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.", "The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.", "AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.", "effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.", "that could have a material effect on the financial statements.", "We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated November 19, 2020 expressed an unqualified opinion thereon.", "Our responsibility is to express an opinion on the Company\u2019s internal control over financial reporting based on our audit.", "We are a public accounting firm registered with the PCAOB and are required  to  be  independent  with  respect  to  the  Company  in  accordance  with  the  U.S.  federal  securities  laws  and  the  applicable  rules  and  regulations  of  the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "We will file the 2021 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.", "Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.", "of our reports dated November 19, 2020, with respect to the consolidated financial statements and schedule of AmerisourceBergen Corporation and subsidiaries and the effectiveness of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries included in this Annual Report (Form 10-K) of AmerisourceBergen Corporation and subsidiaries for the year ended September 30, 2020.", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Yes \u00fe No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.", "While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays.", "A number of patents for widely used brand-name pharmaceutical products will continue to expire during the", "In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that", "increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs.", "Subsequent legislation and rules promulgated by government agencies have made additional changes to federal drug payment policies.", "These  policies  and  other  legislative  developments  (including  potential  revisions  to  or  repeal  of  any  portions  of  the  health  reform  legislation)  may  affect  our businesses directly and/or indirectly (see Government Regulation on page 6 and the risk factor titled Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates on page 12 for further details).", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and  cash  flows.  These  items  include,  but  are  not  limited  to,  the  financial  condition  of  our  customers  and  the  realization  of  accounts  receivable,  decreased availability and demand for our products and services, and delays related to current and future projects.", "While our operational and financial performance may be significantly impacted by COVID-19, it is not possible for us to predict the duration or magnitude of the outbreak and whether it could have a material adverse impact on the Company's financial position, results of operations, or cash flows (see Risk Factor - We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business).", "Our provider solutions include: our Good Neighbor Pharmacy\u00ae program, which enables independent community pharmacies to compete more effectively through  pharmaceutical  benefit  and  merchandising  programs;  Elevate  Provider  Network\u00ae,  our  managed  care  network,  which  connects  our  retail pharmacy customers to payor plans throughout the country and is one of the largest in the United States; generic product purchasing and private label services;  hospital  pharmacy  consulting  designed  to  improve  operational  efficiencies;  and  packaging  solutions  for  institutional  and  retail  healthcare providers.", "We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs.", "We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies.", "If those contracts are not renewed or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.", "We seek patent protection for our proprietary intellectual property from time to time as appropriate.", "third parties may assert infringement claims against us from time to time.", "The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.", "There can be no assurance that we are fully compliant with the DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our operations into compliance.", "These and other requirements will continue to increase the cost of our operations.", "The  regulation  of  public  and  private  health  insurance  and  benefit  programs  can  also  affect  our  business  and  scrutiny  of  the  healthcare  delivery  and reimbursement systems in the United States can be expected to continue at both the state and federal levels.", "In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate certain of our distribution centers, which may have a material adverse effect on our financial condition and results of operations.", "We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.", "We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act.", "requirements could have a significant impact on our results of operations and financial condition.", "that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.", "Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations.", "Our operations, depending on their location, may also be subject  to  state  or  foreign  regulations  affecting  personal  data  protection  and  the  manner  in  which  information  services  or  products  are  provided.  Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws.", "We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.", "Personally identifiable information is also highly regulated in many other countries in which we operate.", "As such regulations continue to evolve, we must comply with applicable privacy and security requirements of these countries, including but not limited to those in the European Union.", "We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with the applicable privacy laws and regulations.", "There can be no assurances that compliance with these requirements will not impose new costs on our business.", "For  more  information  about  us,  visit  our  website  at www.amerisourcebergen.com.  The  contents  of  the  website  are  not  part  of  this  Form  10-K.  Our", "We expect these trends to continue in fiscal 2021, which could have an adverse effect on our results of operations.", "Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products generally use wholesale acquisition cost (\"WAC\") as the reference price.", "We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price.", "If manufacturers change their pricing policies or practices with regard to WAC or if prices charged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our results of operations could be adversely affected.", "we have entered into with brand and generic pharmaceutical manufacturers have a price appreciation component to them.", "As a result, our gross profit from brand- name and generic pharmaceuticals  continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control.", "If the frequency or rate of brand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected.", "If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations will be greater.", "Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.", "Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured.", "Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers.", "The COVID-19 pandemic has increased volatility of the capital and credit markets and has led to a general worsening of economic conditions, which has put financial pressure on many of our customers and may threaten certain customers\u2019 ability to maintain liquidity sufficient to repay their obligations to us as they become due.", "The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on  our  operating  revenue  and  results  of  operations.  As  of  September  30,  2020,  our  two  largest  trade  receivable  balances  due  from  customers  represented approximately 47% and 7% of accounts receivable, net.", "The pharmaceutical products that we purchase are also subject to price inflation and deflation.", "Most of our customers buy pharmaceuticals and other products and services from us on credit.", "Credit is made available to customers based upon our", "Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.", "returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers.", "Volatility of the capital and credit markets, general economic  conditions,  pending  litigation,  and  regulatory  changes  may  adversely  affect  the  solvency  or  creditworthiness  of  our  suppliers.  The  bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.", "Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.", "downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit.", "Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.", "Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings.", "Actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.", "economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability.", "Negative trends in the general economy, including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products.", "Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flow from operations.", "Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced.", "Declining economic conditions may also increase our costs.", "Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.", "We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract.", "A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these  customers  or  GPO  relationships  if  we  are  unable  to  extend,  renew,  renegotiate  or  replace  the  contracts.  The  loss  of  any  significant  customer  or  GPO relationship could adversely affect our revenue, results of operations, and cash flows.", "Additionally, from time to time, significant contracts may be renewed or modified prior to their expiration date in furtherance of our strategic objectives.", "If those contracts are renewed or modified at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.", "Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities.", "WBA accounted for approximately 33% of our revenue in the fiscal year ended September 30, 2020.", "Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the terms under which we extended the duration of the distribution agreement and generics purchasing services agreement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; changes in the economic  terms  under  which  we  distribute  pharmaceuticals  to  WBA,  including  changes  necessitated  by  changing  market  conditions  or  other  unforeseen developments that may arise during the term of the distribution agreement, to the extent that any such changes are not offset by other financial benefits that we are able to obtain through collaboration in other aspects of our strategic relationship with WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the anticipated strategic and financial benefits of the relationship.", "18, 2013 to make certain additional investments in our common stock.", "WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholder Agreement.", "Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock.", "We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration we anticipate pursuing with WBA.", "If we are unable to achieve any of our objectives, the expected future benefits may not be realized fully or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.", "we may have an obligation to pay or credit WBA for failure to supply products.", "We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations.", "At any particular time, we may be in various stages of", "or more acquisitions, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions.", "The impact of a divestiture on our results of operations could also be greater than anticipated.", "Our results of operations and our financial condition may be adversely affected by our global operations.", "Changes or uncertainty in U.S. or foreign policy, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase.", "Any of these factors could adversely affect our business, financial position, and results of operations.", "We are subject to operational and logistical risks that might not be covered by insurance.", "Although we seek to maintain adequate insurance coverage, coverage on acceptable terms might be unavailable, or coverage might not cover our losses or may require large deductibles.", "Uninsured losses or operational losses that result in large deductible payments in order to receive insurance coverage might have an adverse impact on our business operations and our financial position or results of operations.", "Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies.", "There have been increasing efforts by Congress and state", "regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance.", "Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs and could have an adverse impact on our financial position or results of operations.", "Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.", "Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at the federal or state level, could adversely affect our operations. reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute.", "Given the scope of the changes made by the ACA and continuing implementation controversies, we cannot predict the impact of every aspect of the law on our operations.", "Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.", "Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs.", "The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs.", "Any reduction in the Medicaid reimbursement  rates  to  our  customers  may  indirectly  impact  the  prices  that  we  can  charge  our  customers  for  multiple  source  pharmaceuticals  and  cause corresponding declines in our profitability.", "There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business.", "Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.", "There can be no assurance that recent or future rules established by CMS will not have an adverse impact on our business.", "Our customers include covered entities and organizations with significant participation as contract pharmacies, and the unavailability of 340B discounts through contract pharmacy arrangements may adversely affect such customers and, therefore, could adversely affect our business.", "Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers.", "At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have a material adverse effect on our business.", "as Medicare and Medicaid, which may adversely affect our business.", "There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.", "If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.", "continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs.", "Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs.", "Many states have enacted similar statutes which are not necessarily limited to items and services for  which  payment  is  made  by  federal  healthcare  programs.  While  we  believe  that  we  are  in  compliance  with  applicable  laws  and  regulations,  many  of  the regulations applicable to us, including those", "We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse.", "They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations.", "If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal and state healthcare programs.", "Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.", "Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future and lawsuits could be brought against the Company by other plaintiffs under other theories related to opioid abuse.", "We are deeply committed to diversion control efforts, have sophisticated systems in place to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in significant due diligence and ongoing monitoring of customers.", "While we are vigorously defending ourselves in these lawsuits, the allegations may negatively affect our business in various ways, including through increased costs and harm to our reputation.", "We are currently engaged in advanced discussions, which are ongoing, with the objective of reaching potential terms (which would include monetary payments and certain changes to our anti-diversion programs) for a global resolution of the multi-district opioid litigation involving certain state and local governmental entities and other related state court litigation described in Note 14 of the Notes to Consolidated Financial Statements.", "We have recorded a charge of $6.6 billion in the fourth quarter of the fiscal year ended September 30, 2020 related to the global settlement and other related opioid litigation.", "Until such time as a plaintiff participates in a global settlement or otherwise resolves its lawsuit, we will continue to litigate and prepare for trial in the cases pending in the multi-district opioid litigation, those remanded from the multi-district opioid litigation to federal district courts, as well as  in  state  courts  where  lawsuits  have  been  filed,  and  we  intend  to  continue  to  vigorously  defend  ourselves  in  all  such  cases.  Since  these  matters  are  still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief, including changes to our anti-diversion programs, that may affect how we operate our business.", "Further, any final settlement amongst parties may differ materially from our advanced  discussions  related  to  global  resolution  of  the  multi-district  opioid  litigation.  The  inability  to  reach  a  global  settlement  of  the  multi-district  opioid litigation and adverse resolution of any of these lawsuits or investigations could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders.", "If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company's results of operations, cash flows, or financial condition.", "Our business, results of operations, and cash flows could be adversely affected by legal proceedings.", "Each of our businesses may cause us to become involved in legal disputes or proceedings.", "The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations  and  financial  condition.  Violations  of  various  federal  and  state  laws,  including  with  respect  to  the  marketing,  sale,  purchase,  and  dispensing  of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs.", "Any settlement, judgment or fine could materially adversely affect our results of operations.", "Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations  and damages arising from resultant  false  claims,  if the litigation  proceeds whether or not government  authorities  decide  to intervene  in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.", "In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement with the Office of Inspector General of the U.S.", "Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.", "Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.", "There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives.", "We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent.", "In addition, U.S. federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations.  There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.", "Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the 2017 Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties  regarding  the  geographic  mix  of  earnings  in  any  particular  period,  and  other  factors,  material  adjustments  to  our  tax  estimates  may  impact  our provision for income taxes and our earnings per share, as well as our cash flows, in the period in which any such adjustments would be made.", "Further, we cannot predict the impact of any efforts to change or repeal the 2017 Tax Act or enact alternative legislation by the incoming presidential administration or the next Congress.", "Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market.", "The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls.", "If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses.", "From time to time, we may face audits or investigations by one or", "As such, we are subject to tax laws and regulations of the U.S.", "The qui tam provisions of the federal and various state civil False", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.", "We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations.", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties.", "That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.", "Any extended disruption in our ability to service our customers could have a material adverse effect on our revenue, results of operations, and cash flows.", "An economic slowdown or recession related to COVID-19 may affect our customers' ability to obtain credit to finance their business on acceptable terms, which could result in reduced spending on our products and services.", "For example, the continued spread of COVID-19 has led to disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets.", "Certain of our employees have contracted COVID-19 which", "Since April 2020, COVID-19 has adversely  impacted  and may continue  to adversely  impact  our revenue,  results of operations,  and cash flows.", "Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.", "In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.", "Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value.", "goodwill, indefinite-lived intangible assets, or long-lived assets is determined.", "Any such charge could have a material adverse impact on our results of operations.", "Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.", "U.S. generally accepted accounting principles (\"GAAP\") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual", "The Company anticipates that it will continue to pay quarterly cash dividends in the future.", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and cash flows (refer to our COVID-19 risk factor in Item 1A.", "\u2022 Distribution, selling, and administrative expenses increased 3.9% from the prior fiscal year primarily due to an increase in operating costs to support our revenue growth;", "We are currently in advanced discussions, which are ongoing, with the states and various plaintiffs\u2019 representatives that would be necessary to reach a global settlement of the Multidistrict Litigation (\"MDL\") and other related state-court litigation brought by certain state and local governmental entities to be paid over 18 years in which our payment would be $6.5 billion assuming all parties participate.", "While a global settlement remains subject to contingencies that could impact  whether  the  parties  ultimately  decide  to  move  forward,  we  believe  a  global  settlement  is  probable  and  our  loss  related  thereto  can  be reasonably estimated as of September 30, 2020;", "\u2022 Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2020 was higher than the U.S. statutory rate due to our operating loss, the tax benefits associated with our decision to permanently exit the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.  Our  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of PharMEDium's assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international  income.  The  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  also  impacted  by  a  $37.0  million  decrease  to  the Company's transition tax related to the U.S.", "If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "Changes to any of the above factors may have a material impact to our annual LIFO provision.", "In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018.", "District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018.", "In September 2020, the United States Court of Appeals for the Second Circuit reversed the District Court\u2019s decision, and, as a result, we accrued $14.8 million in the fourth quarter of the fiscal year ended September 30, 2020 as we revised our estimated liability for the 2017 and 2018 calendar years.", "Gross profit in the current fiscal year was favorably impacted by increases in", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $9.1 million and $145.9 million during the fiscal years", "Consolidated Financial Statements) and $115.4 million of litigation costs that related to legal fees in connection with opioid lawsuits and investigations, $34.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, $38.0 million related to our business transformation efforts, and $12.6 million of acquisition-related deal and integration costs and other restructuring initiatives.", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "Prior to October 1, 2019, we recognized interest expense associated with financing obligations in connection with lease construction assets (see Note 1 of the Notes to Consolidated Financial Statements).", "Upon adoption of the new lease standard as of October 1, 2019, we began recognizing  rent  expense  related  to  these  leases  in  Distribution,  Selling,  and  Administrative  expenses  in  our  Consolidated  Statements  of  Operations.  Interest income was lower in the current fiscal year as a result of a decline in investment interest rates, which was offset in part by a $1.0 billion increase in average invested cash balances compared to the prior fiscal year.", "borrowing facilities, and strategic decisions to deploy our invested cash.", "Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September  30,  2020  was  higher  than  the  U.S.  statutory  rate  due  to  our  operating  loss,  the  tax  benefits  associated  with  our  decision  to  permanently  exit  the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.", "Our effective tax rate in the fiscal year ended September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of  PharMEDium's  assets  (see  Note  1  of  the  Notes  to  Consolidated  Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $145.9 million and $35.9 million during the fiscal years", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D.", "We  recorded  a  $570.0  million  impairment  of  PharMEDium's  long-lived  assets  in  the  fiscal  year  ended  September  30,  2019  (see  Note  1  of  the  Notes  to Consolidated Financial Statements).", "increase in operating expenses.     We recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the fiscal year ended September 30, 2019.", "We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in the fiscal year September 30, 2018 in connection with our", "We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the fiscal year ended", "to an increase in interest income due to a $752 million increase in our average invested cash balance during the fiscal year ended September 30, 2019 and an increase in investment interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D.", "specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019.", "Our effective tax rates were 11.7% and (37.2)% in the fiscal years ended September 30, 2019 and 2018, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2019 was primarily impacted by the $570.0 million impairment of PharMEDium assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "The effective tax rate in the fiscal year ended September 30, 2019 was  also  impacted  by  a  $37.0  million  decrease  to  the  Company's  transition  tax  related  to  the  2017  Tax  Act.  Our  effective  tax  rate  in  the  fiscal  year  ended September 30, 2018 was primarily impacted by the effect of 2017 Tax Act.", "Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act.", "Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018.", "Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were also favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.", "Actual results may differ from these estimates due to uncertainties inherent in such estimates.", "Below are those policies applied in preparing our financial statements that management believes are the most dependent upon the application of estimates and assumptions.", "Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit.", "trends, and our customers' financial strength, credit standing, payment and default history, and macroeconomic conditions.", "Changes in the aforementioned factors, among others, may lead to adjustments in our allowance for doubtful accounts.", "The calculation of the required allowance requires judgment by our management as to the impact of these and other factors on the ultimate realization of our trade receivables.", "For the fiscal year ended September 30, 2018, we recorded a $42.3 million loss in connection with the January 2018 consolidations of Profarma and the", "We write off balances against the reserves when collectability is deemed remote.", "The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments.", "We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed.  Such  valuations  require  management  to  make  significant  judgments,  estimates,  and  assumptions,  especially  with  respect  to  intangible  assets.", "Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.", "For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite- lived intangible assets, respectively.", "If we conclude based on our qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative analysis.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2020, with the exception of our testing of goodwill and indefinite-lived intangibles in the MWI and the Profarma reporting units.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of our testing  in  the  Profarma  reporting  unit.  In  the  fourth  quarter  of  fiscal  2018,  we  elected  to  bypass  performing  the  qualitative  assessment  and  went  directly  to performing our annual quantitative assessments of goodwill and indefinite-lived intangible assets.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium.", "Schedule II of this Form 10-K sets forth a rollforward of allowances for returns and doubtful accounts.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction.", "The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan.", "While we use  the  best  available  information  to  prepare  our  cash  flows  and  discount  rate  assumptions,  actual  future  cash  flows  and/or  market  conditions  could  differ significantly resulting in future impairment charges related to recorded goodwill balances.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "We estimate the fair value of our indefinite- lived intangibles using the relief from royalty method.", "We believe the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "We recorded a goodwill impairment of $59.7 million in our Profarma reporting unit in connection with our fiscal 2018 annual  impairment  test.  No  goodwill  impairments  were  recorded  in  the  fiscal  years  ended  September  30,  2020  and  2019.  No  indefinite-lived  intangible impairments were recorded in the fiscal years ended September 30, 2020, 2019, and 2018.", "we performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value.", "We believed that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represents a Level 3 nonrecurring fair value measurement.", "We allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.", "regulatory matters, ongoing operational challenges, and lower-than-expected operating results, we updated our recoverability assessment of PharMEDium\u2019s long- lived assets as of December 31, 2019.", "Using forecasted undiscounted cash flows that were based on the weighted average of multiple strategic alternatives, we concluded that the carrying value of the PharMEDium long-lived asset group was not recoverable as of December 31, 2019.", "The forecasted undiscounted cash flows as of December 31, 2019 were lower than the forecasted undiscounted cash flows as of September 30, 2019 due to a change in weighting of multiple strategic alternatives and lower  operating  results  in  the  three  months  ended  December  31,  2019  compared  to  expectations.  We  then  performed  an  impairment  test  by  comparing  the PharMEDium asset group's fair value of $145 million to its carrying value, which resulted in a $138.0 million impairment loss in the three months ended December 31, 2019.", "We perform a recoverability assessment of our long-lived assets when impairment indicators are present.", "that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represented a Level 3 nonrecurring fair value measurement.", "We allocated $123.2 million of the impairment to finite-lived intangibles, $11.6 million of the impairment to property and equipment, and $3.2 million to ROU assets.", "After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.", "In the normal course of business, our tax returns are subject to examination by various taxing authorities.", "Such examinations may result in future tax and interest assessments by these taxing authorities.", "Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations.", "We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.", "If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $52.9 million in the fiscal year ended September 30, 2020.", "respectively,  has  been  determined  using  the  LIFO  method.  If  we  had  used  the  first-in,  first-out  method  of  inventory  valuation,  which  approximates  current replacement cost, inventories would have been approximately $1,519.2 million and $1,511.8 million higher than the amounts reported as of September 30, 2020 and 2019, respectively.", "We recorded LIFO expenses of $7.4 million and $67.3 million in the fiscal years ended September 30, 2020 and 2018, respectively.", "We recorded a LIFO credit of $22.5 million in the fiscal year ended September 30, 2019.", "Changes to any of the above factors can have a material impact to our annual LIFO provision.", "We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain.", "The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year.", "We record a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency and whether a reasonable estimate of the loss or the range of the loss can made in the footnotes to our financial statements.", "We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made.", "Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 14 of the Notes to Consolidated Financial Statements.", "provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock.", "purchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities.", "Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that are expected to be made over 18 years (see below).", "distribution of prescription opioid pain medications, we recorded a $6.6 billion ($5.5 billion, net of an income tax benefit) charge.", "We are in advanced discussions, which are ongoing, to reach a global settlement of the MDL and related state-court litigation brought by certain state and local governmental entities in which our payment would be over 18 years to resolve cases currently filed and that could be filed by states, counties, municipalities, and other government entities.", "aforementioned litigation accrual has not and is not expected to have an impact on our compliance with our debt covenants or our ability to pay dividends.", "We have the ability to repatriate the majority of our cash and cash equivalents held by our foreign subsidiaries without incurring significant additional taxes upon repatriation.", "require the use of our credit facilities to fund short-term capital needs.", "Our cash balance in the fiscal years ended September 30, 2020 and 2019 needed to be supplemented  by  intra-period  credit  facility  borrowings  to  cover  short-term  working  capital  needs.  The  largest  amount  of  intra-period  borrowings  under  our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 2020 and 2019 was $39.6 million and $240.6 million, respectively.", "We had $117.4 million, $606.0 million, and $25,115.3 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2020, 2019, and 2018, respectively.", "We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D.", "Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon our debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2020) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable.", "We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based upon our debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2020).", "We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time.", "The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of September 30, 2020.", "The maturities on the notes will vary, but may not  exceed  365  days  from  the  date  of  issuance.  The  notes  will  bear  interest,  if  interest  bearing,  or  will  be  sold  at  a  discount  from  their  face  amounts.  The commercial  paper  program  does  not  increase  our  borrowing  capacity  as  it  is  fully  backed  by  our  Multi-Currency  Revolving  Credit  Facility.  There  were  no borrowings outstanding under our commercial paper program as of September 30, 2020 and 2019.", "have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters.", "Interest rates are based upon prevailing market rates for short-term commercial paper or  LIBOR  plus  a  program  fee.  We  pay  a  customary  unused  fee  at  prevailing  market  rates,  annually,  to  maintain  the  availability  under  the  Receivables Securitization Facility.", "The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "As of September 30, 2020 and 2019, our cash and cash equivalents held by foreign subsidiaries were $675.9 million and $826.8 million, respectively, and", "We used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a", "We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion", "In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.", "We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources.", "Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice.", "The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "During the fiscal year ended September 30, 2018, we purchased $663.1 million of our common stock under this program, which included $24.0 million of September 2018 purchases that cash settled in October 2018.", "During the fiscal year ended September 30, 2019, we purchased $125.8  million  of  our  common  stock  under  this  program,  which  excluded  $24.0  million  of  September  2018  purchases  that  cash  settled  in  October  2018,  to complete our authorization under this program.", "In October 2018, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions.", "During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019.", "During the fiscal year ended September 30, 2020, we purchased $405.6 million of our common stock, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019.", "As of September 30, 2020, we had $55.5 million of availability remaining under this program.", "In October 2020, we repaid the $400 million October 2018 Term Loan that became due.", "In addition to the 2027 Notes, the 2030 Notes, and the 2047 Notes, we have $500 million of 3.40% senior notes due May 15, 2024, $500 million of 3.25%", "In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion in shares of our common", "The 2017 Tax Act required a one-time transition tax to be recognized on historical foreign earnings and profits.", "We currently estimate that our liability related to the  transition  tax  is  $182.6  million,  net  of  overpayments  and  tax  credits,  as  of  September  30,  2020,  which  is  payable  in  installments  over  a  six-year  period commencing in January 2021.", "As of September 30, 2020, a settlement has not been reached, and, therefore, we applied significant judgment in estimating the ultimate amount of the opioid litigation settlement that would be deductible for U.S. federal and state purposes.", "In estimating the amount that would ultimately be deductible, we considered prior U.S. tax case law, the amount and character of the damages sought in the opioid litigation, the inherent uncertainty related to litigation of this nature and magnitude, and other relevant factors.", "While we believe that our estimate of the uncertain tax position appropriately reflects these considerations, it is reasonably possible that the uncertain tax position recognized as of September 30, 2020 may be revised in future periods as the settlement with the various plaintiffs is finalized.", "The remaining amount of the liability represents an estimate of tax positions that we have taken in our tax returns or expect to take in future tax returns which may ultimately not be sustained upon examination by taxing authorities.", "Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers.", "In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms.", "Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.", "Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations.", "Our  liability  for  uncertain  tax  positions  was  $498.3  million  (including  interest  and  penalties)  as  of  September  30,  2020.  Included  in  this  balance  is", "Our  cash  flows  from  operating  activities  can  vary  significantly  from  period  to  period  based  upon  fluctuations  in  our  period  end  working  capital.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "In the fiscal year ended September 30, 2018, we acquired H.D.", "In addition, we made incremental investments in Brazil totaling $78.1 million.", "and $343.6 million in cash dividends paid on our common stock.", "and $339.0 million in cash dividends paid on our common stock.", "senior notes, $639.2 million in purchases of our common stock, and $333.0 million in cash dividends paid on our common stock, offset in part by the issuance of $750.0 million of 3.45% senior notes and $500 million of 4.3% senior notes.", "discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.", "The amount of variable-rate debt fluctuates during the year based on our working capital requirements.", "We had $0.8 billion of variable-rate debt outstanding as of September 30, 2020.", "We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates.", "However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us.", "The unfavorable impact of a hypothetical decrease in", "We currently  expect  to spend approximately  $400 million  for capital  expenditures  during fiscal 2021.", "Net cash used in financing activities in the fiscal year ended September 30, 2020 principally related to $420.4 million in purchases of our common stock,", "Net cash used in financing activities in the fiscal year ended September 30, 2019 principally related to $674.0 million in purchases of our common stock", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "We have market risk exposure to interest rate fluctuations relating to our debt.", "We manage interest rate risk by using a combination of fixed-rate and", "We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents.", "interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt.", "For every $100 million of cash invested that is in excess of variable-rate debt, a 10-basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.", "Revenue from our foreign operations is approximately two percent of our consolidated revenue.", "We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates.", "We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes.", "We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations.", "Our largest exposure to foreign exchange rates exists", "These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.", "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2020, in conformity with U.S. generally accepted accounting principles.", "Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We  conducted  our  audits  in  accordance  with  the  standards  of  the  PCAOB.  Those  standards  require  that  we  plan  and  perform  the  audit  to  obtain  reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of the opioid litigation liability and related uncertain tax position.", "For example, we inspected management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of the opioid litigation liability and the related financial statement footnote disclosures.", "To  test  the  Company\u2019s  opioid  litigation  liability,  our  substantive  audit  procedures  included,  among  others,  testing  the completeness  of  the  opioid  litigation  contingencies  subject  to  evaluation  by  the  Company  and  evaluating  the  Company\u2019s analysis of its assessment of the probability of outcome by considering the progress of settlement discussions involving the opioid litigation and communications with plaintiffs, as well as the experience of other similar entities when evaluating the Company\u2019s  conclusions.  We  inspected  responses  to  inquiry  letters  sent  to  both  internal  and  external  legal  counsel,  held discussions with internal and external legal counsel to confirm our understanding of the settlement discussions, and obtained written representations from executives of the Company.", "We also compared the Company\u2019s assessment with its relevant history of  similar  legal  contingencies  that  have  been  settled  or  otherwise  resolved  to  evaluate  the  consistency  of  the  Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "In addition, we also evaluated the adequacy of the Company\u2019s financial statement disclosures.", "We involved our tax subject matter professionals  in assessing the technical  merits and measurement  of the Company\u2019s tax position related to the opioid litigation liability.", "We examined the Company\u2019s analysis and evaluated the underlying facts upon which  the  tax  position  was  based.  We  used  our  knowledge  of  historical  settlement  activity  to  evaluate  the  Company\u2019s measurement  of the uncertain tax position associated  with the opioid litigation.  This included evaluating third-party  advice obtained by the Company and performing inquiries of the Company\u2019s external income tax advisers.", "We also evaluated the adequacy  of  the  Company\u2019s  financial  statement  disclosures  and  obtained  written  representations  from  executives  of  the Company related to this income tax matter.", "We have served as the Company's auditor since 1985.", "This included testing controls related to the Company\u2019s process for  identification,  recognition,  measurement  and  disclosure  of  legal  contingencies.  For  example,  we  tested  controls  over management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures.", "We also tested controls over management\u2019s assessment of the likelihood of the resolution of the matters through settlement or litigation.", "To test the Company\u2019s legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company\u2019s analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal and external legal counsel to confirm our understanding of the allegations,  and  obtaining  written  representations  from  executives  of  the  Company.  We  also  compared  the  Company\u2019s assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, and for those legal contingencies for which the Company has determined that a loss is either probable or reasonably possible, but the Company is unable to estimate the range of loss, and is therefore required to be disclosed, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies.", "We assessed the Company\u2019s  estimate  of  the  amount  of  the  loss,  for  both  contingencies  that  are  probable  and  reasonably  possible,  through inspection of responses to inquiry letters sent to both internal and external legal counsel, direct discussions with internal and external  legal  counsel,  inspection  of  court  rulings,  and  inspection  of  settlement  agreements.  We  also  obtained  written representations from executives of the Company.", "All intercompany accounts and transactions have been eliminated in consolidation.", "ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.", "performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.", "The Company did not elect the hindsight practical expedient in determining the lease term.", "The adoption of ASC 842 did not and will not have a material impact on the Company's results of operations or cash flows.", "An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances.", "The Company does not expect the adoption of this new accounting guidance to have a material impact on its financial position, results of operations, or cash flows.", "ASU 2019-12 removes certain exceptions to the general principles in ASC 740 in order to reduce the cost and complexity of its application.", "The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.", "The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "The Company's trade accounts receivables are exposed to credit risk.", "Deposits held with banks may exceed the amount of insurance", "Gain Contingencies: The Company records gain contingencies when they are realized.", "Gains from antitrust litigation settlements are realized upon the", "If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method.", "The Company believes the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "recoverability assessment of its long-lived assets when impairment indicators are present.", "This represents a Level 3 nonrecurring fair value measurement.", "This represented a Level 3 nonrecurring fair value measurement.", "Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.", "Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.", "contains a lease based on the facts and circumstances present.", "The Company does not recognize on the balance sheet leases with terms of one year or less.", "The Company's leases do not contain residual value guarantees.", "further obligation to provide services related to such products.", "Service revenue is recognized over the period that services are provided to the customer.", "The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company\u2019s common stock.", "Share-based  compensation  expense  is  recognized  over  the  requisite  service  period  within  Distribution,  Selling,  and  Administrative  in  the  Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees.", "Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.", "The ultimate outcome of any outstanding claim may be different than the Company's estimate.", "The purchase price exceeded the fair value of the net tangible and intangible assets acquired by", "The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively.", "Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.", "The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "These represent Level 2 nonrecurring fair value measurements.", "The Company is not obligated to provide future financial support to Profarma.", "A  reconciliation  of  the  statutory  U.S.  federal  income  tax  rate  to  the  Company's  consolidated  effective  income  tax  rate  is  as  follows  for  the  periods", "The estimated tax benefit is higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction can now be carried back to years with higher statutory tax rates.", "resulting from the recognition of the above discrete tax benefits.", "A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income.", "To phase in the tax rate increase, the canton of Bern has granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years.", "It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.", "During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $13.9 million.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to have an impact on the Company's compliance with its debt covenants.", "The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility.", "Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "An additional covenant requires compliance with a financial leverage ratio test.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to impact the Company's ability to pay dividends.", "employees at a price not less than the fair market value of the common stock on the date the option is granted.", "This unfunded plan, under which 2.96 million shares of", "The risk-free rates during the terms of such options are based upon the U.S.", "Performance  stock  units  are  granted  to  certain  executive  employees  under  the  Plan  and  represent  common  stock  potentially  issuable  in  the  future.", "The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "uncertainty  remains  with  regard  to  whether  such  matters  will  proceed  to  trial,  whether  settlements  will  be  reached,  and  the  amount  and  terms  of  any  such settlements.", "If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.", "While a global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move forward, the Company believes a global settlement is probable and its loss related thereto can be reasonably estimated as of September 30, 2020.", "Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events.", "The Company will regularly review these opioid litigation matters to determine whether its accrual is adequate.", "The amount of ultimate loss may differ materially from the $6.6 billion accrual.", "Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations.", "The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.", "The Company cannot predict how these matters would be affected by a global settlement.", "The Company's responses often require time and effort and can result in considerable costs being incurred.", "None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds", "approximate fair value based upon the relatively short-term nature of these financial instruments.", "The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.", "The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.", "AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.", "effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.", "that could have a material effect on the financial statements.", "We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated November 19, 2020 expressed an unqualified opinion thereon.", "Our responsibility is to express an opinion on the Company\u2019s internal control over financial reporting based on our audit.", "We are a public accounting firm registered with the PCAOB and are required  to  be  independent  with  respect  to  the  Company  in  accordance  with  the  U.S.  federal  securities  laws  and  the  applicable  rules  and  regulations  of  the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "We will file the 2021 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.", "Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.", "of our reports dated November 19, 2020, with respect to the consolidated financial statements and schedule of AmerisourceBergen Corporation and subsidiaries and the effectiveness of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries included in this Annual Report (Form 10-K) of AmerisourceBergen Corporation and subsidiaries for the year ended September 30, 2020.", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Yes \u00fe No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.", "While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays.", "A number of patents for widely used brand-name pharmaceutical products will continue to expire during the", "In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that", "increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs.", "Subsequent legislation and rules promulgated by government agencies have made additional changes to federal drug payment policies.", "These  policies  and  other  legislative  developments  (including  potential  revisions  to  or  repeal  of  any  portions  of  the  health  reform  legislation)  may  affect  our businesses directly and/or indirectly (see Government Regulation on page 6 and the risk factor titled Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates on page 12 for further details).", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and  cash  flows.  These  items  include,  but  are  not  limited  to,  the  financial  condition  of  our  customers  and  the  realization  of  accounts  receivable,  decreased availability and demand for our products and services, and delays related to current and future projects.", "While our operational and financial performance may be significantly impacted by COVID-19, it is not possible for us to predict the duration or magnitude of the outbreak and whether it could have a material adverse impact on the Company's financial position, results of operations, or cash flows (see Risk Factor - We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business).", "Our provider solutions include: our Good Neighbor Pharmacy\u00ae program, which enables independent community pharmacies to compete more effectively through  pharmaceutical  benefit  and  merchandising  programs;  Elevate  Provider  Network\u00ae,  our  managed  care  network,  which  connects  our  retail pharmacy customers to payor plans throughout the country and is one of the largest in the United States; generic product purchasing and private label services;  hospital  pharmacy  consulting  designed  to  improve  operational  efficiencies;  and  packaging  solutions  for  institutional  and  retail  healthcare providers.", "We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs.", "We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies.", "If those contracts are not renewed or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.", "We seek patent protection for our proprietary intellectual property from time to time as appropriate.", "third parties may assert infringement claims against us from time to time.", "The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.", "There can be no assurance that we are fully compliant with the DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our operations into compliance.", "These and other requirements will continue to increase the cost of our operations.", "The  regulation  of  public  and  private  health  insurance  and  benefit  programs  can  also  affect  our  business  and  scrutiny  of  the  healthcare  delivery  and reimbursement systems in the United States can be expected to continue at both the state and federal levels.", "In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate certain of our distribution centers, which may have a material adverse effect on our financial condition and results of operations.", "We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.", "We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act.", "requirements could have a significant impact on our results of operations and financial condition.", "that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.", "Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations.", "Our operations, depending on their location, may also be subject  to  state  or  foreign  regulations  affecting  personal  data  protection  and  the  manner  in  which  information  services  or  products  are  provided.  Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws.", "We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.", "Personally identifiable information is also highly regulated in many other countries in which we operate.", "As such regulations continue to evolve, we must comply with applicable privacy and security requirements of these countries, including but not limited to those in the European Union.", "We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with the applicable privacy laws and regulations.", "There can be no assurances that compliance with these requirements will not impose new costs on our business.", "For  more  information  about  us,  visit  our  website  at www.amerisourcebergen.com.  The  contents  of  the  website  are  not  part  of  this  Form  10-K.  Our", "We expect these trends to continue in fiscal 2021, which could have an adverse effect on our results of operations.", "Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products generally use wholesale acquisition cost (\"WAC\") as the reference price.", "We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price.", "If manufacturers change their pricing policies or practices with regard to WAC or if prices charged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our results of operations could be adversely affected.", "we have entered into with brand and generic pharmaceutical manufacturers have a price appreciation component to them.", "As a result, our gross profit from brand- name and generic pharmaceuticals  continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control.", "If the frequency or rate of brand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected.", "If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations will be greater.", "Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.", "Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured.", "Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers.", "The COVID-19 pandemic has increased volatility of the capital and credit markets and has led to a general worsening of economic conditions, which has put financial pressure on many of our customers and may threaten certain customers\u2019 ability to maintain liquidity sufficient to repay their obligations to us as they become due.", "The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on  our  operating  revenue  and  results  of  operations.  As  of  September  30,  2020,  our  two  largest  trade  receivable  balances  due  from  customers  represented approximately 47% and 7% of accounts receivable, net.", "The pharmaceutical products that we purchase are also subject to price inflation and deflation.", "Most of our customers buy pharmaceuticals and other products and services from us on credit.", "Credit is made available to customers based upon our", "Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.", "returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers.", "Volatility of the capital and credit markets, general economic  conditions,  pending  litigation,  and  regulatory  changes  may  adversely  affect  the  solvency  or  creditworthiness  of  our  suppliers.  The  bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.", "Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.", "downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit.", "Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.", "Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings.", "Actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.", "economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability.", "Negative trends in the general economy, including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products.", "Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flow from operations.", "Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced.", "Declining economic conditions may also increase our costs.", "Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.", "We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract.", "A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these  customers  or  GPO  relationships  if  we  are  unable  to  extend,  renew,  renegotiate  or  replace  the  contracts.  The  loss  of  any  significant  customer  or  GPO relationship could adversely affect our revenue, results of operations, and cash flows.", "Additionally, from time to time, significant contracts may be renewed or modified prior to their expiration date in furtherance of our strategic objectives.", "If those contracts are renewed or modified at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.", "Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities.", "WBA accounted for approximately 33% of our revenue in the fiscal year ended September 30, 2020.", "Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the terms under which we extended the duration of the distribution agreement and generics purchasing services agreement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; changes in the economic  terms  under  which  we  distribute  pharmaceuticals  to  WBA,  including  changes  necessitated  by  changing  market  conditions  or  other  unforeseen developments that may arise during the term of the distribution agreement, to the extent that any such changes are not offset by other financial benefits that we are able to obtain through collaboration in other aspects of our strategic relationship with WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the anticipated strategic and financial benefits of the relationship.", "18, 2013 to make certain additional investments in our common stock.", "WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholder Agreement.", "Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock.", "We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration we anticipate pursuing with WBA.", "If we are unable to achieve any of our objectives, the expected future benefits may not be realized fully or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.", "we may have an obligation to pay or credit WBA for failure to supply products.", "We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations.", "At any particular time, we may be in various stages of", "or more acquisitions, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions.", "The impact of a divestiture on our results of operations could also be greater than anticipated.", "Our results of operations and our financial condition may be adversely affected by our global operations.", "Changes or uncertainty in U.S. or foreign policy, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase.", "Any of these factors could adversely affect our business, financial position, and results of operations.", "We are subject to operational and logistical risks that might not be covered by insurance.", "Although we seek to maintain adequate insurance coverage, coverage on acceptable terms might be unavailable, or coverage might not cover our losses or may require large deductibles.", "Uninsured losses or operational losses that result in large deductible payments in order to receive insurance coverage might have an adverse impact on our business operations and our financial position or results of operations.", "Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies.", "There have been increasing efforts by Congress and state", "regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance.", "Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs and could have an adverse impact on our financial position or results of operations.", "Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.", "Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at the federal or state level, could adversely affect our operations. reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute.", "Given the scope of the changes made by the ACA and continuing implementation controversies, we cannot predict the impact of every aspect of the law on our operations.", "Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.", "Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs.", "The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs.", "Any reduction in the Medicaid reimbursement  rates  to  our  customers  may  indirectly  impact  the  prices  that  we  can  charge  our  customers  for  multiple  source  pharmaceuticals  and  cause corresponding declines in our profitability.", "There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business.", "Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.", "There can be no assurance that recent or future rules established by CMS will not have an adverse impact on our business.", "Our customers include covered entities and organizations with significant participation as contract pharmacies, and the unavailability of 340B discounts through contract pharmacy arrangements may adversely affect such customers and, therefore, could adversely affect our business.", "Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers.", "At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have a material adverse effect on our business.", "as Medicare and Medicaid, which may adversely affect our business.", "There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.", "If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.", "continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs.", "Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs.", "Many states have enacted similar statutes which are not necessarily limited to items and services for  which  payment  is  made  by  federal  healthcare  programs.  While  we  believe  that  we  are  in  compliance  with  applicable  laws  and  regulations,  many  of  the regulations applicable to us, including those", "We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse.", "They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations.", "If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal and state healthcare programs.", "Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.", "Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future and lawsuits could be brought against the Company by other plaintiffs under other theories related to opioid abuse.", "We are deeply committed to diversion control efforts, have sophisticated systems in place to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in significant due diligence and ongoing monitoring of customers.", "While we are vigorously defending ourselves in these lawsuits, the allegations may negatively affect our business in various ways, including through increased costs and harm to our reputation.", "We are currently engaged in advanced discussions, which are ongoing, with the objective of reaching potential terms (which would include monetary payments and certain changes to our anti-diversion programs) for a global resolution of the multi-district opioid litigation involving certain state and local governmental entities and other related state court litigation described in Note 14 of the Notes to Consolidated Financial Statements.", "We have recorded a charge of $6.6 billion in the fourth quarter of the fiscal year ended September 30, 2020 related to the global settlement and other related opioid litigation.", "Until such time as a plaintiff participates in a global settlement or otherwise resolves its lawsuit, we will continue to litigate and prepare for trial in the cases pending in the multi-district opioid litigation, those remanded from the multi-district opioid litigation to federal district courts, as well as  in  state  courts  where  lawsuits  have  been  filed,  and  we  intend  to  continue  to  vigorously  defend  ourselves  in  all  such  cases.  Since  these  matters  are  still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief, including changes to our anti-diversion programs, that may affect how we operate our business.", "Further, any final settlement amongst parties may differ materially from our advanced  discussions  related  to  global  resolution  of  the  multi-district  opioid  litigation.  The  inability  to  reach  a  global  settlement  of  the  multi-district  opioid litigation and adverse resolution of any of these lawsuits or investigations could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders.", "If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company's results of operations, cash flows, or financial condition.", "Our business, results of operations, and cash flows could be adversely affected by legal proceedings.", "Each of our businesses may cause us to become involved in legal disputes or proceedings.", "The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations  and  financial  condition.  Violations  of  various  federal  and  state  laws,  including  with  respect  to  the  marketing,  sale,  purchase,  and  dispensing  of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs.", "Any settlement, judgment or fine could materially adversely affect our results of operations.", "Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations  and damages arising from resultant  false  claims,  if the litigation  proceeds whether or not government  authorities  decide  to intervene  in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.", "In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement with the Office of Inspector General of the U.S.", "Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.", "Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.", "There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives.", "We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent.", "In addition, U.S. federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations.  There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.", "Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the 2017 Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties  regarding  the  geographic  mix  of  earnings  in  any  particular  period,  and  other  factors,  material  adjustments  to  our  tax  estimates  may  impact  our provision for income taxes and our earnings per share, as well as our cash flows, in the period in which any such adjustments would be made.", "Further, we cannot predict the impact of any efforts to change or repeal the 2017 Tax Act or enact alternative legislation by the incoming presidential administration or the next Congress.", "Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market.", "The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls.", "If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses.", "From time to time, we may face audits or investigations by one or", "As such, we are subject to tax laws and regulations of the U.S.", "The qui tam provisions of the federal and various state civil False", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.", "We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations.", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties.", "That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.", "Any extended disruption in our ability to service our customers could have a material adverse effect on our revenue, results of operations, and cash flows.", "An economic slowdown or recession related to COVID-19 may affect our customers' ability to obtain credit to finance their business on acceptable terms, which could result in reduced spending on our products and services.", "For example, the continued spread of COVID-19 has led to disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets.", "Certain of our employees have contracted COVID-19 which", "Since April 2020, COVID-19 has adversely  impacted  and may continue  to adversely  impact  our revenue,  results of operations,  and cash flows.", "Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.", "In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.", "Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value.", "goodwill, indefinite-lived intangible assets, or long-lived assets is determined.", "Any such charge could have a material adverse impact on our results of operations.", "Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.", "U.S. generally accepted accounting principles (\"GAAP\") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual", "The Company anticipates that it will continue to pay quarterly cash dividends in the future.", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and cash flows (refer to our COVID-19 risk factor in Item 1A.", "\u2022 Distribution, selling, and administrative expenses increased 3.9% from the prior fiscal year primarily due to an increase in operating costs to support our revenue growth;", "We are currently in advanced discussions, which are ongoing, with the states and various plaintiffs\u2019 representatives that would be necessary to reach a global settlement of the Multidistrict Litigation (\"MDL\") and other related state-court litigation brought by certain state and local governmental entities to be paid over 18 years in which our payment would be $6.5 billion assuming all parties participate.", "While a global settlement remains subject to contingencies that could impact  whether  the  parties  ultimately  decide  to  move  forward,  we  believe  a  global  settlement  is  probable  and  our  loss  related  thereto  can  be reasonably estimated as of September 30, 2020;", "\u2022 Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2020 was higher than the U.S. statutory rate due to our operating loss, the tax benefits associated with our decision to permanently exit the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.  Our  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of PharMEDium's assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international  income.  The  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  also  impacted  by  a  $37.0  million  decrease  to  the Company's transition tax related to the U.S.", "If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "Changes to any of the above factors may have a material impact to our annual LIFO provision.", "In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018.", "District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018.", "In September 2020, the United States Court of Appeals for the Second Circuit reversed the District Court\u2019s decision, and, as a result, we accrued $14.8 million in the fourth quarter of the fiscal year ended September 30, 2020 as we revised our estimated liability for the 2017 and 2018 calendar years.", "Gross profit in the current fiscal year was favorably impacted by increases in", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $9.1 million and $145.9 million during the fiscal years", "Consolidated Financial Statements) and $115.4 million of litigation costs that related to legal fees in connection with opioid lawsuits and investigations, $34.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, $38.0 million related to our business transformation efforts, and $12.6 million of acquisition-related deal and integration costs and other restructuring initiatives.", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "Prior to October 1, 2019, we recognized interest expense associated with financing obligations in connection with lease construction assets (see Note 1 of the Notes to Consolidated Financial Statements).", "Upon adoption of the new lease standard as of October 1, 2019, we began recognizing  rent  expense  related  to  these  leases  in  Distribution,  Selling,  and  Administrative  expenses  in  our  Consolidated  Statements  of  Operations.  Interest income was lower in the current fiscal year as a result of a decline in investment interest rates, which was offset in part by a $1.0 billion increase in average invested cash balances compared to the prior fiscal year.", "borrowing facilities, and strategic decisions to deploy our invested cash.", "Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September  30,  2020  was  higher  than  the  U.S.  statutory  rate  due  to  our  operating  loss,  the  tax  benefits  associated  with  our  decision  to  permanently  exit  the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.", "Our effective tax rate in the fiscal year ended September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of  PharMEDium's  assets  (see  Note  1  of  the  Notes  to  Consolidated  Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $145.9 million and $35.9 million during the fiscal years", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D.", "We  recorded  a  $570.0  million  impairment  of  PharMEDium's  long-lived  assets  in  the  fiscal  year  ended  September  30,  2019  (see  Note  1  of  the  Notes  to Consolidated Financial Statements).", "increase in operating expenses.     We recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the fiscal year ended September 30, 2019.", "We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in the fiscal year September 30, 2018 in connection with our", "We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the fiscal year ended", "to an increase in interest income due to a $752 million increase in our average invested cash balance during the fiscal year ended September 30, 2019 and an increase in investment interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D.", "specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019.", "Our effective tax rates were 11.7% and (37.2)% in the fiscal years ended September 30, 2019 and 2018, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2019 was primarily impacted by the $570.0 million impairment of PharMEDium assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "The effective tax rate in the fiscal year ended September 30, 2019 was  also  impacted  by  a  $37.0  million  decrease  to  the  Company's  transition  tax  related  to  the  2017  Tax  Act.  Our  effective  tax  rate  in  the  fiscal  year  ended September 30, 2018 was primarily impacted by the effect of 2017 Tax Act.", "Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act.", "Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018.", "Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were also favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.", "Actual results may differ from these estimates due to uncertainties inherent in such estimates.", "Below are those policies applied in preparing our financial statements that management believes are the most dependent upon the application of estimates and assumptions.", "Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit.", "trends, and our customers' financial strength, credit standing, payment and default history, and macroeconomic conditions.", "Changes in the aforementioned factors, among others, may lead to adjustments in our allowance for doubtful accounts.", "The calculation of the required allowance requires judgment by our management as to the impact of these and other factors on the ultimate realization of our trade receivables.", "For the fiscal year ended September 30, 2018, we recorded a $42.3 million loss in connection with the January 2018 consolidations of Profarma and the", "We write off balances against the reserves when collectability is deemed remote.", "The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments.", "We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed.  Such  valuations  require  management  to  make  significant  judgments,  estimates,  and  assumptions,  especially  with  respect  to  intangible  assets.", "Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.", "For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite- lived intangible assets, respectively.", "If we conclude based on our qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative analysis.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2020, with the exception of our testing of goodwill and indefinite-lived intangibles in the MWI and the Profarma reporting units.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of our testing  in  the  Profarma  reporting  unit.  In  the  fourth  quarter  of  fiscal  2018,  we  elected  to  bypass  performing  the  qualitative  assessment  and  went  directly  to performing our annual quantitative assessments of goodwill and indefinite-lived intangible assets.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium.", "Schedule II of this Form 10-K sets forth a rollforward of allowances for returns and doubtful accounts.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction.", "The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan.", "While we use  the  best  available  information  to  prepare  our  cash  flows  and  discount  rate  assumptions,  actual  future  cash  flows  and/or  market  conditions  could  differ significantly resulting in future impairment charges related to recorded goodwill balances.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "We estimate the fair value of our indefinite- lived intangibles using the relief from royalty method.", "We believe the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "We recorded a goodwill impairment of $59.7 million in our Profarma reporting unit in connection with our fiscal 2018 annual  impairment  test.  No  goodwill  impairments  were  recorded  in  the  fiscal  years  ended  September  30,  2020  and  2019.  No  indefinite-lived  intangible impairments were recorded in the fiscal years ended September 30, 2020, 2019, and 2018.", "we performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value.", "We believed that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represents a Level 3 nonrecurring fair value measurement.", "We allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.", "regulatory matters, ongoing operational challenges, and lower-than-expected operating results, we updated our recoverability assessment of PharMEDium\u2019s long- lived assets as of December 31, 2019.", "Using forecasted undiscounted cash flows that were based on the weighted average of multiple strategic alternatives, we concluded that the carrying value of the PharMEDium long-lived asset group was not recoverable as of December 31, 2019.", "The forecasted undiscounted cash flows as of December 31, 2019 were lower than the forecasted undiscounted cash flows as of September 30, 2019 due to a change in weighting of multiple strategic alternatives and lower  operating  results  in  the  three  months  ended  December  31,  2019  compared  to  expectations.  We  then  performed  an  impairment  test  by  comparing  the PharMEDium asset group's fair value of $145 million to its carrying value, which resulted in a $138.0 million impairment loss in the three months ended December 31, 2019.", "We perform a recoverability assessment of our long-lived assets when impairment indicators are present.", "that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represented a Level 3 nonrecurring fair value measurement.", "We allocated $123.2 million of the impairment to finite-lived intangibles, $11.6 million of the impairment to property and equipment, and $3.2 million to ROU assets.", "After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.", "In the normal course of business, our tax returns are subject to examination by various taxing authorities.", "Such examinations may result in future tax and interest assessments by these taxing authorities.", "Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations.", "We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.", "If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $52.9 million in the fiscal year ended September 30, 2020.", "respectively,  has  been  determined  using  the  LIFO  method.  If  we  had  used  the  first-in,  first-out  method  of  inventory  valuation,  which  approximates  current replacement cost, inventories would have been approximately $1,519.2 million and $1,511.8 million higher than the amounts reported as of September 30, 2020 and 2019, respectively.", "We recorded LIFO expenses of $7.4 million and $67.3 million in the fiscal years ended September 30, 2020 and 2018, respectively.", "We recorded a LIFO credit of $22.5 million in the fiscal year ended September 30, 2019.", "Changes to any of the above factors can have a material impact to our annual LIFO provision.", "We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain.", "The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year.", "We record a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency and whether a reasonable estimate of the loss or the range of the loss can made in the footnotes to our financial statements.", "We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made.", "Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 14 of the Notes to Consolidated Financial Statements.", "provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock.", "purchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities.", "Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that are expected to be made over 18 years (see below).", "distribution of prescription opioid pain medications, we recorded a $6.6 billion ($5.5 billion, net of an income tax benefit) charge.", "We are in advanced discussions, which are ongoing, to reach a global settlement of the MDL and related state-court litigation brought by certain state and local governmental entities in which our payment would be over 18 years to resolve cases currently filed and that could be filed by states, counties, municipalities, and other government entities.", "aforementioned litigation accrual has not and is not expected to have an impact on our compliance with our debt covenants or our ability to pay dividends.", "We have the ability to repatriate the majority of our cash and cash equivalents held by our foreign subsidiaries without incurring significant additional taxes upon repatriation.", "require the use of our credit facilities to fund short-term capital needs.", "Our cash balance in the fiscal years ended September 30, 2020 and 2019 needed to be supplemented  by  intra-period  credit  facility  borrowings  to  cover  short-term  working  capital  needs.  The  largest  amount  of  intra-period  borrowings  under  our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 2020 and 2019 was $39.6 million and $240.6 million, respectively.", "We had $117.4 million, $606.0 million, and $25,115.3 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2020, 2019, and 2018, respectively.", "We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D.", "Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon our debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2020) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable.", "We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based upon our debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2020).", "We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time.", "The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of September 30, 2020.", "The maturities on the notes will vary, but may not  exceed  365  days  from  the  date  of  issuance.  The  notes  will  bear  interest,  if  interest  bearing,  or  will  be  sold  at  a  discount  from  their  face  amounts.  The commercial  paper  program  does  not  increase  our  borrowing  capacity  as  it  is  fully  backed  by  our  Multi-Currency  Revolving  Credit  Facility.  There  were  no borrowings outstanding under our commercial paper program as of September 30, 2020 and 2019.", "have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters.", "Interest rates are based upon prevailing market rates for short-term commercial paper or  LIBOR  plus  a  program  fee.  We  pay  a  customary  unused  fee  at  prevailing  market  rates,  annually,  to  maintain  the  availability  under  the  Receivables Securitization Facility.", "The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "As of September 30, 2020 and 2019, our cash and cash equivalents held by foreign subsidiaries were $675.9 million and $826.8 million, respectively, and", "We used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a", "We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion", "In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.", "We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources.", "Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice.", "The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "During the fiscal year ended September 30, 2018, we purchased $663.1 million of our common stock under this program, which included $24.0 million of September 2018 purchases that cash settled in October 2018.", "During the fiscal year ended September 30, 2019, we purchased $125.8  million  of  our  common  stock  under  this  program,  which  excluded  $24.0  million  of  September  2018  purchases  that  cash  settled  in  October  2018,  to complete our authorization under this program.", "In October 2018, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions.", "During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019.", "During the fiscal year ended September 30, 2020, we purchased $405.6 million of our common stock, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019.", "As of September 30, 2020, we had $55.5 million of availability remaining under this program.", "In October 2020, we repaid the $400 million October 2018 Term Loan that became due.", "In addition to the 2027 Notes, the 2030 Notes, and the 2047 Notes, we have $500 million of 3.40% senior notes due May 15, 2024, $500 million of 3.25%", "In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion in shares of our common", "The 2017 Tax Act required a one-time transition tax to be recognized on historical foreign earnings and profits.", "We currently estimate that our liability related to the  transition  tax  is  $182.6  million,  net  of  overpayments  and  tax  credits,  as  of  September  30,  2020,  which  is  payable  in  installments  over  a  six-year  period commencing in January 2021.", "As of September 30, 2020, a settlement has not been reached, and, therefore, we applied significant judgment in estimating the ultimate amount of the opioid litigation settlement that would be deductible for U.S. federal and state purposes.", "In estimating the amount that would ultimately be deductible, we considered prior U.S. tax case law, the amount and character of the damages sought in the opioid litigation, the inherent uncertainty related to litigation of this nature and magnitude, and other relevant factors.", "While we believe that our estimate of the uncertain tax position appropriately reflects these considerations, it is reasonably possible that the uncertain tax position recognized as of September 30, 2020 may be revised in future periods as the settlement with the various plaintiffs is finalized.", "The remaining amount of the liability represents an estimate of tax positions that we have taken in our tax returns or expect to take in future tax returns which may ultimately not be sustained upon examination by taxing authorities.", "Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers.", "In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms.", "Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.", "Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations.", "Our  liability  for  uncertain  tax  positions  was  $498.3  million  (including  interest  and  penalties)  as  of  September  30,  2020.  Included  in  this  balance  is", "Our  cash  flows  from  operating  activities  can  vary  significantly  from  period  to  period  based  upon  fluctuations  in  our  period  end  working  capital.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "In the fiscal year ended September 30, 2018, we acquired H.D.", "In addition, we made incremental investments in Brazil totaling $78.1 million.", "and $343.6 million in cash dividends paid on our common stock.", "and $339.0 million in cash dividends paid on our common stock.", "senior notes, $639.2 million in purchases of our common stock, and $333.0 million in cash dividends paid on our common stock, offset in part by the issuance of $750.0 million of 3.45% senior notes and $500 million of 4.3% senior notes.", "discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.", "The amount of variable-rate debt fluctuates during the year based on our working capital requirements.", "We had $0.8 billion of variable-rate debt outstanding as of September 30, 2020.", "We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates.", "However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us.", "The unfavorable impact of a hypothetical decrease in", "We currently  expect  to spend approximately  $400 million  for capital  expenditures  during fiscal 2021.", "Net cash used in financing activities in the fiscal year ended September 30, 2020 principally related to $420.4 million in purchases of our common stock,", "Net cash used in financing activities in the fiscal year ended September 30, 2019 principally related to $674.0 million in purchases of our common stock", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "We have market risk exposure to interest rate fluctuations relating to our debt.", "We manage interest rate risk by using a combination of fixed-rate and", "We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents.", "interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt.", "For every $100 million of cash invested that is in excess of variable-rate debt, a 10-basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.", "Revenue from our foreign operations is approximately two percent of our consolidated revenue.", "We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates.", "We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes.", "We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations.", "Our largest exposure to foreign exchange rates exists", "These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.", "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2020, in conformity with U.S. generally accepted accounting principles.", "Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We  conducted  our  audits  in  accordance  with  the  standards  of  the  PCAOB.  Those  standards  require  that  we  plan  and  perform  the  audit  to  obtain  reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of the opioid litigation liability and related uncertain tax position.", "For example, we inspected management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of the opioid litigation liability and the related financial statement footnote disclosures.", "To  test  the  Company\u2019s  opioid  litigation  liability,  our  substantive  audit  procedures  included,  among  others,  testing  the completeness  of  the  opioid  litigation  contingencies  subject  to  evaluation  by  the  Company  and  evaluating  the  Company\u2019s analysis of its assessment of the probability of outcome by considering the progress of settlement discussions involving the opioid litigation and communications with plaintiffs, as well as the experience of other similar entities when evaluating the Company\u2019s  conclusions.  We  inspected  responses  to  inquiry  letters  sent  to  both  internal  and  external  legal  counsel,  held discussions with internal and external legal counsel to confirm our understanding of the settlement discussions, and obtained written representations from executives of the Company.", "We also compared the Company\u2019s assessment with its relevant history of  similar  legal  contingencies  that  have  been  settled  or  otherwise  resolved  to  evaluate  the  consistency  of  the  Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "In addition, we also evaluated the adequacy of the Company\u2019s financial statement disclosures.", "We involved our tax subject matter professionals  in assessing the technical  merits and measurement  of the Company\u2019s tax position related to the opioid litigation liability.", "We examined the Company\u2019s analysis and evaluated the underlying facts upon which  the  tax  position  was  based.  We  used  our  knowledge  of  historical  settlement  activity  to  evaluate  the  Company\u2019s measurement  of the uncertain tax position associated  with the opioid litigation.  This included evaluating third-party  advice obtained by the Company and performing inquiries of the Company\u2019s external income tax advisers.", "We also evaluated the adequacy  of  the  Company\u2019s  financial  statement  disclosures  and  obtained  written  representations  from  executives  of  the Company related to this income tax matter.", "We have served as the Company's auditor since 1985.", "This included testing controls related to the Company\u2019s process for  identification,  recognition,  measurement  and  disclosure  of  legal  contingencies.  For  example,  we  tested  controls  over management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures.", "We also tested controls over management\u2019s assessment of the likelihood of the resolution of the matters through settlement or litigation.", "To test the Company\u2019s legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company\u2019s analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal and external legal counsel to confirm our understanding of the allegations,  and  obtaining  written  representations  from  executives  of  the  Company.  We  also  compared  the  Company\u2019s assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, and for those legal contingencies for which the Company has determined that a loss is either probable or reasonably possible, but the Company is unable to estimate the range of loss, and is therefore required to be disclosed, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies.", "We assessed the Company\u2019s  estimate  of  the  amount  of  the  loss,  for  both  contingencies  that  are  probable  and  reasonably  possible,  through inspection of responses to inquiry letters sent to both internal and external legal counsel, direct discussions with internal and external  legal  counsel,  inspection  of  court  rulings,  and  inspection  of  settlement  agreements.  We  also  obtained  written representations from executives of the Company.", "All intercompany accounts and transactions have been eliminated in consolidation.", "ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.", "performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.", "The Company did not elect the hindsight practical expedient in determining the lease term.", "The adoption of ASC 842 did not and will not have a material impact on the Company's results of operations or cash flows.", "An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances.", "The Company does not expect the adoption of this new accounting guidance to have a material impact on its financial position, results of operations, or cash flows.", "ASU 2019-12 removes certain exceptions to the general principles in ASC 740 in order to reduce the cost and complexity of its application.", "The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.", "The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "The Company's trade accounts receivables are exposed to credit risk.", "Deposits held with banks may exceed the amount of insurance", "Gain Contingencies: The Company records gain contingencies when they are realized.", "Gains from antitrust litigation settlements are realized upon the", "If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method.", "The Company believes the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "recoverability assessment of its long-lived assets when impairment indicators are present.", "This represents a Level 3 nonrecurring fair value measurement.", "This represented a Level 3 nonrecurring fair value measurement.", "Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.", "Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.", "contains a lease based on the facts and circumstances present.", "The Company does not recognize on the balance sheet leases with terms of one year or less.", "The Company's leases do not contain residual value guarantees.", "further obligation to provide services related to such products.", "Service revenue is recognized over the period that services are provided to the customer.", "The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company\u2019s common stock.", "Share-based  compensation  expense  is  recognized  over  the  requisite  service  period  within  Distribution,  Selling,  and  Administrative  in  the  Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees.", "Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.", "The ultimate outcome of any outstanding claim may be different than the Company's estimate.", "The purchase price exceeded the fair value of the net tangible and intangible assets acquired by", "The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively.", "Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.", "The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "These represent Level 2 nonrecurring fair value measurements.", "The Company is not obligated to provide future financial support to Profarma.", "A  reconciliation  of  the  statutory  U.S.  federal  income  tax  rate  to  the  Company's  consolidated  effective  income  tax  rate  is  as  follows  for  the  periods", "The estimated tax benefit is higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction can now be carried back to years with higher statutory tax rates.", "resulting from the recognition of the above discrete tax benefits.", "A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income.", "To phase in the tax rate increase, the canton of Bern has granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years.", "It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.", "During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $13.9 million.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to have an impact on the Company's compliance with its debt covenants.", "The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility.", "Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "An additional covenant requires compliance with a financial leverage ratio test.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to impact the Company's ability to pay dividends.", "employees at a price not less than the fair market value of the common stock on the date the option is granted.", "This unfunded plan, under which 2.96 million shares of", "The risk-free rates during the terms of such options are based upon the U.S.", "Performance  stock  units  are  granted  to  certain  executive  employees  under  the  Plan  and  represent  common  stock  potentially  issuable  in  the  future.", "The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "uncertainty  remains  with  regard  to  whether  such  matters  will  proceed  to  trial,  whether  settlements  will  be  reached,  and  the  amount  and  terms  of  any  such settlements.", "If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.", "While a global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move forward, the Company believes a global settlement is probable and its loss related thereto can be reasonably estimated as of September 30, 2020.", "Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events.", "The Company will regularly review these opioid litigation matters to determine whether its accrual is adequate.", "The amount of ultimate loss may differ materially from the $6.6 billion accrual.", "Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations.", "The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.", "The Company cannot predict how these matters would be affected by a global settlement.", "The Company's responses often require time and effort and can result in considerable costs being incurred.", "None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds", "approximate fair value based upon the relatively short-term nature of these financial instruments.", "The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.", "The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.", "AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.", "effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.", "that could have a material effect on the financial statements.", "We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated November 19, 2020 expressed an unqualified opinion thereon.", "Our responsibility is to express an opinion on the Company\u2019s internal control over financial reporting based on our audit.", "We are a public accounting firm registered with the PCAOB and are required  to  be  independent  with  respect  to  the  Company  in  accordance  with  the  U.S.  federal  securities  laws  and  the  applicable  rules  and  regulations  of  the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "We will file the 2021 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.", "Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.", "of our reports dated November 19, 2020, with respect to the consolidated financial statements and schedule of AmerisourceBergen Corporation and subsidiaries and the effectiveness of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries included in this Annual Report (Form 10-K) of AmerisourceBergen Corporation and subsidiaries for the year ended September 30, 2020.", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Yes \u00fe No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.", "While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays.", "A number of patents for widely used brand-name pharmaceutical products will continue to expire during the", "In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that", "increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs.", "Subsequent legislation and rules promulgated by government agencies have made additional changes to federal drug payment policies.", "These  policies  and  other  legislative  developments  (including  potential  revisions  to  or  repeal  of  any  portions  of  the  health  reform  legislation)  may  affect  our businesses directly and/or indirectly (see Government Regulation on page 6 and the risk factor titled Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates on page 12 for further details).", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and  cash  flows.  These  items  include,  but  are  not  limited  to,  the  financial  condition  of  our  customers  and  the  realization  of  accounts  receivable,  decreased availability and demand for our products and services, and delays related to current and future projects.", "While our operational and financial performance may be significantly impacted by COVID-19, it is not possible for us to predict the duration or magnitude of the outbreak and whether it could have a material adverse impact on the Company's financial position, results of operations, or cash flows (see Risk Factor - We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business).", "Our provider solutions include: our Good Neighbor Pharmacy\u00ae program, which enables independent community pharmacies to compete more effectively through  pharmaceutical  benefit  and  merchandising  programs;  Elevate  Provider  Network\u00ae,  our  managed  care  network,  which  connects  our  retail pharmacy customers to payor plans throughout the country and is one of the largest in the United States; generic product purchasing and private label services;  hospital  pharmacy  consulting  designed  to  improve  operational  efficiencies;  and  packaging  solutions  for  institutional  and  retail  healthcare providers.", "We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs.", "We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies.", "If those contracts are not renewed or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.", "We seek patent protection for our proprietary intellectual property from time to time as appropriate.", "third parties may assert infringement claims against us from time to time.", "The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.", "There can be no assurance that we are fully compliant with the DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our operations into compliance.", "These and other requirements will continue to increase the cost of our operations.", "The  regulation  of  public  and  private  health  insurance  and  benefit  programs  can  also  affect  our  business  and  scrutiny  of  the  healthcare  delivery  and reimbursement systems in the United States can be expected to continue at both the state and federal levels.", "In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate certain of our distribution centers, which may have a material adverse effect on our financial condition and results of operations.", "We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.", "We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act.", "requirements could have a significant impact on our results of operations and financial condition.", "that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.", "Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations.", "Our operations, depending on their location, may also be subject  to  state  or  foreign  regulations  affecting  personal  data  protection  and  the  manner  in  which  information  services  or  products  are  provided.  Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws.", "We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.", "Personally identifiable information is also highly regulated in many other countries in which we operate.", "As such regulations continue to evolve, we must comply with applicable privacy and security requirements of these countries, including but not limited to those in the European Union.", "We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with the applicable privacy laws and regulations.", "There can be no assurances that compliance with these requirements will not impose new costs on our business.", "For  more  information  about  us,  visit  our  website  at www.amerisourcebergen.com.  The  contents  of  the  website  are  not  part  of  this  Form  10-K.  Our", "We expect these trends to continue in fiscal 2021, which could have an adverse effect on our results of operations.", "Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products generally use wholesale acquisition cost (\"WAC\") as the reference price.", "We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price.", "If manufacturers change their pricing policies or practices with regard to WAC or if prices charged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our results of operations could be adversely affected.", "we have entered into with brand and generic pharmaceutical manufacturers have a price appreciation component to them.", "As a result, our gross profit from brand- name and generic pharmaceuticals  continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control.", "If the frequency or rate of brand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected.", "If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations will be greater.", "Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.", "Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured.", "Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers.", "The COVID-19 pandemic has increased volatility of the capital and credit markets and has led to a general worsening of economic conditions, which has put financial pressure on many of our customers and may threaten certain customers\u2019 ability to maintain liquidity sufficient to repay their obligations to us as they become due.", "The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on  our  operating  revenue  and  results  of  operations.  As  of  September  30,  2020,  our  two  largest  trade  receivable  balances  due  from  customers  represented approximately 47% and 7% of accounts receivable, net.", "The pharmaceutical products that we purchase are also subject to price inflation and deflation.", "Most of our customers buy pharmaceuticals and other products and services from us on credit.", "Credit is made available to customers based upon our", "Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.", "returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers.", "Volatility of the capital and credit markets, general economic  conditions,  pending  litigation,  and  regulatory  changes  may  adversely  affect  the  solvency  or  creditworthiness  of  our  suppliers.  The  bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.", "Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.", "downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit.", "Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.", "Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings.", "Actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.", "economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability.", "Negative trends in the general economy, including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products.", "Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flow from operations.", "Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced.", "Declining economic conditions may also increase our costs.", "Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.", "We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract.", "A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these  customers  or  GPO  relationships  if  we  are  unable  to  extend,  renew,  renegotiate  or  replace  the  contracts.  The  loss  of  any  significant  customer  or  GPO relationship could adversely affect our revenue, results of operations, and cash flows.", "Additionally, from time to time, significant contracts may be renewed or modified prior to their expiration date in furtherance of our strategic objectives.", "If those contracts are renewed or modified at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.", "Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities.", "WBA accounted for approximately 33% of our revenue in the fiscal year ended September 30, 2020.", "Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the terms under which we extended the duration of the distribution agreement and generics purchasing services agreement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; changes in the economic  terms  under  which  we  distribute  pharmaceuticals  to  WBA,  including  changes  necessitated  by  changing  market  conditions  or  other  unforeseen developments that may arise during the term of the distribution agreement, to the extent that any such changes are not offset by other financial benefits that we are able to obtain through collaboration in other aspects of our strategic relationship with WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the anticipated strategic and financial benefits of the relationship.", "18, 2013 to make certain additional investments in our common stock.", "WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholder Agreement.", "Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock.", "We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration we anticipate pursuing with WBA.", "If we are unable to achieve any of our objectives, the expected future benefits may not be realized fully or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.", "we may have an obligation to pay or credit WBA for failure to supply products.", "We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations.", "At any particular time, we may be in various stages of", "or more acquisitions, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions.", "The impact of a divestiture on our results of operations could also be greater than anticipated.", "Our results of operations and our financial condition may be adversely affected by our global operations.", "Changes or uncertainty in U.S. or foreign policy, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase.", "Any of these factors could adversely affect our business, financial position, and results of operations.", "We are subject to operational and logistical risks that might not be covered by insurance.", "Although we seek to maintain adequate insurance coverage, coverage on acceptable terms might be unavailable, or coverage might not cover our losses or may require large deductibles.", "Uninsured losses or operational losses that result in large deductible payments in order to receive insurance coverage might have an adverse impact on our business operations and our financial position or results of operations.", "Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies.", "There have been increasing efforts by Congress and state", "regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance.", "Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs and could have an adverse impact on our financial position or results of operations.", "Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.", "Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at the federal or state level, could adversely affect our operations. reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute.", "Given the scope of the changes made by the ACA and continuing implementation controversies, we cannot predict the impact of every aspect of the law on our operations.", "Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.", "Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs.", "The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs.", "Any reduction in the Medicaid reimbursement  rates  to  our  customers  may  indirectly  impact  the  prices  that  we  can  charge  our  customers  for  multiple  source  pharmaceuticals  and  cause corresponding declines in our profitability.", "There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business.", "Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.", "There can be no assurance that recent or future rules established by CMS will not have an adverse impact on our business.", "Our customers include covered entities and organizations with significant participation as contract pharmacies, and the unavailability of 340B discounts through contract pharmacy arrangements may adversely affect such customers and, therefore, could adversely affect our business.", "Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers.", "At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have a material adverse effect on our business.", "as Medicare and Medicaid, which may adversely affect our business.", "There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.", "If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.", "continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs.", "Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs.", "Many states have enacted similar statutes which are not necessarily limited to items and services for  which  payment  is  made  by  federal  healthcare  programs.  While  we  believe  that  we  are  in  compliance  with  applicable  laws  and  regulations,  many  of  the regulations applicable to us, including those", "We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse.", "They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations.", "If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal and state healthcare programs.", "Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.", "Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future and lawsuits could be brought against the Company by other plaintiffs under other theories related to opioid abuse.", "We are deeply committed to diversion control efforts, have sophisticated systems in place to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in significant due diligence and ongoing monitoring of customers.", "While we are vigorously defending ourselves in these lawsuits, the allegations may negatively affect our business in various ways, including through increased costs and harm to our reputation.", "We are currently engaged in advanced discussions, which are ongoing, with the objective of reaching potential terms (which would include monetary payments and certain changes to our anti-diversion programs) for a global resolution of the multi-district opioid litigation involving certain state and local governmental entities and other related state court litigation described in Note 14 of the Notes to Consolidated Financial Statements.", "We have recorded a charge of $6.6 billion in the fourth quarter of the fiscal year ended September 30, 2020 related to the global settlement and other related opioid litigation.", "Until such time as a plaintiff participates in a global settlement or otherwise resolves its lawsuit, we will continue to litigate and prepare for trial in the cases pending in the multi-district opioid litigation, those remanded from the multi-district opioid litigation to federal district courts, as well as  in  state  courts  where  lawsuits  have  been  filed,  and  we  intend  to  continue  to  vigorously  defend  ourselves  in  all  such  cases.  Since  these  matters  are  still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief, including changes to our anti-diversion programs, that may affect how we operate our business.", "Further, any final settlement amongst parties may differ materially from our advanced  discussions  related  to  global  resolution  of  the  multi-district  opioid  litigation.  The  inability  to  reach  a  global  settlement  of  the  multi-district  opioid litigation and adverse resolution of any of these lawsuits or investigations could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders.", "If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company's results of operations, cash flows, or financial condition.", "Our business, results of operations, and cash flows could be adversely affected by legal proceedings.", "Each of our businesses may cause us to become involved in legal disputes or proceedings.", "The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations  and  financial  condition.  Violations  of  various  federal  and  state  laws,  including  with  respect  to  the  marketing,  sale,  purchase,  and  dispensing  of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs.", "Any settlement, judgment or fine could materially adversely affect our results of operations.", "Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations  and damages arising from resultant  false  claims,  if the litigation  proceeds whether or not government  authorities  decide  to intervene  in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.", "In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement with the Office of Inspector General of the U.S.", "Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.", "Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.", "There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives.", "We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent.", "In addition, U.S. federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations.  There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.", "Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the 2017 Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties  regarding  the  geographic  mix  of  earnings  in  any  particular  period,  and  other  factors,  material  adjustments  to  our  tax  estimates  may  impact  our provision for income taxes and our earnings per share, as well as our cash flows, in the period in which any such adjustments would be made.", "Further, we cannot predict the impact of any efforts to change or repeal the 2017 Tax Act or enact alternative legislation by the incoming presidential administration or the next Congress.", "Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market.", "The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls.", "If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses.", "From time to time, we may face audits or investigations by one or", "As such, we are subject to tax laws and regulations of the U.S.", "The qui tam provisions of the federal and various state civil False", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.", "We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations.", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties.", "That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.", "Any extended disruption in our ability to service our customers could have a material adverse effect on our revenue, results of operations, and cash flows.", "An economic slowdown or recession related to COVID-19 may affect our customers' ability to obtain credit to finance their business on acceptable terms, which could result in reduced spending on our products and services.", "For example, the continued spread of COVID-19 has led to disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets.", "Certain of our employees have contracted COVID-19 which", "Since April 2020, COVID-19 has adversely  impacted  and may continue  to adversely  impact  our revenue,  results of operations,  and cash flows.", "Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.", "In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.", "Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value.", "goodwill, indefinite-lived intangible assets, or long-lived assets is determined.", "Any such charge could have a material adverse impact on our results of operations.", "Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.", "U.S. generally accepted accounting principles (\"GAAP\") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual", "The Company anticipates that it will continue to pay quarterly cash dividends in the future.", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and cash flows (refer to our COVID-19 risk factor in Item 1A.", "\u2022 Distribution, selling, and administrative expenses increased 3.9% from the prior fiscal year primarily due to an increase in operating costs to support our revenue growth;", "We are currently in advanced discussions, which are ongoing, with the states and various plaintiffs\u2019 representatives that would be necessary to reach a global settlement of the Multidistrict Litigation (\"MDL\") and other related state-court litigation brought by certain state and local governmental entities to be paid over 18 years in which our payment would be $6.5 billion assuming all parties participate.", "While a global settlement remains subject to contingencies that could impact  whether  the  parties  ultimately  decide  to  move  forward,  we  believe  a  global  settlement  is  probable  and  our  loss  related  thereto  can  be reasonably estimated as of September 30, 2020;", "\u2022 Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2020 was higher than the U.S. statutory rate due to our operating loss, the tax benefits associated with our decision to permanently exit the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.  Our  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of PharMEDium's assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international  income.  The  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  also  impacted  by  a  $37.0  million  decrease  to  the Company's transition tax related to the U.S.", "If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "Changes to any of the above factors may have a material impact to our annual LIFO provision.", "In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018.", "District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018.", "In September 2020, the United States Court of Appeals for the Second Circuit reversed the District Court\u2019s decision, and, as a result, we accrued $14.8 million in the fourth quarter of the fiscal year ended September 30, 2020 as we revised our estimated liability for the 2017 and 2018 calendar years.", "Gross profit in the current fiscal year was favorably impacted by increases in", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $9.1 million and $145.9 million during the fiscal years", "Consolidated Financial Statements) and $115.4 million of litigation costs that related to legal fees in connection with opioid lawsuits and investigations, $34.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, $38.0 million related to our business transformation efforts, and $12.6 million of acquisition-related deal and integration costs and other restructuring initiatives.", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "Prior to October 1, 2019, we recognized interest expense associated with financing obligations in connection with lease construction assets (see Note 1 of the Notes to Consolidated Financial Statements).", "Upon adoption of the new lease standard as of October 1, 2019, we began recognizing  rent  expense  related  to  these  leases  in  Distribution,  Selling,  and  Administrative  expenses  in  our  Consolidated  Statements  of  Operations.  Interest income was lower in the current fiscal year as a result of a decline in investment interest rates, which was offset in part by a $1.0 billion increase in average invested cash balances compared to the prior fiscal year.", "borrowing facilities, and strategic decisions to deploy our invested cash.", "Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September  30,  2020  was  higher  than  the  U.S.  statutory  rate  due  to  our  operating  loss,  the  tax  benefits  associated  with  our  decision  to  permanently  exit  the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.", "Our effective tax rate in the fiscal year ended September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of  PharMEDium's  assets  (see  Note  1  of  the  Notes  to  Consolidated  Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $145.9 million and $35.9 million during the fiscal years", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D.", "We  recorded  a  $570.0  million  impairment  of  PharMEDium's  long-lived  assets  in  the  fiscal  year  ended  September  30,  2019  (see  Note  1  of  the  Notes  to Consolidated Financial Statements).", "increase in operating expenses.     We recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the fiscal year ended September 30, 2019.", "We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in the fiscal year September 30, 2018 in connection with our", "We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the fiscal year ended", "to an increase in interest income due to a $752 million increase in our average invested cash balance during the fiscal year ended September 30, 2019 and an increase in investment interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D.", "specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019.", "Our effective tax rates were 11.7% and (37.2)% in the fiscal years ended September 30, 2019 and 2018, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2019 was primarily impacted by the $570.0 million impairment of PharMEDium assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "The effective tax rate in the fiscal year ended September 30, 2019 was  also  impacted  by  a  $37.0  million  decrease  to  the  Company's  transition  tax  related  to  the  2017  Tax  Act.  Our  effective  tax  rate  in  the  fiscal  year  ended September 30, 2018 was primarily impacted by the effect of 2017 Tax Act.", "Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act.", "Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018.", "Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were also favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.", "Actual results may differ from these estimates due to uncertainties inherent in such estimates.", "Below are those policies applied in preparing our financial statements that management believes are the most dependent upon the application of estimates and assumptions.", "Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit.", "trends, and our customers' financial strength, credit standing, payment and default history, and macroeconomic conditions.", "Changes in the aforementioned factors, among others, may lead to adjustments in our allowance for doubtful accounts.", "The calculation of the required allowance requires judgment by our management as to the impact of these and other factors on the ultimate realization of our trade receivables.", "For the fiscal year ended September 30, 2018, we recorded a $42.3 million loss in connection with the January 2018 consolidations of Profarma and the", "We write off balances against the reserves when collectability is deemed remote.", "The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments.", "We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed.  Such  valuations  require  management  to  make  significant  judgments,  estimates,  and  assumptions,  especially  with  respect  to  intangible  assets.", "Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.", "For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite- lived intangible assets, respectively.", "If we conclude based on our qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative analysis.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2020, with the exception of our testing of goodwill and indefinite-lived intangibles in the MWI and the Profarma reporting units.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of our testing  in  the  Profarma  reporting  unit.  In  the  fourth  quarter  of  fiscal  2018,  we  elected  to  bypass  performing  the  qualitative  assessment  and  went  directly  to performing our annual quantitative assessments of goodwill and indefinite-lived intangible assets.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium.", "Schedule II of this Form 10-K sets forth a rollforward of allowances for returns and doubtful accounts.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction.", "The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan.", "While we use  the  best  available  information  to  prepare  our  cash  flows  and  discount  rate  assumptions,  actual  future  cash  flows  and/or  market  conditions  could  differ significantly resulting in future impairment charges related to recorded goodwill balances.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "We estimate the fair value of our indefinite- lived intangibles using the relief from royalty method.", "We believe the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "We recorded a goodwill impairment of $59.7 million in our Profarma reporting unit in connection with our fiscal 2018 annual  impairment  test.  No  goodwill  impairments  were  recorded  in  the  fiscal  years  ended  September  30,  2020  and  2019.  No  indefinite-lived  intangible impairments were recorded in the fiscal years ended September 30, 2020, 2019, and 2018.", "we performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value.", "We believed that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represents a Level 3 nonrecurring fair value measurement.", "We allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.", "regulatory matters, ongoing operational challenges, and lower-than-expected operating results, we updated our recoverability assessment of PharMEDium\u2019s long- lived assets as of December 31, 2019.", "Using forecasted undiscounted cash flows that were based on the weighted average of multiple strategic alternatives, we concluded that the carrying value of the PharMEDium long-lived asset group was not recoverable as of December 31, 2019.", "The forecasted undiscounted cash flows as of December 31, 2019 were lower than the forecasted undiscounted cash flows as of September 30, 2019 due to a change in weighting of multiple strategic alternatives and lower  operating  results  in  the  three  months  ended  December  31,  2019  compared  to  expectations.  We  then  performed  an  impairment  test  by  comparing  the PharMEDium asset group's fair value of $145 million to its carrying value, which resulted in a $138.0 million impairment loss in the three months ended December 31, 2019.", "We perform a recoverability assessment of our long-lived assets when impairment indicators are present.", "that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represented a Level 3 nonrecurring fair value measurement.", "We allocated $123.2 million of the impairment to finite-lived intangibles, $11.6 million of the impairment to property and equipment, and $3.2 million to ROU assets.", "After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.", "In the normal course of business, our tax returns are subject to examination by various taxing authorities.", "Such examinations may result in future tax and interest assessments by these taxing authorities.", "Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations.", "We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.", "If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $52.9 million in the fiscal year ended September 30, 2020.", "respectively,  has  been  determined  using  the  LIFO  method.  If  we  had  used  the  first-in,  first-out  method  of  inventory  valuation,  which  approximates  current replacement cost, inventories would have been approximately $1,519.2 million and $1,511.8 million higher than the amounts reported as of September 30, 2020 and 2019, respectively.", "We recorded LIFO expenses of $7.4 million and $67.3 million in the fiscal years ended September 30, 2020 and 2018, respectively.", "We recorded a LIFO credit of $22.5 million in the fiscal year ended September 30, 2019.", "Changes to any of the above factors can have a material impact to our annual LIFO provision.", "We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain.", "The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year.", "We record a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency and whether a reasonable estimate of the loss or the range of the loss can made in the footnotes to our financial statements.", "We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made.", "Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 14 of the Notes to Consolidated Financial Statements.", "provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock.", "purchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities.", "Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that are expected to be made over 18 years (see below).", "distribution of prescription opioid pain medications, we recorded a $6.6 billion ($5.5 billion, net of an income tax benefit) charge.", "We are in advanced discussions, which are ongoing, to reach a global settlement of the MDL and related state-court litigation brought by certain state and local governmental entities in which our payment would be over 18 years to resolve cases currently filed and that could be filed by states, counties, municipalities, and other government entities.", "aforementioned litigation accrual has not and is not expected to have an impact on our compliance with our debt covenants or our ability to pay dividends.", "We have the ability to repatriate the majority of our cash and cash equivalents held by our foreign subsidiaries without incurring significant additional taxes upon repatriation.", "require the use of our credit facilities to fund short-term capital needs.", "Our cash balance in the fiscal years ended September 30, 2020 and 2019 needed to be supplemented  by  intra-period  credit  facility  borrowings  to  cover  short-term  working  capital  needs.  The  largest  amount  of  intra-period  borrowings  under  our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 2020 and 2019 was $39.6 million and $240.6 million, respectively.", "We had $117.4 million, $606.0 million, and $25,115.3 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2020, 2019, and 2018, respectively.", "We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D.", "Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon our debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2020) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable.", "We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based upon our debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2020).", "We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time.", "The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of September 30, 2020.", "The maturities on the notes will vary, but may not  exceed  365  days  from  the  date  of  issuance.  The  notes  will  bear  interest,  if  interest  bearing,  or  will  be  sold  at  a  discount  from  their  face  amounts.  The commercial  paper  program  does  not  increase  our  borrowing  capacity  as  it  is  fully  backed  by  our  Multi-Currency  Revolving  Credit  Facility.  There  were  no borrowings outstanding under our commercial paper program as of September 30, 2020 and 2019.", "have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters.", "Interest rates are based upon prevailing market rates for short-term commercial paper or  LIBOR  plus  a  program  fee.  We  pay  a  customary  unused  fee  at  prevailing  market  rates,  annually,  to  maintain  the  availability  under  the  Receivables Securitization Facility.", "The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "As of September 30, 2020 and 2019, our cash and cash equivalents held by foreign subsidiaries were $675.9 million and $826.8 million, respectively, and", "We used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a", "We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion", "In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.", "We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources.", "Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice.", "The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "During the fiscal year ended September 30, 2018, we purchased $663.1 million of our common stock under this program, which included $24.0 million of September 2018 purchases that cash settled in October 2018.", "During the fiscal year ended September 30, 2019, we purchased $125.8  million  of  our  common  stock  under  this  program,  which  excluded  $24.0  million  of  September  2018  purchases  that  cash  settled  in  October  2018,  to complete our authorization under this program.", "In October 2018, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions.", "During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019.", "During the fiscal year ended September 30, 2020, we purchased $405.6 million of our common stock, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019.", "As of September 30, 2020, we had $55.5 million of availability remaining under this program.", "In October 2020, we repaid the $400 million October 2018 Term Loan that became due.", "In addition to the 2027 Notes, the 2030 Notes, and the 2047 Notes, we have $500 million of 3.40% senior notes due May 15, 2024, $500 million of 3.25%", "In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion in shares of our common", "The 2017 Tax Act required a one-time transition tax to be recognized on historical foreign earnings and profits.", "We currently estimate that our liability related to the  transition  tax  is  $182.6  million,  net  of  overpayments  and  tax  credits,  as  of  September  30,  2020,  which  is  payable  in  installments  over  a  six-year  period commencing in January 2021.", "As of September 30, 2020, a settlement has not been reached, and, therefore, we applied significant judgment in estimating the ultimate amount of the opioid litigation settlement that would be deductible for U.S. federal and state purposes.", "In estimating the amount that would ultimately be deductible, we considered prior U.S. tax case law, the amount and character of the damages sought in the opioid litigation, the inherent uncertainty related to litigation of this nature and magnitude, and other relevant factors.", "While we believe that our estimate of the uncertain tax position appropriately reflects these considerations, it is reasonably possible that the uncertain tax position recognized as of September 30, 2020 may be revised in future periods as the settlement with the various plaintiffs is finalized.", "The remaining amount of the liability represents an estimate of tax positions that we have taken in our tax returns or expect to take in future tax returns which may ultimately not be sustained upon examination by taxing authorities.", "Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers.", "In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms.", "Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.", "Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations.", "Our  liability  for  uncertain  tax  positions  was  $498.3  million  (including  interest  and  penalties)  as  of  September  30,  2020.  Included  in  this  balance  is", "Our  cash  flows  from  operating  activities  can  vary  significantly  from  period  to  period  based  upon  fluctuations  in  our  period  end  working  capital.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "In the fiscal year ended September 30, 2018, we acquired H.D.", "In addition, we made incremental investments in Brazil totaling $78.1 million.", "and $343.6 million in cash dividends paid on our common stock.", "and $339.0 million in cash dividends paid on our common stock.", "senior notes, $639.2 million in purchases of our common stock, and $333.0 million in cash dividends paid on our common stock, offset in part by the issuance of $750.0 million of 3.45% senior notes and $500 million of 4.3% senior notes.", "discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.", "The amount of variable-rate debt fluctuates during the year based on our working capital requirements.", "We had $0.8 billion of variable-rate debt outstanding as of September 30, 2020.", "We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates.", "However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us.", "The unfavorable impact of a hypothetical decrease in", "We currently  expect  to spend approximately  $400 million  for capital  expenditures  during fiscal 2021.", "Net cash used in financing activities in the fiscal year ended September 30, 2020 principally related to $420.4 million in purchases of our common stock,", "Net cash used in financing activities in the fiscal year ended September 30, 2019 principally related to $674.0 million in purchases of our common stock", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "We have market risk exposure to interest rate fluctuations relating to our debt.", "We manage interest rate risk by using a combination of fixed-rate and", "We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents.", "interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt.", "For every $100 million of cash invested that is in excess of variable-rate debt, a 10-basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.", "Revenue from our foreign operations is approximately two percent of our consolidated revenue.", "We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates.", "We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes.", "We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations.", "Our largest exposure to foreign exchange rates exists", "These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.", "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2020, in conformity with U.S. generally accepted accounting principles.", "Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We  conducted  our  audits  in  accordance  with  the  standards  of  the  PCAOB.  Those  standards  require  that  we  plan  and  perform  the  audit  to  obtain  reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of the opioid litigation liability and related uncertain tax position.", "For example, we inspected management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of the opioid litigation liability and the related financial statement footnote disclosures.", "To  test  the  Company\u2019s  opioid  litigation  liability,  our  substantive  audit  procedures  included,  among  others,  testing  the completeness  of  the  opioid  litigation  contingencies  subject  to  evaluation  by  the  Company  and  evaluating  the  Company\u2019s analysis of its assessment of the probability of outcome by considering the progress of settlement discussions involving the opioid litigation and communications with plaintiffs, as well as the experience of other similar entities when evaluating the Company\u2019s  conclusions.  We  inspected  responses  to  inquiry  letters  sent  to  both  internal  and  external  legal  counsel,  held discussions with internal and external legal counsel to confirm our understanding of the settlement discussions, and obtained written representations from executives of the Company.", "We also compared the Company\u2019s assessment with its relevant history of  similar  legal  contingencies  that  have  been  settled  or  otherwise  resolved  to  evaluate  the  consistency  of  the  Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "In addition, we also evaluated the adequacy of the Company\u2019s financial statement disclosures.", "We involved our tax subject matter professionals  in assessing the technical  merits and measurement  of the Company\u2019s tax position related to the opioid litigation liability.", "We examined the Company\u2019s analysis and evaluated the underlying facts upon which  the  tax  position  was  based.  We  used  our  knowledge  of  historical  settlement  activity  to  evaluate  the  Company\u2019s measurement  of the uncertain tax position associated  with the opioid litigation.  This included evaluating third-party  advice obtained by the Company and performing inquiries of the Company\u2019s external income tax advisers.", "We also evaluated the adequacy  of  the  Company\u2019s  financial  statement  disclosures  and  obtained  written  representations  from  executives  of  the Company related to this income tax matter.", "We have served as the Company's auditor since 1985.", "This included testing controls related to the Company\u2019s process for  identification,  recognition,  measurement  and  disclosure  of  legal  contingencies.  For  example,  we  tested  controls  over management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures.", "We also tested controls over management\u2019s assessment of the likelihood of the resolution of the matters through settlement or litigation.", "To test the Company\u2019s legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company\u2019s analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal and external legal counsel to confirm our understanding of the allegations,  and  obtaining  written  representations  from  executives  of  the  Company.  We  also  compared  the  Company\u2019s assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, and for those legal contingencies for which the Company has determined that a loss is either probable or reasonably possible, but the Company is unable to estimate the range of loss, and is therefore required to be disclosed, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies.", "We assessed the Company\u2019s  estimate  of  the  amount  of  the  loss,  for  both  contingencies  that  are  probable  and  reasonably  possible,  through inspection of responses to inquiry letters sent to both internal and external legal counsel, direct discussions with internal and external  legal  counsel,  inspection  of  court  rulings,  and  inspection  of  settlement  agreements.  We  also  obtained  written representations from executives of the Company.", "All intercompany accounts and transactions have been eliminated in consolidation.", "ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.", "performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.", "The Company did not elect the hindsight practical expedient in determining the lease term.", "The adoption of ASC 842 did not and will not have a material impact on the Company's results of operations or cash flows.", "An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances.", "The Company does not expect the adoption of this new accounting guidance to have a material impact on its financial position, results of operations, or cash flows.", "ASU 2019-12 removes certain exceptions to the general principles in ASC 740 in order to reduce the cost and complexity of its application.", "The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.", "The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "The Company's trade accounts receivables are exposed to credit risk.", "Deposits held with banks may exceed the amount of insurance", "Gain Contingencies: The Company records gain contingencies when they are realized.", "Gains from antitrust litigation settlements are realized upon the", "If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method.", "The Company believes the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "recoverability assessment of its long-lived assets when impairment indicators are present.", "This represents a Level 3 nonrecurring fair value measurement.", "This represented a Level 3 nonrecurring fair value measurement.", "Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.", "Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.", "contains a lease based on the facts and circumstances present.", "The Company does not recognize on the balance sheet leases with terms of one year or less.", "The Company's leases do not contain residual value guarantees.", "further obligation to provide services related to such products.", "Service revenue is recognized over the period that services are provided to the customer.", "The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company\u2019s common stock.", "Share-based  compensation  expense  is  recognized  over  the  requisite  service  period  within  Distribution,  Selling,  and  Administrative  in  the  Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees.", "Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.", "The ultimate outcome of any outstanding claim may be different than the Company's estimate.", "The purchase price exceeded the fair value of the net tangible and intangible assets acquired by", "The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively.", "Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.", "The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "These represent Level 2 nonrecurring fair value measurements.", "The Company is not obligated to provide future financial support to Profarma.", "A  reconciliation  of  the  statutory  U.S.  federal  income  tax  rate  to  the  Company's  consolidated  effective  income  tax  rate  is  as  follows  for  the  periods", "The estimated tax benefit is higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction can now be carried back to years with higher statutory tax rates.", "resulting from the recognition of the above discrete tax benefits.", "A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income.", "To phase in the tax rate increase, the canton of Bern has granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years.", "It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.", "During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $13.9 million.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to have an impact on the Company's compliance with its debt covenants.", "The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility.", "Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "An additional covenant requires compliance with a financial leverage ratio test.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to impact the Company's ability to pay dividends.", "employees at a price not less than the fair market value of the common stock on the date the option is granted.", "This unfunded plan, under which 2.96 million shares of", "The risk-free rates during the terms of such options are based upon the U.S.", "Performance  stock  units  are  granted  to  certain  executive  employees  under  the  Plan  and  represent  common  stock  potentially  issuable  in  the  future.", "The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "uncertainty  remains  with  regard  to  whether  such  matters  will  proceed  to  trial,  whether  settlements  will  be  reached,  and  the  amount  and  terms  of  any  such settlements.", "If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.", "While a global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move forward, the Company believes a global settlement is probable and its loss related thereto can be reasonably estimated as of September 30, 2020.", "Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events.", "The Company will regularly review these opioid litigation matters to determine whether its accrual is adequate.", "The amount of ultimate loss may differ materially from the $6.6 billion accrual.", "Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations.", "The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.", "The Company cannot predict how these matters would be affected by a global settlement.", "The Company's responses often require time and effort and can result in considerable costs being incurred.", "None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds", "approximate fair value based upon the relatively short-term nature of these financial instruments.", "The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.", "The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.", "AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.", "effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.", "that could have a material effect on the financial statements.", "We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated November 19, 2020 expressed an unqualified opinion thereon.", "Our responsibility is to express an opinion on the Company\u2019s internal control over financial reporting based on our audit.", "We are a public accounting firm registered with the PCAOB and are required  to  be  independent  with  respect  to  the  Company  in  accordance  with  the  U.S.  federal  securities  laws  and  the  applicable  rules  and  regulations  of  the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "We will file the 2021 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.", "Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.", "of our reports dated November 19, 2020, with respect to the consolidated financial statements and schedule of AmerisourceBergen Corporation and subsidiaries and the effectiveness of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries included in this Annual Report (Form 10-K) of AmerisourceBergen Corporation and subsidiaries for the year ended September 30, 2020.", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Yes \u00fe No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.", "While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays.", "A number of patents for widely used brand-name pharmaceutical products will continue to expire during the", "In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that", "increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs.", "Subsequent legislation and rules promulgated by government agencies have made additional changes to federal drug payment policies.", "These  policies  and  other  legislative  developments  (including  potential  revisions  to  or  repeal  of  any  portions  of  the  health  reform  legislation)  may  affect  our businesses directly and/or indirectly (see Government Regulation on page 6 and the risk factor titled Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates on page 12 for further details).", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and  cash  flows.  These  items  include,  but  are  not  limited  to,  the  financial  condition  of  our  customers  and  the  realization  of  accounts  receivable,  decreased availability and demand for our products and services, and delays related to current and future projects.", "While our operational and financial performance may be significantly impacted by COVID-19, it is not possible for us to predict the duration or magnitude of the outbreak and whether it could have a material adverse impact on the Company's financial position, results of operations, or cash flows (see Risk Factor - We face risks related to health epidemics and pandemics, and the continued spread of COVID-19 is adversely affecting our business).", "Our provider solutions include: our Good Neighbor Pharmacy\u00ae program, which enables independent community pharmacies to compete more effectively through  pharmaceutical  benefit  and  merchandising  programs;  Elevate  Provider  Network\u00ae,  our  managed  care  network,  which  connects  our  retail pharmacy customers to payor plans throughout the country and is one of the largest in the United States; generic product purchasing and private label services;  hospital  pharmacy  consulting  designed  to  improve  operational  efficiencies;  and  packaging  solutions  for  institutional  and  retail  healthcare providers.", "We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs.", "We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies.", "If those contracts are not renewed or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.", "We seek patent protection for our proprietary intellectual property from time to time as appropriate.", "third parties may assert infringement claims against us from time to time.", "The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.", "There can be no assurance that we are fully compliant with the DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our operations into compliance.", "These and other requirements will continue to increase the cost of our operations.", "The  regulation  of  public  and  private  health  insurance  and  benefit  programs  can  also  affect  our  business  and  scrutiny  of  the  healthcare  delivery  and reimbursement systems in the United States can be expected to continue at both the state and federal levels.", "In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate certain of our distribution centers, which may have a material adverse effect on our financial condition and results of operations.", "We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.", "We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act.", "requirements could have a significant impact on our results of operations and financial condition.", "that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.", "Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations.", "Our operations, depending on their location, may also be subject  to  state  or  foreign  regulations  affecting  personal  data  protection  and  the  manner  in  which  information  services  or  products  are  provided.  Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws.", "We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.", "Personally identifiable information is also highly regulated in many other countries in which we operate.", "As such regulations continue to evolve, we must comply with applicable privacy and security requirements of these countries, including but not limited to those in the European Union.", "We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with the applicable privacy laws and regulations.", "There can be no assurances that compliance with these requirements will not impose new costs on our business.", "For  more  information  about  us,  visit  our  website  at www.amerisourcebergen.com.  The  contents  of  the  website  are  not  part  of  this  Form  10-K.  Our", "We expect these trends to continue in fiscal 2021, which could have an adverse effect on our results of operations.", "Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products generally use wholesale acquisition cost (\"WAC\") as the reference price.", "We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price.", "If manufacturers change their pricing policies or practices with regard to WAC or if prices charged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our results of operations could be adversely affected.", "we have entered into with brand and generic pharmaceutical manufacturers have a price appreciation component to them.", "As a result, our gross profit from brand- name and generic pharmaceuticals  continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control.", "If the frequency or rate of brand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected.", "If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations will be greater.", "Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.", "Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured.", "Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers.", "The COVID-19 pandemic has increased volatility of the capital and credit markets and has led to a general worsening of economic conditions, which has put financial pressure on many of our customers and may threaten certain customers\u2019 ability to maintain liquidity sufficient to repay their obligations to us as they become due.", "The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on  our  operating  revenue  and  results  of  operations.  As  of  September  30,  2020,  our  two  largest  trade  receivable  balances  due  from  customers  represented approximately 47% and 7% of accounts receivable, net.", "The pharmaceutical products that we purchase are also subject to price inflation and deflation.", "Most of our customers buy pharmaceuticals and other products and services from us on credit.", "Credit is made available to customers based upon our", "Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.", "returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers.", "Volatility of the capital and credit markets, general economic  conditions,  pending  litigation,  and  regulatory  changes  may  adversely  affect  the  solvency  or  creditworthiness  of  our  suppliers.  The  bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.", "Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.", "downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit.", "Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.", "Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings.", "Actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.", "economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability.", "Negative trends in the general economy, including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products.", "Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flow from operations.", "Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced.", "Declining economic conditions may also increase our costs.", "Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.", "We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract.", "A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these  customers  or  GPO  relationships  if  we  are  unable  to  extend,  renew,  renegotiate  or  replace  the  contracts.  The  loss  of  any  significant  customer  or  GPO relationship could adversely affect our revenue, results of operations, and cash flows.", "Additionally, from time to time, significant contracts may be renewed or modified prior to their expiration date in furtherance of our strategic objectives.", "If those contracts are renewed or modified at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.", "Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities.", "WBA accounted for approximately 33% of our revenue in the fiscal year ended September 30, 2020.", "Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the terms under which we extended the duration of the distribution agreement and generics purchasing services agreement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; changes in the economic  terms  under  which  we  distribute  pharmaceuticals  to  WBA,  including  changes  necessitated  by  changing  market  conditions  or  other  unforeseen developments that may arise during the term of the distribution agreement, to the extent that any such changes are not offset by other financial benefits that we are able to obtain through collaboration in other aspects of our strategic relationship with WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the anticipated strategic and financial benefits of the relationship.", "18, 2013 to make certain additional investments in our common stock.", "WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholder Agreement.", "Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock.", "We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration we anticipate pursuing with WBA.", "If we are unable to achieve any of our objectives, the expected future benefits may not be realized fully or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.", "we may have an obligation to pay or credit WBA for failure to supply products.", "We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations.", "At any particular time, we may be in various stages of", "or more acquisitions, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions.", "The impact of a divestiture on our results of operations could also be greater than anticipated.", "Our results of operations and our financial condition may be adversely affected by our global operations.", "Changes or uncertainty in U.S. or foreign policy, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase.", "Any of these factors could adversely affect our business, financial position, and results of operations.", "We are subject to operational and logistical risks that might not be covered by insurance.", "Although we seek to maintain adequate insurance coverage, coverage on acceptable terms might be unavailable, or coverage might not cover our losses or may require large deductibles.", "Uninsured losses or operational losses that result in large deductible payments in order to receive insurance coverage might have an adverse impact on our business operations and our financial position or results of operations.", "Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies.", "There have been increasing efforts by Congress and state", "regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance.", "Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs and could have an adverse impact on our financial position or results of operations.", "Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.", "Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at the federal or state level, could adversely affect our operations. reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute.", "Given the scope of the changes made by the ACA and continuing implementation controversies, we cannot predict the impact of every aspect of the law on our operations.", "Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.", "Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs.", "The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs.", "Any reduction in the Medicaid reimbursement  rates  to  our  customers  may  indirectly  impact  the  prices  that  we  can  charge  our  customers  for  multiple  source  pharmaceuticals  and  cause corresponding declines in our profitability.", "There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business.", "Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.", "There can be no assurance that recent or future rules established by CMS will not have an adverse impact on our business.", "Our customers include covered entities and organizations with significant participation as contract pharmacies, and the unavailability of 340B discounts through contract pharmacy arrangements may adversely affect such customers and, therefore, could adversely affect our business.", "Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers.", "At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have a material adverse effect on our business.", "as Medicare and Medicaid, which may adversely affect our business.", "There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.", "If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.", "continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs.", "Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs.", "Many states have enacted similar statutes which are not necessarily limited to items and services for  which  payment  is  made  by  federal  healthcare  programs.  While  we  believe  that  we  are  in  compliance  with  applicable  laws  and  regulations,  many  of  the regulations applicable to us, including those", "We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse.", "They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations.", "If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal and state healthcare programs.", "Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.", "Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future and lawsuits could be brought against the Company by other plaintiffs under other theories related to opioid abuse.", "We are deeply committed to diversion control efforts, have sophisticated systems in place to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in significant due diligence and ongoing monitoring of customers.", "While we are vigorously defending ourselves in these lawsuits, the allegations may negatively affect our business in various ways, including through increased costs and harm to our reputation.", "We are currently engaged in advanced discussions, which are ongoing, with the objective of reaching potential terms (which would include monetary payments and certain changes to our anti-diversion programs) for a global resolution of the multi-district opioid litigation involving certain state and local governmental entities and other related state court litigation described in Note 14 of the Notes to Consolidated Financial Statements.", "We have recorded a charge of $6.6 billion in the fourth quarter of the fiscal year ended September 30, 2020 related to the global settlement and other related opioid litigation.", "Until such time as a plaintiff participates in a global settlement or otherwise resolves its lawsuit, we will continue to litigate and prepare for trial in the cases pending in the multi-district opioid litigation, those remanded from the multi-district opioid litigation to federal district courts, as well as  in  state  courts  where  lawsuits  have  been  filed,  and  we  intend  to  continue  to  vigorously  defend  ourselves  in  all  such  cases.  Since  these  matters  are  still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief, including changes to our anti-diversion programs, that may affect how we operate our business.", "Further, any final settlement amongst parties may differ materially from our advanced  discussions  related  to  global  resolution  of  the  multi-district  opioid  litigation.  The  inability  to  reach  a  global  settlement  of  the  multi-district  opioid litigation and adverse resolution of any of these lawsuits or investigations could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders.", "If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company's results of operations, cash flows, or financial condition.", "Our business, results of operations, and cash flows could be adversely affected by legal proceedings.", "Each of our businesses may cause us to become involved in legal disputes or proceedings.", "The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations  and  financial  condition.  Violations  of  various  federal  and  state  laws,  including  with  respect  to  the  marketing,  sale,  purchase,  and  dispensing  of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs.", "Any settlement, judgment or fine could materially adversely affect our results of operations.", "Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations  and damages arising from resultant  false  claims,  if the litigation  proceeds whether or not government  authorities  decide  to intervene  in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.", "In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement with the Office of Inspector General of the U.S.", "Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.", "Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.", "There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives.", "We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent.", "In addition, U.S. federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations.  There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.", "Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the 2017 Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties  regarding  the  geographic  mix  of  earnings  in  any  particular  period,  and  other  factors,  material  adjustments  to  our  tax  estimates  may  impact  our provision for income taxes and our earnings per share, as well as our cash flows, in the period in which any such adjustments would be made.", "Further, we cannot predict the impact of any efforts to change or repeal the 2017 Tax Act or enact alternative legislation by the incoming presidential administration or the next Congress.", "Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market.", "The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls.", "If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses.", "From time to time, we may face audits or investigations by one or", "As such, we are subject to tax laws and regulations of the U.S.", "The qui tam provisions of the federal and various state civil False", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.", "We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations.", "An adverse outcome under any such investigation or audit could subject us to fines or other penalties.", "That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.", "Any extended disruption in our ability to service our customers could have a material adverse effect on our revenue, results of operations, and cash flows.", "An economic slowdown or recession related to COVID-19 may affect our customers' ability to obtain credit to finance their business on acceptable terms, which could result in reduced spending on our products and services.", "For example, the continued spread of COVID-19 has led to disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets.", "Certain of our employees have contracted COVID-19 which", "Since April 2020, COVID-19 has adversely  impacted  and may continue  to adversely  impact  our revenue,  results of operations,  and cash flows.", "Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.", "In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.", "Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value.", "goodwill, indefinite-lived intangible assets, or long-lived assets is determined.", "Any such charge could have a material adverse impact on our results of operations.", "Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.", "U.S. generally accepted accounting principles (\"GAAP\") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual", "The Company anticipates that it will continue to pay quarterly cash dividends in the future.", "We continue to evaluate and plan for the potential effects of a prolonged disruption and the related impacts on our revenue, results of operations, and cash flows (refer to our COVID-19 risk factor in Item 1A.", "\u2022 Distribution, selling, and administrative expenses increased 3.9% from the prior fiscal year primarily due to an increase in operating costs to support our revenue growth;", "We are currently in advanced discussions, which are ongoing, with the states and various plaintiffs\u2019 representatives that would be necessary to reach a global settlement of the Multidistrict Litigation (\"MDL\") and other related state-court litigation brought by certain state and local governmental entities to be paid over 18 years in which our payment would be $6.5 billion assuming all parties participate.", "While a global settlement remains subject to contingencies that could impact  whether  the  parties  ultimately  decide  to  move  forward,  we  believe  a  global  settlement  is  probable  and  our  loss  related  thereto  can  be reasonably estimated as of September 30, 2020;", "\u2022 Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2020 was higher than the U.S. statutory rate due to our operating loss, the tax benefits associated with our decision to permanently exit the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.  Our  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of PharMEDium's assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international  income.  The  effective  tax  rate  in  the  fiscal  year  ended  September  30,  2019  was  also  impacted  by  a  $37.0  million  decrease  to  the Company's transition tax related to the U.S.", "If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.", "Changes to any of the above factors may have a material impact to our annual LIFO provision.", "In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018.", "District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018.", "In September 2020, the United States Court of Appeals for the Second Circuit reversed the District Court\u2019s decision, and, as a result, we accrued $14.8 million in the fourth quarter of the fiscal year ended September 30, 2020 as we revised our estimated liability for the 2017 and 2018 calendar years.", "Gross profit in the current fiscal year was favorably impacted by increases in", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $9.1 million and $145.9 million during the fiscal years", "Consolidated Financial Statements) and $115.4 million of litigation costs that related to legal fees in connection with opioid lawsuits and investigations, $34.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, $38.0 million related to our business transformation efforts, and $12.6 million of acquisition-related deal and integration costs and other restructuring initiatives.", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "Prior to October 1, 2019, we recognized interest expense associated with financing obligations in connection with lease construction assets (see Note 1 of the Notes to Consolidated Financial Statements).", "Upon adoption of the new lease standard as of October 1, 2019, we began recognizing  rent  expense  related  to  these  leases  in  Distribution,  Selling,  and  Administrative  expenses  in  our  Consolidated  Statements  of  Operations.  Interest income was lower in the current fiscal year as a result of a decline in investment interest rates, which was offset in part by a $1.0 billion increase in average invested cash balances compared to the prior fiscal year.", "borrowing facilities, and strategic decisions to deploy our invested cash.", "Our effective tax rates were 35.8% and 11.7% in the fiscal years ended September 30, 2020 and 2019, respectively.", "Our effective tax rate in the fiscal year ended September  30,  2020  was  higher  than  the  U.S.  statutory  rate  due  to  our  operating  loss,  the  tax  benefits  associated  with  our  decision  to  permanently  exit  the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items (see Note 5 of the Notes to Consolidated Financial Statements) and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.", "Our effective tax rate in the fiscal year ended September  30,  2019  was  primarily  impacted  by  the  $570.0  million  impairment  of  PharMEDium's  assets  (see  Note  1  of  the  Notes  to  Consolidated  Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $145.9 million and $35.9 million during the fiscal years", "Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D.", "position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D.", "We  recorded  a  $570.0  million  impairment  of  PharMEDium's  long-lived  assets  in  the  fiscal  year  ended  September  30,  2019  (see  Note  1  of  the  Notes  to Consolidated Financial Statements).", "increase in operating expenses.     We recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the fiscal year ended September 30, 2019.", "We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in the fiscal year September 30, 2018 in connection with our", "We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the fiscal year ended", "to an increase in interest income due to a $752 million increase in our average invested cash balance during the fiscal year ended September 30, 2019 and an increase in investment interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D.", "specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019.", "Our effective tax rates were 11.7% and (37.2)% in the fiscal years ended September 30, 2019 and 2018, respectively.", "Our effective tax rate in the fiscal year ended September 30, 2019 was primarily impacted by the $570.0 million impairment of PharMEDium assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income.", "The effective tax rate in the fiscal year ended September 30, 2019 was  also  impacted  by  a  $37.0  million  decrease  to  the  Company's  transition  tax  related  to  the  2017  Tax  Act.  Our  effective  tax  rate  in  the  fiscal  year  ended September 30, 2018 was primarily impacted by the effect of 2017 Tax Act.", "Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act.", "Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018.", "Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were also favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.", "Actual results may differ from these estimates due to uncertainties inherent in such estimates.", "Below are those policies applied in preparing our financial statements that management believes are the most dependent upon the application of estimates and assumptions.", "Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit.", "trends, and our customers' financial strength, credit standing, payment and default history, and macroeconomic conditions.", "Changes in the aforementioned factors, among others, may lead to adjustments in our allowance for doubtful accounts.", "The calculation of the required allowance requires judgment by our management as to the impact of these and other factors on the ultimate realization of our trade receivables.", "For the fiscal year ended September 30, 2018, we recorded a $42.3 million loss in connection with the January 2018 consolidations of Profarma and the", "We write off balances against the reserves when collectability is deemed remote.", "The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments.", "We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed.  Such  valuations  require  management  to  make  significant  judgments,  estimates,  and  assumptions,  especially  with  respect  to  intangible  assets.", "Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.", "For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite- lived intangible assets, respectively.", "If we conclude based on our qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative analysis.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2020, with the exception of our testing of goodwill and indefinite-lived intangibles in the MWI and the Profarma reporting units.", "We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of our testing  in  the  Profarma  reporting  unit.  In  the  fourth  quarter  of  fiscal  2018,  we  elected  to  bypass  performing  the  qualitative  assessment  and  went  directly  to performing our annual quantitative assessments of goodwill and indefinite-lived intangible assets.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium.", "Schedule II of this Form 10-K sets forth a rollforward of allowances for returns and doubtful accounts.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction.", "The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan.", "While we use  the  best  available  information  to  prepare  our  cash  flows  and  discount  rate  assumptions,  actual  future  cash  flows  and/or  market  conditions  could  differ significantly resulting in future impairment charges related to recorded goodwill balances.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "We estimate the fair value of our indefinite- lived intangibles using the relief from royalty method.", "We believe the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "We recorded a goodwill impairment of $59.7 million in our Profarma reporting unit in connection with our fiscal 2018 annual  impairment  test.  No  goodwill  impairments  were  recorded  in  the  fiscal  years  ended  September  30,  2020  and  2019.  No  indefinite-lived  intangible impairments were recorded in the fiscal years ended September 30, 2020, 2019, and 2018.", "we performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value.", "We believed that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represents a Level 3 nonrecurring fair value measurement.", "We allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.", "regulatory matters, ongoing operational challenges, and lower-than-expected operating results, we updated our recoverability assessment of PharMEDium\u2019s long- lived assets as of December 31, 2019.", "Using forecasted undiscounted cash flows that were based on the weighted average of multiple strategic alternatives, we concluded that the carrying value of the PharMEDium long-lived asset group was not recoverable as of December 31, 2019.", "The forecasted undiscounted cash flows as of December 31, 2019 were lower than the forecasted undiscounted cash flows as of September 30, 2019 due to a change in weighting of multiple strategic alternatives and lower  operating  results  in  the  three  months  ended  December  31,  2019  compared  to  expectations.  We  then  performed  an  impairment  test  by  comparing  the PharMEDium asset group's fair value of $145 million to its carrying value, which resulted in a $138.0 million impairment loss in the three months ended December 31, 2019.", "We perform a recoverability assessment of our long-lived assets when impairment indicators are present.", "that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment were inherently uncertain and included assumptions that differed from actual results in future periods (see below).", "This represented a Level 3 nonrecurring fair value measurement.", "We allocated $123.2 million of the impairment to finite-lived intangibles, $11.6 million of the impairment to property and equipment, and $3.2 million to ROU assets.", "After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.", "In the normal course of business, our tax returns are subject to examination by various taxing authorities.", "Such examinations may result in future tax and interest assessments by these taxing authorities.", "Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations.", "We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.", "If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $52.9 million in the fiscal year ended September 30, 2020.", "respectively,  has  been  determined  using  the  LIFO  method.  If  we  had  used  the  first-in,  first-out  method  of  inventory  valuation,  which  approximates  current replacement cost, inventories would have been approximately $1,519.2 million and $1,511.8 million higher than the amounts reported as of September 30, 2020 and 2019, respectively.", "We recorded LIFO expenses of $7.4 million and $67.3 million in the fiscal years ended September 30, 2020 and 2018, respectively.", "We recorded a LIFO credit of $22.5 million in the fiscal year ended September 30, 2019.", "Changes to any of the above factors can have a material impact to our annual LIFO provision.", "We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain.", "The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year.", "We record a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency and whether a reasonable estimate of the loss or the range of the loss can made in the footnotes to our financial statements.", "We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made.", "Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 14 of the Notes to Consolidated Financial Statements.", "provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock.", "purchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities.", "Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that are expected to be made over 18 years (see below).", "distribution of prescription opioid pain medications, we recorded a $6.6 billion ($5.5 billion, net of an income tax benefit) charge.", "We are in advanced discussions, which are ongoing, to reach a global settlement of the MDL and related state-court litigation brought by certain state and local governmental entities in which our payment would be over 18 years to resolve cases currently filed and that could be filed by states, counties, municipalities, and other government entities.", "aforementioned litigation accrual has not and is not expected to have an impact on our compliance with our debt covenants or our ability to pay dividends.", "We have the ability to repatriate the majority of our cash and cash equivalents held by our foreign subsidiaries without incurring significant additional taxes upon repatriation.", "require the use of our credit facilities to fund short-term capital needs.", "Our cash balance in the fiscal years ended September 30, 2020 and 2019 needed to be supplemented  by  intra-period  credit  facility  borrowings  to  cover  short-term  working  capital  needs.  The  largest  amount  of  intra-period  borrowings  under  our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 2020 and 2019 was $39.6 million and $240.6 million, respectively.", "We had $117.4 million, $606.0 million, and $25,115.3 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2020, 2019, and 2018, respectively.", "We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D.", "Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon our debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2020) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable.", "We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based upon our debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2020).", "We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time.", "The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of September 30, 2020.", "The maturities on the notes will vary, but may not  exceed  365  days  from  the  date  of  issuance.  The  notes  will  bear  interest,  if  interest  bearing,  or  will  be  sold  at  a  discount  from  their  face  amounts.  The commercial  paper  program  does  not  increase  our  borrowing  capacity  as  it  is  fully  backed  by  our  Multi-Currency  Revolving  Credit  Facility.  There  were  no borrowings outstanding under our commercial paper program as of September 30, 2020 and 2019.", "have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters.", "Interest rates are based upon prevailing market rates for short-term commercial paper or  LIBOR  plus  a  program  fee.  We  pay  a  customary  unused  fee  at  prevailing  market  rates,  annually,  to  maintain  the  availability  under  the  Receivables Securitization Facility.", "The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "As of September 30, 2020 and 2019, our cash and cash equivalents held by foreign subsidiaries were $675.9 million and $826.8 million, respectively, and", "We used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a", "We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion", "In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.", "We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources.", "Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice.", "The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2020.", "During the fiscal year ended September 30, 2018, we purchased $663.1 million of our common stock under this program, which included $24.0 million of September 2018 purchases that cash settled in October 2018.", "During the fiscal year ended September 30, 2019, we purchased $125.8  million  of  our  common  stock  under  this  program,  which  excluded  $24.0  million  of  September  2018  purchases  that  cash  settled  in  October  2018,  to complete our authorization under this program.", "In October 2018, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions.", "During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019.", "During the fiscal year ended September 30, 2020, we purchased $405.6 million of our common stock, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019.", "As of September 30, 2020, we had $55.5 million of availability remaining under this program.", "In October 2020, we repaid the $400 million October 2018 Term Loan that became due.", "In addition to the 2027 Notes, the 2030 Notes, and the 2047 Notes, we have $500 million of 3.40% senior notes due May 15, 2024, $500 million of 3.25%", "In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion in shares of our common", "The 2017 Tax Act required a one-time transition tax to be recognized on historical foreign earnings and profits.", "We currently estimate that our liability related to the  transition  tax  is  $182.6  million,  net  of  overpayments  and  tax  credits,  as  of  September  30,  2020,  which  is  payable  in  installments  over  a  six-year  period commencing in January 2021.", "As of September 30, 2020, a settlement has not been reached, and, therefore, we applied significant judgment in estimating the ultimate amount of the opioid litigation settlement that would be deductible for U.S. federal and state purposes.", "In estimating the amount that would ultimately be deductible, we considered prior U.S. tax case law, the amount and character of the damages sought in the opioid litigation, the inherent uncertainty related to litigation of this nature and magnitude, and other relevant factors.", "While we believe that our estimate of the uncertain tax position appropriately reflects these considerations, it is reasonably possible that the uncertain tax position recognized as of September 30, 2020 may be revised in future periods as the settlement with the various plaintiffs is finalized.", "The remaining amount of the liability represents an estimate of tax positions that we have taken in our tax returns or expect to take in future tax returns which may ultimately not be sustained upon examination by taxing authorities.", "Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers.", "In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms.", "Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.", "Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations.", "Our  liability  for  uncertain  tax  positions  was  $498.3  million  (including  interest  and  penalties)  as  of  September  30,  2020.  Included  in  this  balance  is", "Our  cash  flows  from  operating  activities  can  vary  significantly  from  period  to  period  based  upon  fluctuations  in  our  period  end  working  capital.", "The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.", "In the fiscal year ended September 30, 2018, we acquired H.D.", "In addition, we made incremental investments in Brazil totaling $78.1 million.", "and $343.6 million in cash dividends paid on our common stock.", "and $339.0 million in cash dividends paid on our common stock.", "senior notes, $639.2 million in purchases of our common stock, and $333.0 million in cash dividends paid on our common stock, offset in part by the issuance of $750.0 million of 3.45% senior notes and $500 million of 4.3% senior notes.", "discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.", "The amount of variable-rate debt fluctuates during the year based on our working capital requirements.", "We had $0.8 billion of variable-rate debt outstanding as of September 30, 2020.", "We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates.", "However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us.", "The unfavorable impact of a hypothetical decrease in", "We currently  expect  to spend approximately  $400 million  for capital  expenditures  during fiscal 2021.", "Net cash used in financing activities in the fiscal year ended September 30, 2020 principally related to $420.4 million in purchases of our common stock,", "Net cash used in financing activities in the fiscal year ended September 30, 2019 principally related to $674.0 million in purchases of our common stock", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "We have market risk exposure to interest rate fluctuations relating to our debt.", "We manage interest rate risk by using a combination of fixed-rate and", "We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents.", "interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt.", "For every $100 million of cash invested that is in excess of variable-rate debt, a 10-basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.", "Revenue from our foreign operations is approximately two percent of our consolidated revenue.", "We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates.", "We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes.", "We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations.", "Our largest exposure to foreign exchange rates exists", "These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.", "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2020, in conformity with U.S. generally accepted accounting principles.", "Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We  conducted  our  audits  in  accordance  with  the  standards  of  the  PCAOB.  Those  standards  require  that  we  plan  and  perform  the  audit  to  obtain  reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of the opioid litigation liability and related uncertain tax position.", "For example, we inspected management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of the opioid litigation liability and the related financial statement footnote disclosures.", "To  test  the  Company\u2019s  opioid  litigation  liability,  our  substantive  audit  procedures  included,  among  others,  testing  the completeness  of  the  opioid  litigation  contingencies  subject  to  evaluation  by  the  Company  and  evaluating  the  Company\u2019s analysis of its assessment of the probability of outcome by considering the progress of settlement discussions involving the opioid litigation and communications with plaintiffs, as well as the experience of other similar entities when evaluating the Company\u2019s  conclusions.  We  inspected  responses  to  inquiry  letters  sent  to  both  internal  and  external  legal  counsel,  held discussions with internal and external legal counsel to confirm our understanding of the settlement discussions, and obtained written representations from executives of the Company.", "We also compared the Company\u2019s assessment with its relevant history of  similar  legal  contingencies  that  have  been  settled  or  otherwise  resolved  to  evaluate  the  consistency  of  the  Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "In addition, we also evaluated the adequacy of the Company\u2019s financial statement disclosures.", "We involved our tax subject matter professionals  in assessing the technical  merits and measurement  of the Company\u2019s tax position related to the opioid litigation liability.", "We examined the Company\u2019s analysis and evaluated the underlying facts upon which  the  tax  position  was  based.  We  used  our  knowledge  of  historical  settlement  activity  to  evaluate  the  Company\u2019s measurement  of the uncertain tax position associated  with the opioid litigation.  This included evaluating third-party  advice obtained by the Company and performing inquiries of the Company\u2019s external income tax advisers.", "We also evaluated the adequacy  of  the  Company\u2019s  financial  statement  disclosures  and  obtained  written  representations  from  executives  of  the Company related to this income tax matter.", "We have served as the Company's auditor since 1985.", "This included testing controls related to the Company\u2019s process for  identification,  recognition,  measurement  and  disclosure  of  legal  contingencies.  For  example,  we  tested  controls  over management\u2019s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures.", "We also tested controls over management\u2019s assessment of the likelihood of the resolution of the matters through settlement or litigation.", "To test the Company\u2019s legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company\u2019s analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal and external legal counsel to confirm our understanding of the allegations,  and  obtaining  written  representations  from  executives  of  the  Company.  We  also  compared  the  Company\u2019s assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company\u2019s assessment for outstanding legal contingencies at the balance sheet date.", "For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, and for those legal contingencies for which the Company has determined that a loss is either probable or reasonably possible, but the Company is unable to estimate the range of loss, and is therefore required to be disclosed, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies.", "We assessed the Company\u2019s  estimate  of  the  amount  of  the  loss,  for  both  contingencies  that  are  probable  and  reasonably  possible,  through inspection of responses to inquiry letters sent to both internal and external legal counsel, direct discussions with internal and external  legal  counsel,  inspection  of  court  rulings,  and  inspection  of  settlement  agreements.  We  also  obtained  written representations from executives of the Company.", "All intercompany accounts and transactions have been eliminated in consolidation.", "ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.", "performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.", "The Company did not elect the hindsight practical expedient in determining the lease term.", "The adoption of ASC 842 did not and will not have a material impact on the Company's results of operations or cash flows.", "An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances.", "The Company does not expect the adoption of this new accounting guidance to have a material impact on its financial position, results of operations, or cash flows.", "ASU 2019-12 removes certain exceptions to the general principles in ASC 740 in order to reduce the cost and complexity of its application.", "The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.", "The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated.", "The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued.", "The Company's trade accounts receivables are exposed to credit risk.", "Deposits held with banks may exceed the amount of insurance", "Gain Contingencies: The Company records gain contingencies when they are realized.", "Gains from antitrust litigation settlements are realized upon the", "If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis.", "If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized.", "If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.", "fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date.", "The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method.", "The Company believes the relief from royalty method is a widely used valuation technique for such assets.", "The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.", "The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit.", "recoverability assessment of its long-lived assets when impairment indicators are present.", "This represents a Level 3 nonrecurring fair value measurement.", "This represented a Level 3 nonrecurring fair value measurement.", "Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.", "Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.", "contains a lease based on the facts and circumstances present.", "The Company does not recognize on the balance sheet leases with terms of one year or less.", "The Company's leases do not contain residual value guarantees.", "further obligation to provide services related to such products.", "Service revenue is recognized over the period that services are provided to the customer.", "The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company\u2019s common stock.", "Share-based  compensation  expense  is  recognized  over  the  requisite  service  period  within  Distribution,  Selling,  and  Administrative  in  the  Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees.", "Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.", "The ultimate outcome of any outstanding claim may be different than the Company's estimate.", "The purchase price exceeded the fair value of the net tangible and intangible assets acquired by", "The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively.", "Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.", "The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill.", "Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.", "These represent Level 2 nonrecurring fair value measurements.", "The Company is not obligated to provide future financial support to Profarma.", "A  reconciliation  of  the  statutory  U.S.  federal  income  tax  rate  to  the  Company's  consolidated  effective  income  tax  rate  is  as  follows  for  the  periods", "The estimated tax benefit is higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction can now be carried back to years with higher statutory tax rates.", "resulting from the recognition of the above discrete tax benefits.", "A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income.", "To phase in the tax rate increase, the canton of Bern has granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years.", "It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.", "During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $13.9 million.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to have an impact on the Company's compliance with its debt covenants.", "The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility.", "Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million.", "An additional covenant requires compliance with a financial leverage ratio test.", "The opioid litigation accrual discussed in Note 14 has not and is not expected to impact the Company's ability to pay dividends.", "employees at a price not less than the fair market value of the common stock on the date the option is granted.", "This unfunded plan, under which 2.96 million shares of", "The risk-free rates during the terms of such options are based upon the U.S.", "Performance  stock  units  are  granted  to  certain  executive  employees  under  the  Plan  and  represent  common  stock  potentially  issuable  in  the  future.", "The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "uncertainty  remains  with  regard  to  whether  such  matters  will  proceed  to  trial,  whether  settlements  will  be  reached,  and  the  amount  and  terms  of  any  such settlements.", "If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.", "While a global settlement remains subject to contingencies that could impact whether the parties ultimately decide to move forward, the Company believes a global settlement is probable and its loss related thereto can be reasonably estimated as of September 30, 2020.", "Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events.", "The Company will regularly review these opioid litigation matters to determine whether its accrual is adequate.", "The amount of ultimate loss may differ materially from the $6.6 billion accrual.", "Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations.", "The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.", "The Company cannot predict how these matters would be affected by a global settlement.", "The Company's responses often require time and effort and can result in considerable costs being incurred.", "None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds", "approximate fair value based upon the relatively short-term nature of these financial instruments.", "The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.", "The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.", "AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.", "effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.", "that could have a material effect on the financial statements.", "We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated November 19, 2020 expressed an unqualified opinion thereon.", "Our responsibility is to express an opinion on the Company\u2019s internal control over financial reporting based on our audit.", "We are a public accounting firm registered with the PCAOB and are required  to  be  independent  with  respect  to  the  Company  in  accordance  with  the  U.S.  federal  securities  laws  and  the  applicable  rules  and  regulations  of  the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "We will file the 2021 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.", "Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.", "of our reports dated November 19, 2020, with respect to the consolidated financial statements and schedule of AmerisourceBergen Corporation and subsidiaries and the effectiveness of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries included in this Annual Report (Form 10-K) of AmerisourceBergen Corporation and subsidiaries for the year ended September 30, 2020.", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the", "Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the", "The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the"], "Governance": ["AmerisourceBergen  is  one  of  the  largest  global  pharmaceutical  sourcing  and  distribution  services  companies,  helping  both  healthcare  providers  and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.", "We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers.", "Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services,  including  data  analytics,  outcomes  research,  reimbursement  and  pharmaceutical  consulting  services,  niche  premium  logistics  services,  inventory management, pharmacy automation, pharmacy management, and packaging solutions.", "such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases.", "We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry.", "In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business. next several years.", "We consider  the  increase  in  generic  usage  a  favorable  trend  because  generic  pharmaceuticals  have  historically  provided  us  with  a  greater  gross  profit  margin opportunity than brand-name products, although their lower prices reduce revenue growth.", "Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.", "The number of individuals age 65 and over in the United States is expected to exceed 63 million by 2024 and is the most rapidly", "spread  of  COVID-19.  In  connection  with  the  mitigation  and  containment  procedures  recommended  by  the  WHO  and  imposed  by  federal,  state,  and  local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "In our pharmaceutical  distribution  business, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers.", "We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.", "Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business, and we believe we are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:", "\u2022 Optimize and Grow Our Pharmaceutical Distribution and Strategic Global Sourcing Businesses.  We believe we are well positioned in size and market", "Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A.", "breadth to continue to grow our distribution businesses as we invest to improve our operating and capital efficiencies.", "Distribution, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value- added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.", "We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products.", "We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products.", "We are well positioned to service and support many of the new biotechnology therapies that are expected to be coming to market in the near future.", "We have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland.", "We  source  generics  globally,  offer  a  value-added  generic  formulary  program  to  our  healthcare  provider  customers,  and  monitor  our  customers' compliance with our generics program.", "We also provide data and other valuable services to our manufacturer customers, which includes our international presence in Switzerland where we lead our global manufacturer relations and commercialization strategy.", "We are organized based upon the products and services we provide to our customers.", "Our operations as of September 30, 2020 are comprised  of  the  Pharmaceutical  Distribution  Services  reportable  segment  and  other  operating  segments  that  are  not  significant  enough  to  require  separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation.", "In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments.", "\u2022 Optimize  and  Grow  Our  Global  Commercialization  Services  and  Animal  Health  Businesses.  Our  consulting  service  businesses  help  global", "In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time,", "We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes.", "We believe we have one of the lowest operating cost structures among all pharmaceutical distributors.", "Our robust distribution facility network includes a national distribution center in Columbus, OH, which offers pharmaceutical manufacturers a single shipping destination.", "World Courier is  a  leading  global  specialty  transportation  and  logistics  provider  for  the  biopharmaceutical  industry.  World  Courier  further  strengthens  our  service offerings  to  global  pharmaceutical  manufacturers  and  provides  an  established  platform  for  the  introduction  of  our  specialty  services  outside  North America.", "MWI also offers its customers a variety of value-added services, including its e- commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI.", "We continue to seek opportunities to expand our offerings in our Global Commercialization Services and Animal Health businesses.", "Pharmaceutical  Distribution  Services  also  has  support  professionals  focused  on  its  various  technologies  and  service  offerings.  Pharmaceutical  Distribution Services\u2019 sales teams also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their needs.", "Our other operating segments each have independent sales forces that specialize in their respective product and service offerings.", "In addition, we have an enterprise-wide marketing team that coordinates branding and all other marketing activities across the Company.", "We are typically the primary  source  of  supply  for  our  healthcare  provider  customers.  Our  manufacturer  customers  include  branded,  generic,  and  biotechnology  manufacturers  of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers.", "In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.", "The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations.", "We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal year ended September 30, 2020.", "The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers.", "We believe that our relationships with our suppliers are strong.", "The 10 largest suppliers in fiscal year ended September 30, 2020 accounted for approximately 46% of our purchases.", "As a result, the pharmaceutical distribution facilities in the United States all now operate under a single ERP system.", "We  have  a  diverse  customer  base  that  includes  institutional  and  retail  healthcare  providers  as  well  as  pharmaceutical  manufacturers.", "All of our other operating segments operate the majority of their businesses on their own common operating systems resulting in the ability to rapidly deploy new capabilities.", "We continue to make investments to enhance and upgrade the operating systems utilized by our other operating segments.", "pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems. are intended to strengthen customer relationships by helping customers to reduce operating costs, and by providing them a platform for a number of the basic and value-added services, including product demand data, inventory replenishment, single-source billing, third-party claims processing, real-time price and incentive updates, and price labels. make substantial investments to expand its electronic interface with its suppliers.", "The warehouse operating systems have improved Pharmaceutical Distribution Services\u2019 productivity and operating leverage.", "Pharmaceutical Distribution  Services  competes  with  both  McKesson  and  Cardinal,  as  well  as  national  generic  distributors  and  regional  distributors  within  pharmaceutical distribution.  In  addition,  we  compete  with  manufacturers  who  sell  directly  to  customers,  chain  drugstores  who  manage  their  own  warehousing,  specialty distributors, and packaging and healthcare technology companies.", "conduct  of  our  business  or  that  are  made  available  as  products  or  services  to  customers.  We  generally  seek  to  protect  such  intellectual  property  through  a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections. our medication and supply dispensing equipment, certain warehousing equipment, and some of our proprietary packaging solutions.", "Additionally, we are improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.", "We will continue  to invest in advanced  information  systems and automated  warehouse technology.  For example,  in an effort  to comply with future", "Pharmaceutical Distribution Services has made significant investments in its electronic ordering systems.", "A significant portion of our data center operations, which were previously outsourced to third-party providers, is now insourced.", "We  face  a  highly  competitive  global  environment  in  the  distribution  of pharmaceuticals  and  related  healthcare  services.  Our largest  competitors  are", "All of the principal trademarks and service marks used in the course of our business have been", "As of September 30, 2020, we had approximately 22,000 employees, of which approximately 21,000 were full-time employees.", "More than 56% of our workforce is comprised of women, 49% is comprised of individuals with ethnically diverse backgrounds, and 30% of our Board of Directors are women.", "Additionally, our Executive Management Committee is made up of 43% women.", "any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations.", "However, we believe we have adequate contingency plans in place to assure delivery of pharmaceuticals to our customers in the event of any such disruptions.", "We expect that the FDA, and eventually comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers.", "Approximately 2% of our employees are covered by collective bargaining agreements.", "We believe that our relationship with our employees is good.", "Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material.", "The reader should not consider this list to be a complete statement of all risks and uncertainties.", "Industry and Economic Risks Our results of operations could be adversely impacted by manufacturer pricing changes.", "Distribution Services reportable segment profit and our consolidated operating earnings.", "If such initiatives are passed or finalized and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.", "Competition and industry consolidation may erode our profit.", "recent years the healthcare industry has been subject to increasing consolidation, including among pharmaceutical manufacturers, retail pharmacies, and health insurers, which may create further competitive pressures on our pharmaceutical distribution business.", "If we do not compete successfully, it could have a material and adverse effect on our business and results of operations.", "The impact on us will be greater if consolidation among our customers, suppliers, and competitors gives the resulting enterprises greater bargaining power, which could lead to greater pressure on us to reduce prices for our products and services.", "The following discussion describes certain risk factors that we believe could affect our business and prospects.", "Declining economic conditions could adversely affect our results of operations and financial condition.", "If the economic conditions in the United States or in the countries where we do business deteriorate, our results of operations or financial condition could be adversely affected.", "Our top ten customers, including governmental agencies and GPOs, represented approximately 64% of revenue in the fiscal year ended September 30, 2020.", "Our operations and performance depend on economic conditions in the United States and other countries where we do business.", "Walgreens Boots Alliance Development GmbH (\"WBAD\") provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf.", "This reflected our expectation that partnering strategically with WBA would result in various benefits including, among other things, continued cost savings as a  result  of our generics  purchasing  services  arrangement  with WBAD, as well as the potential  for exploring  innovation  together  and sharing best practices.", "The processes and initiatives needed to achieve and maintain these benefits are complex, costly, and time-consuming.", "Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management time and attention.", "A disruption in our distribution or generic purchasing services arrangements with WBA could adversely affect our business and financial results.", "In addition, upon the expiration or termination of the distribution agreement or generics purchasing services arrangement, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.", "Moreover, if the economic benefits we are able to obtain through the generics purchasing services arrangement with WBA decline due to changes in market conditions or other changes impacting the fees and rebates that generic manufacturers make available through the arrangement, our margins and results of operations could also be adversely affected.", "Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate. assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated.", "We are the primary distributor of pharmaceutical products for WBA.", "If our operations are seriously disrupted for any reason deemed within our control,", "Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBA.", "As part of our strategy we seek to pursue acquisitions of and investments in other companies.", "Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio in order to determine whether an asset or business may no longer help us meet our objectives.", "When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives.", "We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above.", "At any particular time, our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition.", "Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability.", "Regulation of pharmaceutical  distribution  is  intended  to  prevent  diversion  and  the  introduction  of  counterfeit,  adulterated,  and/or  mislabeled  drugs  into  the  pharmaceutical distribution system.", "pedigree  requirements,  and  will  require  all  supply-chain  stakeholders  to  participate  in  an  electronic,  interoperable  prescription  drug  traceability  system  by November 2023.", "Acquisitions involve numerous risks and uncertainties and may be of businesses in which we lack operational or market experience.", "Our operations in jurisdictions outside of the United States are subject to various risks inherent in global operations.", "We have distribution centers and facilities located in the United States and throughout the world.", "Our business exposes us to risks that are inherent in the", "The healthcare industry in the United States is highly regulated at the federal and state levels.", "Our international operations may also be subject to local regulations containing record-keeping and other obligations related to our distribution operations in those locations.", "including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.", "distribution system may change their interpretation or approach to implementing or complying with those standards, in a manner that may adversely affect our business.", "Federal,  state  and  local  governmental  and  regulatory  agencies  are  conducting  investigations  of  us  and  others  in  the  supply  chain,  including  pharmaceutical manufacturers and other pharmaceutical wholesale distributors, regarding the distribution of opioid medications.", "In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the supply chain by state and local governmental entities and other plaintiffs for claims related to the Company\u2019s distribution of opioid medications.", "Litigation is costly, time-consuming, and disruptive to ordinary business operations.", "Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.", "We are a large corporation with operations in the United States and select global markets.", "We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business.", "more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations.", "customers  and  suppliers.  The  COVID-19  pandemic  is  adversely  affecting,  and  is  expected  to  continue  to  adversely  affect,  our  operations,  supply  chains  and distribution network, and we have experienced and expect to continue to experience unpredictable reductions in supply and demand for certain of our products and services.", "Further, it is possible that the manufacturers that produce the products that we distribute may experience delays or shutdowns due to COVID-19, such as from disruptions in their supply chains or in a suspension of production at their own facilities.", "Accordingly, we expect the continued spread of COVID-19 to adversely affect the supply of products and/or potentially disrupt our ability to deliver products to customers.", "resulted in our decision to temporarily close, and subsequently reopen, a small number of our distribution centers in accordance with our internal protocols.", "We have implemented measures designed to keep our employees safe and have protocols in place to address business continuity issues at our distribution centers and other locations, but a widespread or sustained outbreak of COVID-19 at one or more locations could disrupt our ability to service our customers.", "instance, demand for certain animal health products in our MWI business declined during the COVID-19 pandemic, and this reduced demand may continue as customers reduce or postpone purchases viewed as discretionary.", "We also face risks related to a downturn in our customers' respective businesses, including the operations of our retail pharmacy and health systems customers.", "enhancing and upgrading our information technology systems, may take longer than originally expected to complete as we focus on COVID-19-related issues.", "Additionally, a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "We also face risks related to our employees' health and the impact it may have on operations.", "Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.", "We continue to make substantial investments in data centers and information systems, including, but not limited to, the expanded implementation of our primary ERP system to integrate certain  of  our  key  business  areas.  Third-party  service  providers  are  also  responsible  for  managing  a  portion  of  our  information  systems.  To  the  extent  our information systems are not successfully implemented or fail, or to the extent there are data center interruptions, our business and results of operations may be adversely affected.", "Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.", "technologies, and the increased sophistication and activities of perpetrators of cyber attacks.", "A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, cause loss of customers or revenue, increase our costs, result in litigation and/or regulatory action, and/or cause other losses, any of which might have a materially adverse impact on our business operations and our financial position or results of operations.", "As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us.", "Although we believe that we have robust information security procedures, controls and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.", "adversely affecting our business,\u201d a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time.", "and other severe hazards or accidents in the United States or in other countries in which we operate or are located could adversely affect our operations and financial performance.", "Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure  of one or more  of distribution  centers  or outsourcing  facilities,  temporary  or long-term  disruption in the  supply of products,  delay in the  delivery  of products to our distribution centers, and/or disruption of our ability to deliver products to customers.", "Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.", "(including  Puerto  Rico)  and  select  global  markets.  We  lease  facilities  in  Chesterbrook,  Pennsylvania  and  in  Conshohocken,  Pennsylvania  for  our  corporate headquarters.", "Pharmaceutical Distribution Services has a robust distribution facility network in the United States.", "We consider all of our operating and office properties to be in satisfactory condition.", "The following is a list of our executive officers and their ages and positions as of November 15, 2020.", "biotech  manufacturers  improve  patient  access  to  products  and  enhance  patient  care.  We  deliver  innovative  programs  and  services  designed  to  increase  the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "We are organized based upon the products and services we provide to our customers.", "Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant  enough  to  require  separate  reportable  segment  disclosure  and,  therefore,  have  been  included  in  Other  for  the  purpose  of  our  reportable  segment presentation.", "We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and", "In connection with the mitigation and containment procedures recommended by the WHO and imposed by federal, state, and local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "\u2022 Revenue increased 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;", "Increased sales to Walgreens, our largest customer $2.8 Increased sales to specialty physician practices $2.8 Increased sales to other customers $4.1", "We currently expect our revenue growth percentage to be in the mid-single digits in fiscal 2021.", "Our future revenue growth will continue to be affected by", "Revenue increased by 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "A  number  of  our  contracts  with  customers,  including  group  purchasing  organizations,  are  typically  subject  to  expiration  each  year.  We  may  lose  a", "As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.10% in the current fiscal year decreased 3 basis points compared to the prior fiscal year primarily due to increased sales to our larger customers, which typically have lower gross profit margins.", "Our cost of goods sold includes a LIFO provision that is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "We incurred remediation costs in connection with the suspended production activities at PharMEDium.", "We also incurred shutdown costs in connection with permanently exiting the PharMEDium compounding business.", "primarily  due  to  an  increase  in  operating  costs  to  support  our  revenue  growth  and  costs  incurred  in  connection  with  permanently  exiting  the  PharMEDium compounding business, such as contract termination fees, offset in part by operational synergies realized from the integration of H.D.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Increased sales to Walgreens, our largest customer $5.6 Increased sales to specialty physician practices $3.0 Increased sales to other customers $1.7 Increased sales due to Profarma and H.D.", "Revenue increased by 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility had been suspended since December 2017.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.", "As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 4 basis points from the prior fiscal year primarily due to a lower contribution from our pharmaceutical compounding operations.", "We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends.", "Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly.", "We identify our reporting units based upon our management reporting structure, beginning with our operating segments.", "We aggregate two or more components within an operating segment that have similar economic characteristics.", "We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment.", "Our reporting units include Pharmaceutical Distribution Services, Profarma, ABCS, World Courier, and MWI.", "While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.", "Food and Drug Administration (\"FDA\") inspections of PharMEDium's compounding facilities, we voluntarily suspended production activities", "The decision to permanently exit the PharMEDium business was due to a number of factors including, but not limited  to,  ongoing  operational,  regulatory,  and  commercial  challenges,  such  as  PharMEDium's  decision  in  January  2020  to  suspend  production  at  the compounding  facility  in  New  Jersey  pending  facility  upgrades  related  to  the  air  handling  and  filtration  systems.  In  connection  with  the  decision  to  exit  the PharMEDium  business,  we  recorded  an  impairment  of  PharMEDium's  assets  of  $223.7  million  in  the  three  months  ended  March  31,  2020,  which  included impairments of the remaining finite-lived intangible assets and the majority of the remaining tangible assets.", "The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "The increase in inventories was due to an increase in business volume.", "We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance.", "Significant  capital  expenditures  in  fiscal  2020 included  investments  in various  technology  initiatives,  including  costs  related  to  enhancing  and  upgrading  our primary information technology operating systems.", "Significant capital expenditures in fiscal 2019 included costs associated with the construction of a new support facility and technology initiatives, including costs related to enhancing and upgrading our information technology systems.", "Significant capital expenditures in fiscal 2018 included technology initiatives, including costs related to enhancing and upgrading our information technology systems and costs associated with expanding distribution capacity.", "We acquired businesses to support our animal health business for $54.0 million and $70.0 million in the fiscal years ended September 30, 2019 and 2018,", "Among the factors that could cause actual results to differ materially from those projected, anticipated, or  implied  are  the  following:  unfavorable  trends  in  brand  and  generic  pharmaceutical  pricing,  including  in  rate  or  frequency  of  price  inflation  or  deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government  enforcement  initiatives  to  detect  and  prevent  suspicious  orders  of  controlled  substances  and  the  diversion  of  controlled  substances;  continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale,  purchase  and/or  dispensing  of  pharmaceutical  products  or  services,  and  associated  reserves  and  costs;  failure  to  comply  with  the  Corporate  Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse  resolution  of  any  contract  or  other  dispute  with  customers  or  suppliers;  changes  to  customer  or  supplier  payment  terms,  including  as  a  result  of  the COVID-19 impact on such payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative  initiatives  that  could  adversely  affect  the  Company\u2019s  tax  positions  and/or  the  Company\u2019s  tax  liabilities  or  adverse  resolution  of  challenges  to  the Company\u2019s  tax  positions;  managing  foreign  expansion,  including  non-compliance  with  the  U.S.  Foreign  Corrupt  Practices  Act,  anti-bribery  laws,  economic sanctions and import laws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data;  natural  disasters  or other unexpected  events that affect  the Company\u2019s operations;  the impairment  of goodwill or other intangible  assets (including  any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and  abroad;  and  other  economic,  business,  competitive,  legal,  tax,  regulatory  and/or  operational  factors  affecting  the  Company\u2019s  business  generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this Management's Discussion and Analysis of Financial Condition and Results of Operations, (ii) in Item 1A (Risk Factors), (iii) Item 1 (Business), (iv) elsewhere in this report, and (v) in other reports filed by the Company pursuant to the Securities Exchange Act.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of legal contingencies.", "The acquisition strengthens  the  Company's  core  business,  expands  and  enhances  its  strategic  scale  in  pharmaceutical  distribution,  and  expands  the  Company's  support  for independent community pharmacies.", "Smith has been integrated into the Pharmaceutical Distribution reportable segment.", "The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years.", "Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.", "decision to permanently exit the PharMEDium compounding business.", "Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith, and restructuring activities related to our consulting business.", "We  adopted  a  Code  of  Ethics  for  Designated  Senior  Officers  that  applies  to  our  Chief  Executive  Officer,  Chief  Financial  Officer,  and  Corporate", "AmerisourceBergen  is  one  of  the  largest  global  pharmaceutical  sourcing  and  distribution  services  companies,  helping  both  healthcare  providers  and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.", "We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers.", "Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services,  including  data  analytics,  outcomes  research,  reimbursement  and  pharmaceutical  consulting  services,  niche  premium  logistics  services,  inventory management, pharmacy automation, pharmacy management, and packaging solutions.", "such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases.", "We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry.", "In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business. next several years.", "We consider  the  increase  in  generic  usage  a  favorable  trend  because  generic  pharmaceuticals  have  historically  provided  us  with  a  greater  gross  profit  margin opportunity than brand-name products, although their lower prices reduce revenue growth.", "Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.", "The number of individuals age 65 and over in the United States is expected to exceed 63 million by 2024 and is the most rapidly", "spread  of  COVID-19.  In  connection  with  the  mitigation  and  containment  procedures  recommended  by  the  WHO  and  imposed  by  federal,  state,  and  local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "In our pharmaceutical  distribution  business, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers.", "We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.", "Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business, and we believe we are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:", "\u2022 Optimize and Grow Our Pharmaceutical Distribution and Strategic Global Sourcing Businesses.  We believe we are well positioned in size and market", "Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A.", "breadth to continue to grow our distribution businesses as we invest to improve our operating and capital efficiencies.", "Distribution, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value- added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.", "We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products.", "We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products.", "We are well positioned to service and support many of the new biotechnology therapies that are expected to be coming to market in the near future.", "We have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland.", "We  source  generics  globally,  offer  a  value-added  generic  formulary  program  to  our  healthcare  provider  customers,  and  monitor  our  customers' compliance with our generics program.", "We also provide data and other valuable services to our manufacturer customers, which includes our international presence in Switzerland where we lead our global manufacturer relations and commercialization strategy.", "We are organized based upon the products and services we provide to our customers.", "Our operations as of September 30, 2020 are comprised  of  the  Pharmaceutical  Distribution  Services  reportable  segment  and  other  operating  segments  that  are  not  significant  enough  to  require  separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation.", "In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments.", "\u2022 Optimize  and  Grow  Our  Global  Commercialization  Services  and  Animal  Health  Businesses.  Our  consulting  service  businesses  help  global", "In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time,", "We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes.", "We believe we have one of the lowest operating cost structures among all pharmaceutical distributors.", "Our robust distribution facility network includes a national distribution center in Columbus, OH, which offers pharmaceutical manufacturers a single shipping destination.", "World Courier is  a  leading  global  specialty  transportation  and  logistics  provider  for  the  biopharmaceutical  industry.  World  Courier  further  strengthens  our  service offerings  to  global  pharmaceutical  manufacturers  and  provides  an  established  platform  for  the  introduction  of  our  specialty  services  outside  North America.", "MWI also offers its customers a variety of value-added services, including its e- commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI.", "We continue to seek opportunities to expand our offerings in our Global Commercialization Services and Animal Health businesses.", "Pharmaceutical  Distribution  Services  also  has  support  professionals  focused  on  its  various  technologies  and  service  offerings.  Pharmaceutical  Distribution Services\u2019 sales teams also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their needs.", "Our other operating segments each have independent sales forces that specialize in their respective product and service offerings.", "In addition, we have an enterprise-wide marketing team that coordinates branding and all other marketing activities across the Company.", "We are typically the primary  source  of  supply  for  our  healthcare  provider  customers.  Our  manufacturer  customers  include  branded,  generic,  and  biotechnology  manufacturers  of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers.", "In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.", "The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations.", "We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal year ended September 30, 2020.", "The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers.", "We believe that our relationships with our suppliers are strong.", "The 10 largest suppliers in fiscal year ended September 30, 2020 accounted for approximately 46% of our purchases.", "As a result, the pharmaceutical distribution facilities in the United States all now operate under a single ERP system.", "We  have  a  diverse  customer  base  that  includes  institutional  and  retail  healthcare  providers  as  well  as  pharmaceutical  manufacturers.", "All of our other operating segments operate the majority of their businesses on their own common operating systems resulting in the ability to rapidly deploy new capabilities.", "We continue to make investments to enhance and upgrade the operating systems utilized by our other operating segments.", "pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems. are intended to strengthen customer relationships by helping customers to reduce operating costs, and by providing them a platform for a number of the basic and value-added services, including product demand data, inventory replenishment, single-source billing, third-party claims processing, real-time price and incentive updates, and price labels. make substantial investments to expand its electronic interface with its suppliers.", "The warehouse operating systems have improved Pharmaceutical Distribution Services\u2019 productivity and operating leverage.", "Pharmaceutical Distribution  Services  competes  with  both  McKesson  and  Cardinal,  as  well  as  national  generic  distributors  and  regional  distributors  within  pharmaceutical distribution.  In  addition,  we  compete  with  manufacturers  who  sell  directly  to  customers,  chain  drugstores  who  manage  their  own  warehousing,  specialty distributors, and packaging and healthcare technology companies.", "conduct  of  our  business  or  that  are  made  available  as  products  or  services  to  customers.  We  generally  seek  to  protect  such  intellectual  property  through  a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections. our medication and supply dispensing equipment, certain warehousing equipment, and some of our proprietary packaging solutions.", "Additionally, we are improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.", "We will continue  to invest in advanced  information  systems and automated  warehouse technology.  For example,  in an effort  to comply with future", "Pharmaceutical Distribution Services has made significant investments in its electronic ordering systems.", "A significant portion of our data center operations, which were previously outsourced to third-party providers, is now insourced.", "We  face  a  highly  competitive  global  environment  in  the  distribution  of pharmaceuticals  and  related  healthcare  services.  Our largest  competitors  are", "All of the principal trademarks and service marks used in the course of our business have been", "As of September 30, 2020, we had approximately 22,000 employees, of which approximately 21,000 were full-time employees.", "More than 56% of our workforce is comprised of women, 49% is comprised of individuals with ethnically diverse backgrounds, and 30% of our Board of Directors are women.", "Additionally, our Executive Management Committee is made up of 43% women.", "any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations.", "However, we believe we have adequate contingency plans in place to assure delivery of pharmaceuticals to our customers in the event of any such disruptions.", "We expect that the FDA, and eventually comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers.", "Approximately 2% of our employees are covered by collective bargaining agreements.", "We believe that our relationship with our employees is good.", "Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material.", "The reader should not consider this list to be a complete statement of all risks and uncertainties.", "Industry and Economic Risks Our results of operations could be adversely impacted by manufacturer pricing changes.", "Distribution Services reportable segment profit and our consolidated operating earnings.", "If such initiatives are passed or finalized and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.", "Competition and industry consolidation may erode our profit.", "recent years the healthcare industry has been subject to increasing consolidation, including among pharmaceutical manufacturers, retail pharmacies, and health insurers, which may create further competitive pressures on our pharmaceutical distribution business.", "If we do not compete successfully, it could have a material and adverse effect on our business and results of operations.", "The impact on us will be greater if consolidation among our customers, suppliers, and competitors gives the resulting enterprises greater bargaining power, which could lead to greater pressure on us to reduce prices for our products and services.", "The following discussion describes certain risk factors that we believe could affect our business and prospects.", "Declining economic conditions could adversely affect our results of operations and financial condition.", "If the economic conditions in the United States or in the countries where we do business deteriorate, our results of operations or financial condition could be adversely affected.", "Our top ten customers, including governmental agencies and GPOs, represented approximately 64% of revenue in the fiscal year ended September 30, 2020.", "Our operations and performance depend on economic conditions in the United States and other countries where we do business.", "Walgreens Boots Alliance Development GmbH (\"WBAD\") provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf.", "This reflected our expectation that partnering strategically with WBA would result in various benefits including, among other things, continued cost savings as a  result  of our generics  purchasing  services  arrangement  with WBAD, as well as the potential  for exploring  innovation  together  and sharing best practices.", "The processes and initiatives needed to achieve and maintain these benefits are complex, costly, and time-consuming.", "Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management time and attention.", "A disruption in our distribution or generic purchasing services arrangements with WBA could adversely affect our business and financial results.", "In addition, upon the expiration or termination of the distribution agreement or generics purchasing services arrangement, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.", "Moreover, if the economic benefits we are able to obtain through the generics purchasing services arrangement with WBA decline due to changes in market conditions or other changes impacting the fees and rebates that generic manufacturers make available through the arrangement, our margins and results of operations could also be adversely affected.", "Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate. assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated.", "We are the primary distributor of pharmaceutical products for WBA.", "If our operations are seriously disrupted for any reason deemed within our control,", "Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBA.", "As part of our strategy we seek to pursue acquisitions of and investments in other companies.", "Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio in order to determine whether an asset or business may no longer help us meet our objectives.", "When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives.", "We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above.", "At any particular time, our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition.", "Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability.", "Regulation of pharmaceutical  distribution  is  intended  to  prevent  diversion  and  the  introduction  of  counterfeit,  adulterated,  and/or  mislabeled  drugs  into  the  pharmaceutical distribution system.", "pedigree  requirements,  and  will  require  all  supply-chain  stakeholders  to  participate  in  an  electronic,  interoperable  prescription  drug  traceability  system  by November 2023.", "Acquisitions involve numerous risks and uncertainties and may be of businesses in which we lack operational or market experience.", "Our operations in jurisdictions outside of the United States are subject to various risks inherent in global operations.", "We have distribution centers and facilities located in the United States and throughout the world.", "Our business exposes us to risks that are inherent in the", "The healthcare industry in the United States is highly regulated at the federal and state levels.", "Our international operations may also be subject to local regulations containing record-keeping and other obligations related to our distribution operations in those locations.", "including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.", "distribution system may change their interpretation or approach to implementing or complying with those standards, in a manner that may adversely affect our business.", "Federal,  state  and  local  governmental  and  regulatory  agencies  are  conducting  investigations  of  us  and  others  in  the  supply  chain,  including  pharmaceutical manufacturers and other pharmaceutical wholesale distributors, regarding the distribution of opioid medications.", "In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the supply chain by state and local governmental entities and other plaintiffs for claims related to the Company\u2019s distribution of opioid medications.", "Litigation is costly, time-consuming, and disruptive to ordinary business operations.", "Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.", "We are a large corporation with operations in the United States and select global markets.", "We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business.", "more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations.", "customers  and  suppliers.  The  COVID-19  pandemic  is  adversely  affecting,  and  is  expected  to  continue  to  adversely  affect,  our  operations,  supply  chains  and distribution network, and we have experienced and expect to continue to experience unpredictable reductions in supply and demand for certain of our products and services.", "Further, it is possible that the manufacturers that produce the products that we distribute may experience delays or shutdowns due to COVID-19, such as from disruptions in their supply chains or in a suspension of production at their own facilities.", "Accordingly, we expect the continued spread of COVID-19 to adversely affect the supply of products and/or potentially disrupt our ability to deliver products to customers.", "resulted in our decision to temporarily close, and subsequently reopen, a small number of our distribution centers in accordance with our internal protocols.", "We have implemented measures designed to keep our employees safe and have protocols in place to address business continuity issues at our distribution centers and other locations, but a widespread or sustained outbreak of COVID-19 at one or more locations could disrupt our ability to service our customers.", "instance, demand for certain animal health products in our MWI business declined during the COVID-19 pandemic, and this reduced demand may continue as customers reduce or postpone purchases viewed as discretionary.", "We also face risks related to a downturn in our customers' respective businesses, including the operations of our retail pharmacy and health systems customers.", "enhancing and upgrading our information technology systems, may take longer than originally expected to complete as we focus on COVID-19-related issues.", "Additionally, a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "We also face risks related to our employees' health and the impact it may have on operations.", "Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.", "We continue to make substantial investments in data centers and information systems, including, but not limited to, the expanded implementation of our primary ERP system to integrate certain  of  our  key  business  areas.  Third-party  service  providers  are  also  responsible  for  managing  a  portion  of  our  information  systems.  To  the  extent  our information systems are not successfully implemented or fail, or to the extent there are data center interruptions, our business and results of operations may be adversely affected.", "Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.", "technologies, and the increased sophistication and activities of perpetrators of cyber attacks.", "A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, cause loss of customers or revenue, increase our costs, result in litigation and/or regulatory action, and/or cause other losses, any of which might have a materially adverse impact on our business operations and our financial position or results of operations.", "As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us.", "Although we believe that we have robust information security procedures, controls and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.", "adversely affecting our business,\u201d a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time.", "and other severe hazards or accidents in the United States or in other countries in which we operate or are located could adversely affect our operations and financial performance.", "Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure  of one or more  of distribution  centers  or outsourcing  facilities,  temporary  or long-term  disruption in the  supply of products,  delay in the  delivery  of products to our distribution centers, and/or disruption of our ability to deliver products to customers.", "Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.", "(including  Puerto  Rico)  and  select  global  markets.  We  lease  facilities  in  Chesterbrook,  Pennsylvania  and  in  Conshohocken,  Pennsylvania  for  our  corporate headquarters.", "Pharmaceutical Distribution Services has a robust distribution facility network in the United States.", "We consider all of our operating and office properties to be in satisfactory condition.", "The following is a list of our executive officers and their ages and positions as of November 15, 2020.", "biotech  manufacturers  improve  patient  access  to  products  and  enhance  patient  care.  We  deliver  innovative  programs  and  services  designed  to  increase  the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "We are organized based upon the products and services we provide to our customers.", "Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant  enough  to  require  separate  reportable  segment  disclosure  and,  therefore,  have  been  included  in  Other  for  the  purpose  of  our  reportable  segment presentation.", "We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and", "In connection with the mitigation and containment procedures recommended by the WHO and imposed by federal, state, and local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "\u2022 Revenue increased 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;", "Increased sales to Walgreens, our largest customer $2.8 Increased sales to specialty physician practices $2.8 Increased sales to other customers $4.1", "We currently expect our revenue growth percentage to be in the mid-single digits in fiscal 2021.", "Our future revenue growth will continue to be affected by", "Revenue increased by 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "A  number  of  our  contracts  with  customers,  including  group  purchasing  organizations,  are  typically  subject  to  expiration  each  year.  We  may  lose  a", "As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.10% in the current fiscal year decreased 3 basis points compared to the prior fiscal year primarily due to increased sales to our larger customers, which typically have lower gross profit margins.", "Our cost of goods sold includes a LIFO provision that is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "We incurred remediation costs in connection with the suspended production activities at PharMEDium.", "We also incurred shutdown costs in connection with permanently exiting the PharMEDium compounding business.", "primarily  due  to  an  increase  in  operating  costs  to  support  our  revenue  growth  and  costs  incurred  in  connection  with  permanently  exiting  the  PharMEDium compounding business, such as contract termination fees, offset in part by operational synergies realized from the integration of H.D.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Increased sales to Walgreens, our largest customer $5.6 Increased sales to specialty physician practices $3.0 Increased sales to other customers $1.7 Increased sales due to Profarma and H.D.", "Revenue increased by 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility had been suspended since December 2017.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.", "As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 4 basis points from the prior fiscal year primarily due to a lower contribution from our pharmaceutical compounding operations.", "We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends.", "Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly.", "We identify our reporting units based upon our management reporting structure, beginning with our operating segments.", "We aggregate two or more components within an operating segment that have similar economic characteristics.", "We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment.", "Our reporting units include Pharmaceutical Distribution Services, Profarma, ABCS, World Courier, and MWI.", "While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.", "Food and Drug Administration (\"FDA\") inspections of PharMEDium's compounding facilities, we voluntarily suspended production activities", "The decision to permanently exit the PharMEDium business was due to a number of factors including, but not limited  to,  ongoing  operational,  regulatory,  and  commercial  challenges,  such  as  PharMEDium's  decision  in  January  2020  to  suspend  production  at  the compounding  facility  in  New  Jersey  pending  facility  upgrades  related  to  the  air  handling  and  filtration  systems.  In  connection  with  the  decision  to  exit  the PharMEDium  business,  we  recorded  an  impairment  of  PharMEDium's  assets  of  $223.7  million  in  the  three  months  ended  March  31,  2020,  which  included impairments of the remaining finite-lived intangible assets and the majority of the remaining tangible assets.", "The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "The increase in inventories was due to an increase in business volume.", "We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance.", "Significant  capital  expenditures  in  fiscal  2020 included  investments  in various  technology  initiatives,  including  costs  related  to  enhancing  and  upgrading  our primary information technology operating systems.", "Significant capital expenditures in fiscal 2019 included costs associated with the construction of a new support facility and technology initiatives, including costs related to enhancing and upgrading our information technology systems.", "Significant capital expenditures in fiscal 2018 included technology initiatives, including costs related to enhancing and upgrading our information technology systems and costs associated with expanding distribution capacity.", "We acquired businesses to support our animal health business for $54.0 million and $70.0 million in the fiscal years ended September 30, 2019 and 2018,", "Among the factors that could cause actual results to differ materially from those projected, anticipated, or  implied  are  the  following:  unfavorable  trends  in  brand  and  generic  pharmaceutical  pricing,  including  in  rate  or  frequency  of  price  inflation  or  deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government  enforcement  initiatives  to  detect  and  prevent  suspicious  orders  of  controlled  substances  and  the  diversion  of  controlled  substances;  continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale,  purchase  and/or  dispensing  of  pharmaceutical  products  or  services,  and  associated  reserves  and  costs;  failure  to  comply  with  the  Corporate  Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse  resolution  of  any  contract  or  other  dispute  with  customers  or  suppliers;  changes  to  customer  or  supplier  payment  terms,  including  as  a  result  of  the COVID-19 impact on such payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative  initiatives  that  could  adversely  affect  the  Company\u2019s  tax  positions  and/or  the  Company\u2019s  tax  liabilities  or  adverse  resolution  of  challenges  to  the Company\u2019s  tax  positions;  managing  foreign  expansion,  including  non-compliance  with  the  U.S.  Foreign  Corrupt  Practices  Act,  anti-bribery  laws,  economic sanctions and import laws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data;  natural  disasters  or other unexpected  events that affect  the Company\u2019s operations;  the impairment  of goodwill or other intangible  assets (including  any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and  abroad;  and  other  economic,  business,  competitive,  legal,  tax,  regulatory  and/or  operational  factors  affecting  the  Company\u2019s  business  generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this Management's Discussion and Analysis of Financial Condition and Results of Operations, (ii) in Item 1A (Risk Factors), (iii) Item 1 (Business), (iv) elsewhere in this report, and (v) in other reports filed by the Company pursuant to the Securities Exchange Act.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of legal contingencies.", "The acquisition strengthens  the  Company's  core  business,  expands  and  enhances  its  strategic  scale  in  pharmaceutical  distribution,  and  expands  the  Company's  support  for independent community pharmacies.", "Smith has been integrated into the Pharmaceutical Distribution reportable segment.", "The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years.", "Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.", "decision to permanently exit the PharMEDium compounding business.", "Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith, and restructuring activities related to our consulting business.", "We  adopted  a  Code  of  Ethics  for  Designated  Senior  Officers  that  applies  to  our  Chief  Executive  Officer,  Chief  Financial  Officer,  and  Corporate", "AmerisourceBergen  is  one  of  the  largest  global  pharmaceutical  sourcing  and  distribution  services  companies,  helping  both  healthcare  providers  and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.", "We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers.", "Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services,  including  data  analytics,  outcomes  research,  reimbursement  and  pharmaceutical  consulting  services,  niche  premium  logistics  services,  inventory management, pharmacy automation, pharmacy management, and packaging solutions.", "such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases.", "We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry.", "In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business. next several years.", "We consider  the  increase  in  generic  usage  a  favorable  trend  because  generic  pharmaceuticals  have  historically  provided  us  with  a  greater  gross  profit  margin opportunity than brand-name products, although their lower prices reduce revenue growth.", "Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.", "The number of individuals age 65 and over in the United States is expected to exceed 63 million by 2024 and is the most rapidly", "spread  of  COVID-19.  In  connection  with  the  mitigation  and  containment  procedures  recommended  by  the  WHO  and  imposed  by  federal,  state,  and  local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "In our pharmaceutical  distribution  business, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers.", "We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.", "Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business, and we believe we are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:", "\u2022 Optimize and Grow Our Pharmaceutical Distribution and Strategic Global Sourcing Businesses.  We believe we are well positioned in size and market", "Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A.", "breadth to continue to grow our distribution businesses as we invest to improve our operating and capital efficiencies.", "Distribution, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value- added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.", "We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products.", "We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products.", "We are well positioned to service and support many of the new biotechnology therapies that are expected to be coming to market in the near future.", "We have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland.", "We  source  generics  globally,  offer  a  value-added  generic  formulary  program  to  our  healthcare  provider  customers,  and  monitor  our  customers' compliance with our generics program.", "We also provide data and other valuable services to our manufacturer customers, which includes our international presence in Switzerland where we lead our global manufacturer relations and commercialization strategy.", "We are organized based upon the products and services we provide to our customers.", "Our operations as of September 30, 2020 are comprised  of  the  Pharmaceutical  Distribution  Services  reportable  segment  and  other  operating  segments  that  are  not  significant  enough  to  require  separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation.", "In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments.", "\u2022 Optimize  and  Grow  Our  Global  Commercialization  Services  and  Animal  Health  Businesses.  Our  consulting  service  businesses  help  global", "In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time,", "We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes.", "We believe we have one of the lowest operating cost structures among all pharmaceutical distributors.", "Our robust distribution facility network includes a national distribution center in Columbus, OH, which offers pharmaceutical manufacturers a single shipping destination.", "World Courier is  a  leading  global  specialty  transportation  and  logistics  provider  for  the  biopharmaceutical  industry.  World  Courier  further  strengthens  our  service offerings  to  global  pharmaceutical  manufacturers  and  provides  an  established  platform  for  the  introduction  of  our  specialty  services  outside  North America.", "MWI also offers its customers a variety of value-added services, including its e- commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI.", "We continue to seek opportunities to expand our offerings in our Global Commercialization Services and Animal Health businesses.", "Pharmaceutical  Distribution  Services  also  has  support  professionals  focused  on  its  various  technologies  and  service  offerings.  Pharmaceutical  Distribution Services\u2019 sales teams also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their needs.", "Our other operating segments each have independent sales forces that specialize in their respective product and service offerings.", "In addition, we have an enterprise-wide marketing team that coordinates branding and all other marketing activities across the Company.", "We are typically the primary  source  of  supply  for  our  healthcare  provider  customers.  Our  manufacturer  customers  include  branded,  generic,  and  biotechnology  manufacturers  of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers.", "In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.", "The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations.", "We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal year ended September 30, 2020.", "The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers.", "We believe that our relationships with our suppliers are strong.", "The 10 largest suppliers in fiscal year ended September 30, 2020 accounted for approximately 46% of our purchases.", "As a result, the pharmaceutical distribution facilities in the United States all now operate under a single ERP system.", "We  have  a  diverse  customer  base  that  includes  institutional  and  retail  healthcare  providers  as  well  as  pharmaceutical  manufacturers.", "All of our other operating segments operate the majority of their businesses on their own common operating systems resulting in the ability to rapidly deploy new capabilities.", "We continue to make investments to enhance and upgrade the operating systems utilized by our other operating segments.", "pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems. are intended to strengthen customer relationships by helping customers to reduce operating costs, and by providing them a platform for a number of the basic and value-added services, including product demand data, inventory replenishment, single-source billing, third-party claims processing, real-time price and incentive updates, and price labels. make substantial investments to expand its electronic interface with its suppliers.", "The warehouse operating systems have improved Pharmaceutical Distribution Services\u2019 productivity and operating leverage.", "Pharmaceutical Distribution  Services  competes  with  both  McKesson  and  Cardinal,  as  well  as  national  generic  distributors  and  regional  distributors  within  pharmaceutical distribution.  In  addition,  we  compete  with  manufacturers  who  sell  directly  to  customers,  chain  drugstores  who  manage  their  own  warehousing,  specialty distributors, and packaging and healthcare technology companies.", "conduct  of  our  business  or  that  are  made  available  as  products  or  services  to  customers.  We  generally  seek  to  protect  such  intellectual  property  through  a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections. our medication and supply dispensing equipment, certain warehousing equipment, and some of our proprietary packaging solutions.", "Additionally, we are improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.", "We will continue  to invest in advanced  information  systems and automated  warehouse technology.  For example,  in an effort  to comply with future", "Pharmaceutical Distribution Services has made significant investments in its electronic ordering systems.", "A significant portion of our data center operations, which were previously outsourced to third-party providers, is now insourced.", "We  face  a  highly  competitive  global  environment  in  the  distribution  of pharmaceuticals  and  related  healthcare  services.  Our largest  competitors  are", "All of the principal trademarks and service marks used in the course of our business have been", "As of September 30, 2020, we had approximately 22,000 employees, of which approximately 21,000 were full-time employees.", "More than 56% of our workforce is comprised of women, 49% is comprised of individuals with ethnically diverse backgrounds, and 30% of our Board of Directors are women.", "Additionally, our Executive Management Committee is made up of 43% women.", "any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations.", "However, we believe we have adequate contingency plans in place to assure delivery of pharmaceuticals to our customers in the event of any such disruptions.", "We expect that the FDA, and eventually comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers.", "Approximately 2% of our employees are covered by collective bargaining agreements.", "We believe that our relationship with our employees is good.", "Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material.", "The reader should not consider this list to be a complete statement of all risks and uncertainties.", "Industry and Economic Risks Our results of operations could be adversely impacted by manufacturer pricing changes.", "Distribution Services reportable segment profit and our consolidated operating earnings.", "If such initiatives are passed or finalized and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.", "Competition and industry consolidation may erode our profit.", "recent years the healthcare industry has been subject to increasing consolidation, including among pharmaceutical manufacturers, retail pharmacies, and health insurers, which may create further competitive pressures on our pharmaceutical distribution business.", "If we do not compete successfully, it could have a material and adverse effect on our business and results of operations.", "The impact on us will be greater if consolidation among our customers, suppliers, and competitors gives the resulting enterprises greater bargaining power, which could lead to greater pressure on us to reduce prices for our products and services.", "The following discussion describes certain risk factors that we believe could affect our business and prospects.", "Declining economic conditions could adversely affect our results of operations and financial condition.", "If the economic conditions in the United States or in the countries where we do business deteriorate, our results of operations or financial condition could be adversely affected.", "Our top ten customers, including governmental agencies and GPOs, represented approximately 64% of revenue in the fiscal year ended September 30, 2020.", "Our operations and performance depend on economic conditions in the United States and other countries where we do business.", "Walgreens Boots Alliance Development GmbH (\"WBAD\") provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf.", "This reflected our expectation that partnering strategically with WBA would result in various benefits including, among other things, continued cost savings as a  result  of our generics  purchasing  services  arrangement  with WBAD, as well as the potential  for exploring  innovation  together  and sharing best practices.", "The processes and initiatives needed to achieve and maintain these benefits are complex, costly, and time-consuming.", "Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management time and attention.", "A disruption in our distribution or generic purchasing services arrangements with WBA could adversely affect our business and financial results.", "In addition, upon the expiration or termination of the distribution agreement or generics purchasing services arrangement, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.", "Moreover, if the economic benefits we are able to obtain through the generics purchasing services arrangement with WBA decline due to changes in market conditions or other changes impacting the fees and rebates that generic manufacturers make available through the arrangement, our margins and results of operations could also be adversely affected.", "Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate. assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated.", "We are the primary distributor of pharmaceutical products for WBA.", "If our operations are seriously disrupted for any reason deemed within our control,", "Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBA.", "As part of our strategy we seek to pursue acquisitions of and investments in other companies.", "Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio in order to determine whether an asset or business may no longer help us meet our objectives.", "When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives.", "We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above.", "At any particular time, our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition.", "Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability.", "Regulation of pharmaceutical  distribution  is  intended  to  prevent  diversion  and  the  introduction  of  counterfeit,  adulterated,  and/or  mislabeled  drugs  into  the  pharmaceutical distribution system.", "pedigree  requirements,  and  will  require  all  supply-chain  stakeholders  to  participate  in  an  electronic,  interoperable  prescription  drug  traceability  system  by November 2023.", "Acquisitions involve numerous risks and uncertainties and may be of businesses in which we lack operational or market experience.", "Our operations in jurisdictions outside of the United States are subject to various risks inherent in global operations.", "We have distribution centers and facilities located in the United States and throughout the world.", "Our business exposes us to risks that are inherent in the", "The healthcare industry in the United States is highly regulated at the federal and state levels.", "Our international operations may also be subject to local regulations containing record-keeping and other obligations related to our distribution operations in those locations.", "including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.", "distribution system may change their interpretation or approach to implementing or complying with those standards, in a manner that may adversely affect our business.", "Federal,  state  and  local  governmental  and  regulatory  agencies  are  conducting  investigations  of  us  and  others  in  the  supply  chain,  including  pharmaceutical manufacturers and other pharmaceutical wholesale distributors, regarding the distribution of opioid medications.", "In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the supply chain by state and local governmental entities and other plaintiffs for claims related to the Company\u2019s distribution of opioid medications.", "Litigation is costly, time-consuming, and disruptive to ordinary business operations.", "Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.", "We are a large corporation with operations in the United States and select global markets.", "We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business.", "more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations.", "customers  and  suppliers.  The  COVID-19  pandemic  is  adversely  affecting,  and  is  expected  to  continue  to  adversely  affect,  our  operations,  supply  chains  and distribution network, and we have experienced and expect to continue to experience unpredictable reductions in supply and demand for certain of our products and services.", "Further, it is possible that the manufacturers that produce the products that we distribute may experience delays or shutdowns due to COVID-19, such as from disruptions in their supply chains or in a suspension of production at their own facilities.", "Accordingly, we expect the continued spread of COVID-19 to adversely affect the supply of products and/or potentially disrupt our ability to deliver products to customers.", "resulted in our decision to temporarily close, and subsequently reopen, a small number of our distribution centers in accordance with our internal protocols.", "We have implemented measures designed to keep our employees safe and have protocols in place to address business continuity issues at our distribution centers and other locations, but a widespread or sustained outbreak of COVID-19 at one or more locations could disrupt our ability to service our customers.", "instance, demand for certain animal health products in our MWI business declined during the COVID-19 pandemic, and this reduced demand may continue as customers reduce or postpone purchases viewed as discretionary.", "We also face risks related to a downturn in our customers' respective businesses, including the operations of our retail pharmacy and health systems customers.", "enhancing and upgrading our information technology systems, may take longer than originally expected to complete as we focus on COVID-19-related issues.", "Additionally, a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "We also face risks related to our employees' health and the impact it may have on operations.", "Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.", "We continue to make substantial investments in data centers and information systems, including, but not limited to, the expanded implementation of our primary ERP system to integrate certain  of  our  key  business  areas.  Third-party  service  providers  are  also  responsible  for  managing  a  portion  of  our  information  systems.  To  the  extent  our information systems are not successfully implemented or fail, or to the extent there are data center interruptions, our business and results of operations may be adversely affected.", "Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.", "technologies, and the increased sophistication and activities of perpetrators of cyber attacks.", "A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, cause loss of customers or revenue, increase our costs, result in litigation and/or regulatory action, and/or cause other losses, any of which might have a materially adverse impact on our business operations and our financial position or results of operations.", "As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us.", "Although we believe that we have robust information security procedures, controls and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.", "adversely affecting our business,\u201d a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time.", "and other severe hazards or accidents in the United States or in other countries in which we operate or are located could adversely affect our operations and financial performance.", "Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure  of one or more  of distribution  centers  or outsourcing  facilities,  temporary  or long-term  disruption in the  supply of products,  delay in the  delivery  of products to our distribution centers, and/or disruption of our ability to deliver products to customers.", "Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.", "(including  Puerto  Rico)  and  select  global  markets.  We  lease  facilities  in  Chesterbrook,  Pennsylvania  and  in  Conshohocken,  Pennsylvania  for  our  corporate headquarters.", "Pharmaceutical Distribution Services has a robust distribution facility network in the United States.", "We consider all of our operating and office properties to be in satisfactory condition.", "The following is a list of our executive officers and their ages and positions as of November 15, 2020.", "biotech  manufacturers  improve  patient  access  to  products  and  enhance  patient  care.  We  deliver  innovative  programs  and  services  designed  to  increase  the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "We are organized based upon the products and services we provide to our customers.", "Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant  enough  to  require  separate  reportable  segment  disclosure  and,  therefore,  have  been  included  in  Other  for  the  purpose  of  our  reportable  segment presentation.", "We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and", "In connection with the mitigation and containment procedures recommended by the WHO and imposed by federal, state, and local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "\u2022 Revenue increased 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;", "Increased sales to Walgreens, our largest customer $2.8 Increased sales to specialty physician practices $2.8 Increased sales to other customers $4.1", "We currently expect our revenue growth percentage to be in the mid-single digits in fiscal 2021.", "Our future revenue growth will continue to be affected by", "Revenue increased by 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "A  number  of  our  contracts  with  customers,  including  group  purchasing  organizations,  are  typically  subject  to  expiration  each  year.  We  may  lose  a", "As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.10% in the current fiscal year decreased 3 basis points compared to the prior fiscal year primarily due to increased sales to our larger customers, which typically have lower gross profit margins.", "Our cost of goods sold includes a LIFO provision that is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "We incurred remediation costs in connection with the suspended production activities at PharMEDium.", "We also incurred shutdown costs in connection with permanently exiting the PharMEDium compounding business.", "primarily  due  to  an  increase  in  operating  costs  to  support  our  revenue  growth  and  costs  incurred  in  connection  with  permanently  exiting  the  PharMEDium compounding business, such as contract termination fees, offset in part by operational synergies realized from the integration of H.D.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Increased sales to Walgreens, our largest customer $5.6 Increased sales to specialty physician practices $3.0 Increased sales to other customers $1.7 Increased sales due to Profarma and H.D.", "Revenue increased by 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility had been suspended since December 2017.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.", "As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 4 basis points from the prior fiscal year primarily due to a lower contribution from our pharmaceutical compounding operations.", "We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends.", "Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly.", "We identify our reporting units based upon our management reporting structure, beginning with our operating segments.", "We aggregate two or more components within an operating segment that have similar economic characteristics.", "We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment.", "Our reporting units include Pharmaceutical Distribution Services, Profarma, ABCS, World Courier, and MWI.", "While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.", "Food and Drug Administration (\"FDA\") inspections of PharMEDium's compounding facilities, we voluntarily suspended production activities", "The decision to permanently exit the PharMEDium business was due to a number of factors including, but not limited  to,  ongoing  operational,  regulatory,  and  commercial  challenges,  such  as  PharMEDium's  decision  in  January  2020  to  suspend  production  at  the compounding  facility  in  New  Jersey  pending  facility  upgrades  related  to  the  air  handling  and  filtration  systems.  In  connection  with  the  decision  to  exit  the PharMEDium  business,  we  recorded  an  impairment  of  PharMEDium's  assets  of  $223.7  million  in  the  three  months  ended  March  31,  2020,  which  included impairments of the remaining finite-lived intangible assets and the majority of the remaining tangible assets.", "The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "The increase in inventories was due to an increase in business volume.", "We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance.", "Significant  capital  expenditures  in  fiscal  2020 included  investments  in various  technology  initiatives,  including  costs  related  to  enhancing  and  upgrading  our primary information technology operating systems.", "Significant capital expenditures in fiscal 2019 included costs associated with the construction of a new support facility and technology initiatives, including costs related to enhancing and upgrading our information technology systems.", "Significant capital expenditures in fiscal 2018 included technology initiatives, including costs related to enhancing and upgrading our information technology systems and costs associated with expanding distribution capacity.", "We acquired businesses to support our animal health business for $54.0 million and $70.0 million in the fiscal years ended September 30, 2019 and 2018,", "Among the factors that could cause actual results to differ materially from those projected, anticipated, or  implied  are  the  following:  unfavorable  trends  in  brand  and  generic  pharmaceutical  pricing,  including  in  rate  or  frequency  of  price  inflation  or  deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government  enforcement  initiatives  to  detect  and  prevent  suspicious  orders  of  controlled  substances  and  the  diversion  of  controlled  substances;  continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale,  purchase  and/or  dispensing  of  pharmaceutical  products  or  services,  and  associated  reserves  and  costs;  failure  to  comply  with  the  Corporate  Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse  resolution  of  any  contract  or  other  dispute  with  customers  or  suppliers;  changes  to  customer  or  supplier  payment  terms,  including  as  a  result  of  the COVID-19 impact on such payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative  initiatives  that  could  adversely  affect  the  Company\u2019s  tax  positions  and/or  the  Company\u2019s  tax  liabilities  or  adverse  resolution  of  challenges  to  the Company\u2019s  tax  positions;  managing  foreign  expansion,  including  non-compliance  with  the  U.S.  Foreign  Corrupt  Practices  Act,  anti-bribery  laws,  economic sanctions and import laws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data;  natural  disasters  or other unexpected  events that affect  the Company\u2019s operations;  the impairment  of goodwill or other intangible  assets (including  any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and  abroad;  and  other  economic,  business,  competitive,  legal,  tax,  regulatory  and/or  operational  factors  affecting  the  Company\u2019s  business  generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this Management's Discussion and Analysis of Financial Condition and Results of Operations, (ii) in Item 1A (Risk Factors), (iii) Item 1 (Business), (iv) elsewhere in this report, and (v) in other reports filed by the Company pursuant to the Securities Exchange Act.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of legal contingencies.", "The acquisition strengthens  the  Company's  core  business,  expands  and  enhances  its  strategic  scale  in  pharmaceutical  distribution,  and  expands  the  Company's  support  for independent community pharmacies.", "Smith has been integrated into the Pharmaceutical Distribution reportable segment.", "The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years.", "Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.", "decision to permanently exit the PharMEDium compounding business.", "Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith, and restructuring activities related to our consulting business.", "We  adopted  a  Code  of  Ethics  for  Designated  Senior  Officers  that  applies  to  our  Chief  Executive  Officer,  Chief  Financial  Officer,  and  Corporate", "AmerisourceBergen  is  one  of  the  largest  global  pharmaceutical  sourcing  and  distribution  services  companies,  helping  both  healthcare  providers  and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.", "We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers.", "Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services,  including  data  analytics,  outcomes  research,  reimbursement  and  pharmaceutical  consulting  services,  niche  premium  logistics  services,  inventory management, pharmacy automation, pharmacy management, and packaging solutions.", "such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases.", "We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry.", "In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business. next several years.", "We consider  the  increase  in  generic  usage  a  favorable  trend  because  generic  pharmaceuticals  have  historically  provided  us  with  a  greater  gross  profit  margin opportunity than brand-name products, although their lower prices reduce revenue growth.", "Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.", "The number of individuals age 65 and over in the United States is expected to exceed 63 million by 2024 and is the most rapidly", "spread  of  COVID-19.  In  connection  with  the  mitigation  and  containment  procedures  recommended  by  the  WHO  and  imposed  by  federal,  state,  and  local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "In our pharmaceutical  distribution  business, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers.", "We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.", "Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business, and we believe we are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:", "\u2022 Optimize and Grow Our Pharmaceutical Distribution and Strategic Global Sourcing Businesses.  We believe we are well positioned in size and market", "Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A.", "breadth to continue to grow our distribution businesses as we invest to improve our operating and capital efficiencies.", "Distribution, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value- added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.", "We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products.", "We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products.", "We are well positioned to service and support many of the new biotechnology therapies that are expected to be coming to market in the near future.", "We have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland.", "We  source  generics  globally,  offer  a  value-added  generic  formulary  program  to  our  healthcare  provider  customers,  and  monitor  our  customers' compliance with our generics program.", "We also provide data and other valuable services to our manufacturer customers, which includes our international presence in Switzerland where we lead our global manufacturer relations and commercialization strategy.", "We are organized based upon the products and services we provide to our customers.", "Our operations as of September 30, 2020 are comprised  of  the  Pharmaceutical  Distribution  Services  reportable  segment  and  other  operating  segments  that  are  not  significant  enough  to  require  separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation.", "In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments.", "\u2022 Optimize  and  Grow  Our  Global  Commercialization  Services  and  Animal  Health  Businesses.  Our  consulting  service  businesses  help  global", "In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time,", "We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes.", "We believe we have one of the lowest operating cost structures among all pharmaceutical distributors.", "Our robust distribution facility network includes a national distribution center in Columbus, OH, which offers pharmaceutical manufacturers a single shipping destination.", "World Courier is  a  leading  global  specialty  transportation  and  logistics  provider  for  the  biopharmaceutical  industry.  World  Courier  further  strengthens  our  service offerings  to  global  pharmaceutical  manufacturers  and  provides  an  established  platform  for  the  introduction  of  our  specialty  services  outside  North America.", "MWI also offers its customers a variety of value-added services, including its e- commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI.", "We continue to seek opportunities to expand our offerings in our Global Commercialization Services and Animal Health businesses.", "Pharmaceutical  Distribution  Services  also  has  support  professionals  focused  on  its  various  technologies  and  service  offerings.  Pharmaceutical  Distribution Services\u2019 sales teams also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their needs.", "Our other operating segments each have independent sales forces that specialize in their respective product and service offerings.", "In addition, we have an enterprise-wide marketing team that coordinates branding and all other marketing activities across the Company.", "We are typically the primary  source  of  supply  for  our  healthcare  provider  customers.  Our  manufacturer  customers  include  branded,  generic,  and  biotechnology  manufacturers  of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers.", "In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.", "The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations.", "We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal year ended September 30, 2020.", "The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers.", "We believe that our relationships with our suppliers are strong.", "The 10 largest suppliers in fiscal year ended September 30, 2020 accounted for approximately 46% of our purchases.", "As a result, the pharmaceutical distribution facilities in the United States all now operate under a single ERP system.", "We  have  a  diverse  customer  base  that  includes  institutional  and  retail  healthcare  providers  as  well  as  pharmaceutical  manufacturers.", "All of our other operating segments operate the majority of their businesses on their own common operating systems resulting in the ability to rapidly deploy new capabilities.", "We continue to make investments to enhance and upgrade the operating systems utilized by our other operating segments.", "pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems. are intended to strengthen customer relationships by helping customers to reduce operating costs, and by providing them a platform for a number of the basic and value-added services, including product demand data, inventory replenishment, single-source billing, third-party claims processing, real-time price and incentive updates, and price labels. make substantial investments to expand its electronic interface with its suppliers.", "The warehouse operating systems have improved Pharmaceutical Distribution Services\u2019 productivity and operating leverage.", "Pharmaceutical Distribution  Services  competes  with  both  McKesson  and  Cardinal,  as  well  as  national  generic  distributors  and  regional  distributors  within  pharmaceutical distribution.  In  addition,  we  compete  with  manufacturers  who  sell  directly  to  customers,  chain  drugstores  who  manage  their  own  warehousing,  specialty distributors, and packaging and healthcare technology companies.", "conduct  of  our  business  or  that  are  made  available  as  products  or  services  to  customers.  We  generally  seek  to  protect  such  intellectual  property  through  a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections. our medication and supply dispensing equipment, certain warehousing equipment, and some of our proprietary packaging solutions.", "Additionally, we are improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.", "We will continue  to invest in advanced  information  systems and automated  warehouse technology.  For example,  in an effort  to comply with future", "Pharmaceutical Distribution Services has made significant investments in its electronic ordering systems.", "A significant portion of our data center operations, which were previously outsourced to third-party providers, is now insourced.", "We  face  a  highly  competitive  global  environment  in  the  distribution  of pharmaceuticals  and  related  healthcare  services.  Our largest  competitors  are", "All of the principal trademarks and service marks used in the course of our business have been", "As of September 30, 2020, we had approximately 22,000 employees, of which approximately 21,000 were full-time employees.", "More than 56% of our workforce is comprised of women, 49% is comprised of individuals with ethnically diverse backgrounds, and 30% of our Board of Directors are women.", "Additionally, our Executive Management Committee is made up of 43% women.", "any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations.", "However, we believe we have adequate contingency plans in place to assure delivery of pharmaceuticals to our customers in the event of any such disruptions.", "We expect that the FDA, and eventually comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers.", "Approximately 2% of our employees are covered by collective bargaining agreements.", "We believe that our relationship with our employees is good.", "Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material.", "The reader should not consider this list to be a complete statement of all risks and uncertainties.", "Industry and Economic Risks Our results of operations could be adversely impacted by manufacturer pricing changes.", "Distribution Services reportable segment profit and our consolidated operating earnings.", "If such initiatives are passed or finalized and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.", "Competition and industry consolidation may erode our profit.", "recent years the healthcare industry has been subject to increasing consolidation, including among pharmaceutical manufacturers, retail pharmacies, and health insurers, which may create further competitive pressures on our pharmaceutical distribution business.", "If we do not compete successfully, it could have a material and adverse effect on our business and results of operations.", "The impact on us will be greater if consolidation among our customers, suppliers, and competitors gives the resulting enterprises greater bargaining power, which could lead to greater pressure on us to reduce prices for our products and services.", "The following discussion describes certain risk factors that we believe could affect our business and prospects.", "Declining economic conditions could adversely affect our results of operations and financial condition.", "If the economic conditions in the United States or in the countries where we do business deteriorate, our results of operations or financial condition could be adversely affected.", "Our top ten customers, including governmental agencies and GPOs, represented approximately 64% of revenue in the fiscal year ended September 30, 2020.", "Our operations and performance depend on economic conditions in the United States and other countries where we do business.", "Walgreens Boots Alliance Development GmbH (\"WBAD\") provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf.", "This reflected our expectation that partnering strategically with WBA would result in various benefits including, among other things, continued cost savings as a  result  of our generics  purchasing  services  arrangement  with WBAD, as well as the potential  for exploring  innovation  together  and sharing best practices.", "The processes and initiatives needed to achieve and maintain these benefits are complex, costly, and time-consuming.", "Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management time and attention.", "A disruption in our distribution or generic purchasing services arrangements with WBA could adversely affect our business and financial results.", "In addition, upon the expiration or termination of the distribution agreement or generics purchasing services arrangement, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.", "Moreover, if the economic benefits we are able to obtain through the generics purchasing services arrangement with WBA decline due to changes in market conditions or other changes impacting the fees and rebates that generic manufacturers make available through the arrangement, our margins and results of operations could also be adversely affected.", "Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate. assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated.", "We are the primary distributor of pharmaceutical products for WBA.", "If our operations are seriously disrupted for any reason deemed within our control,", "Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBA.", "As part of our strategy we seek to pursue acquisitions of and investments in other companies.", "Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio in order to determine whether an asset or business may no longer help us meet our objectives.", "When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives.", "We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above.", "At any particular time, our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition.", "Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability.", "Regulation of pharmaceutical  distribution  is  intended  to  prevent  diversion  and  the  introduction  of  counterfeit,  adulterated,  and/or  mislabeled  drugs  into  the  pharmaceutical distribution system.", "pedigree  requirements,  and  will  require  all  supply-chain  stakeholders  to  participate  in  an  electronic,  interoperable  prescription  drug  traceability  system  by November 2023.", "Acquisitions involve numerous risks and uncertainties and may be of businesses in which we lack operational or market experience.", "Our operations in jurisdictions outside of the United States are subject to various risks inherent in global operations.", "We have distribution centers and facilities located in the United States and throughout the world.", "Our business exposes us to risks that are inherent in the", "The healthcare industry in the United States is highly regulated at the federal and state levels.", "Our international operations may also be subject to local regulations containing record-keeping and other obligations related to our distribution operations in those locations.", "including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.", "distribution system may change their interpretation or approach to implementing or complying with those standards, in a manner that may adversely affect our business.", "Federal,  state  and  local  governmental  and  regulatory  agencies  are  conducting  investigations  of  us  and  others  in  the  supply  chain,  including  pharmaceutical manufacturers and other pharmaceutical wholesale distributors, regarding the distribution of opioid medications.", "In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the supply chain by state and local governmental entities and other plaintiffs for claims related to the Company\u2019s distribution of opioid medications.", "Litigation is costly, time-consuming, and disruptive to ordinary business operations.", "Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.", "We are a large corporation with operations in the United States and select global markets.", "We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business.", "more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations.", "customers  and  suppliers.  The  COVID-19  pandemic  is  adversely  affecting,  and  is  expected  to  continue  to  adversely  affect,  our  operations,  supply  chains  and distribution network, and we have experienced and expect to continue to experience unpredictable reductions in supply and demand for certain of our products and services.", "Further, it is possible that the manufacturers that produce the products that we distribute may experience delays or shutdowns due to COVID-19, such as from disruptions in their supply chains or in a suspension of production at their own facilities.", "Accordingly, we expect the continued spread of COVID-19 to adversely affect the supply of products and/or potentially disrupt our ability to deliver products to customers.", "resulted in our decision to temporarily close, and subsequently reopen, a small number of our distribution centers in accordance with our internal protocols.", "We have implemented measures designed to keep our employees safe and have protocols in place to address business continuity issues at our distribution centers and other locations, but a widespread or sustained outbreak of COVID-19 at one or more locations could disrupt our ability to service our customers.", "instance, demand for certain animal health products in our MWI business declined during the COVID-19 pandemic, and this reduced demand may continue as customers reduce or postpone purchases viewed as discretionary.", "We also face risks related to a downturn in our customers' respective businesses, including the operations of our retail pharmacy and health systems customers.", "enhancing and upgrading our information technology systems, may take longer than originally expected to complete as we focus on COVID-19-related issues.", "Additionally, a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "We also face risks related to our employees' health and the impact it may have on operations.", "Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.", "We continue to make substantial investments in data centers and information systems, including, but not limited to, the expanded implementation of our primary ERP system to integrate certain  of  our  key  business  areas.  Third-party  service  providers  are  also  responsible  for  managing  a  portion  of  our  information  systems.  To  the  extent  our information systems are not successfully implemented or fail, or to the extent there are data center interruptions, our business and results of operations may be adversely affected.", "Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.", "technologies, and the increased sophistication and activities of perpetrators of cyber attacks.", "A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, cause loss of customers or revenue, increase our costs, result in litigation and/or regulatory action, and/or cause other losses, any of which might have a materially adverse impact on our business operations and our financial position or results of operations.", "As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us.", "Although we believe that we have robust information security procedures, controls and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.", "adversely affecting our business,\u201d a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time.", "and other severe hazards or accidents in the United States or in other countries in which we operate or are located could adversely affect our operations and financial performance.", "Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure  of one or more  of distribution  centers  or outsourcing  facilities,  temporary  or long-term  disruption in the  supply of products,  delay in the  delivery  of products to our distribution centers, and/or disruption of our ability to deliver products to customers.", "Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.", "(including  Puerto  Rico)  and  select  global  markets.  We  lease  facilities  in  Chesterbrook,  Pennsylvania  and  in  Conshohocken,  Pennsylvania  for  our  corporate headquarters.", "Pharmaceutical Distribution Services has a robust distribution facility network in the United States.", "We consider all of our operating and office properties to be in satisfactory condition.", "The following is a list of our executive officers and their ages and positions as of November 15, 2020.", "biotech  manufacturers  improve  patient  access  to  products  and  enhance  patient  care.  We  deliver  innovative  programs  and  services  designed  to  increase  the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "We are organized based upon the products and services we provide to our customers.", "Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant  enough  to  require  separate  reportable  segment  disclosure  and,  therefore,  have  been  included  in  Other  for  the  purpose  of  our  reportable  segment presentation.", "We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and", "In connection with the mitigation and containment procedures recommended by the WHO and imposed by federal, state, and local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "\u2022 Revenue increased 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;", "Increased sales to Walgreens, our largest customer $2.8 Increased sales to specialty physician practices $2.8 Increased sales to other customers $4.1", "We currently expect our revenue growth percentage to be in the mid-single digits in fiscal 2021.", "Our future revenue growth will continue to be affected by", "Revenue increased by 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "A  number  of  our  contracts  with  customers,  including  group  purchasing  organizations,  are  typically  subject  to  expiration  each  year.  We  may  lose  a", "As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.10% in the current fiscal year decreased 3 basis points compared to the prior fiscal year primarily due to increased sales to our larger customers, which typically have lower gross profit margins.", "Our cost of goods sold includes a LIFO provision that is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "We incurred remediation costs in connection with the suspended production activities at PharMEDium.", "We also incurred shutdown costs in connection with permanently exiting the PharMEDium compounding business.", "primarily  due  to  an  increase  in  operating  costs  to  support  our  revenue  growth  and  costs  incurred  in  connection  with  permanently  exiting  the  PharMEDium compounding business, such as contract termination fees, offset in part by operational synergies realized from the integration of H.D.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Increased sales to Walgreens, our largest customer $5.6 Increased sales to specialty physician practices $3.0 Increased sales to other customers $1.7 Increased sales due to Profarma and H.D.", "Revenue increased by 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility had been suspended since December 2017.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.", "As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 4 basis points from the prior fiscal year primarily due to a lower contribution from our pharmaceutical compounding operations.", "We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends.", "Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly.", "We identify our reporting units based upon our management reporting structure, beginning with our operating segments.", "We aggregate two or more components within an operating segment that have similar economic characteristics.", "We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment.", "Our reporting units include Pharmaceutical Distribution Services, Profarma, ABCS, World Courier, and MWI.", "While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.", "Food and Drug Administration (\"FDA\") inspections of PharMEDium's compounding facilities, we voluntarily suspended production activities", "The decision to permanently exit the PharMEDium business was due to a number of factors including, but not limited  to,  ongoing  operational,  regulatory,  and  commercial  challenges,  such  as  PharMEDium's  decision  in  January  2020  to  suspend  production  at  the compounding  facility  in  New  Jersey  pending  facility  upgrades  related  to  the  air  handling  and  filtration  systems.  In  connection  with  the  decision  to  exit  the PharMEDium  business,  we  recorded  an  impairment  of  PharMEDium's  assets  of  $223.7  million  in  the  three  months  ended  March  31,  2020,  which  included impairments of the remaining finite-lived intangible assets and the majority of the remaining tangible assets.", "The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "The increase in inventories was due to an increase in business volume.", "We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance.", "Significant  capital  expenditures  in  fiscal  2020 included  investments  in various  technology  initiatives,  including  costs  related  to  enhancing  and  upgrading  our primary information technology operating systems.", "Significant capital expenditures in fiscal 2019 included costs associated with the construction of a new support facility and technology initiatives, including costs related to enhancing and upgrading our information technology systems.", "Significant capital expenditures in fiscal 2018 included technology initiatives, including costs related to enhancing and upgrading our information technology systems and costs associated with expanding distribution capacity.", "We acquired businesses to support our animal health business for $54.0 million and $70.0 million in the fiscal years ended September 30, 2019 and 2018,", "Among the factors that could cause actual results to differ materially from those projected, anticipated, or  implied  are  the  following:  unfavorable  trends  in  brand  and  generic  pharmaceutical  pricing,  including  in  rate  or  frequency  of  price  inflation  or  deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government  enforcement  initiatives  to  detect  and  prevent  suspicious  orders  of  controlled  substances  and  the  diversion  of  controlled  substances;  continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale,  purchase  and/or  dispensing  of  pharmaceutical  products  or  services,  and  associated  reserves  and  costs;  failure  to  comply  with  the  Corporate  Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse  resolution  of  any  contract  or  other  dispute  with  customers  or  suppliers;  changes  to  customer  or  supplier  payment  terms,  including  as  a  result  of  the COVID-19 impact on such payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative  initiatives  that  could  adversely  affect  the  Company\u2019s  tax  positions  and/or  the  Company\u2019s  tax  liabilities  or  adverse  resolution  of  challenges  to  the Company\u2019s  tax  positions;  managing  foreign  expansion,  including  non-compliance  with  the  U.S.  Foreign  Corrupt  Practices  Act,  anti-bribery  laws,  economic sanctions and import laws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data;  natural  disasters  or other unexpected  events that affect  the Company\u2019s operations;  the impairment  of goodwill or other intangible  assets (including  any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and  abroad;  and  other  economic,  business,  competitive,  legal,  tax,  regulatory  and/or  operational  factors  affecting  the  Company\u2019s  business  generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this Management's Discussion and Analysis of Financial Condition and Results of Operations, (ii) in Item 1A (Risk Factors), (iii) Item 1 (Business), (iv) elsewhere in this report, and (v) in other reports filed by the Company pursuant to the Securities Exchange Act.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of legal contingencies.", "The acquisition strengthens  the  Company's  core  business,  expands  and  enhances  its  strategic  scale  in  pharmaceutical  distribution,  and  expands  the  Company's  support  for independent community pharmacies.", "Smith has been integrated into the Pharmaceutical Distribution reportable segment.", "The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years.", "Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.", "decision to permanently exit the PharMEDium compounding business.", "Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith, and restructuring activities related to our consulting business.", "We  adopted  a  Code  of  Ethics  for  Designated  Senior  Officers  that  applies  to  our  Chief  Executive  Officer,  Chief  Financial  Officer,  and  Corporate", "AmerisourceBergen  is  one  of  the  largest  global  pharmaceutical  sourcing  and  distribution  services  companies,  helping  both  healthcare  providers  and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.", "We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers.", "Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services,  including  data  analytics,  outcomes  research,  reimbursement  and  pharmaceutical  consulting  services,  niche  premium  logistics  services,  inventory management, pharmacy automation, pharmacy management, and packaging solutions.", "such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases.", "We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry.", "In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business. next several years.", "We consider  the  increase  in  generic  usage  a  favorable  trend  because  generic  pharmaceuticals  have  historically  provided  us  with  a  greater  gross  profit  margin opportunity than brand-name products, although their lower prices reduce revenue growth.", "Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.", "The number of individuals age 65 and over in the United States is expected to exceed 63 million by 2024 and is the most rapidly", "spread  of  COVID-19.  In  connection  with  the  mitigation  and  containment  procedures  recommended  by  the  WHO  and  imposed  by  federal,  state,  and  local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "In our pharmaceutical  distribution  business, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers.", "We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.", "Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business, and we believe we are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:", "\u2022 Optimize and Grow Our Pharmaceutical Distribution and Strategic Global Sourcing Businesses.  We believe we are well positioned in size and market", "Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A.", "breadth to continue to grow our distribution businesses as we invest to improve our operating and capital efficiencies.", "Distribution, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value- added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.", "We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products.", "We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products.", "We are well positioned to service and support many of the new biotechnology therapies that are expected to be coming to market in the near future.", "We have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland.", "We  source  generics  globally,  offer  a  value-added  generic  formulary  program  to  our  healthcare  provider  customers,  and  monitor  our  customers' compliance with our generics program.", "We also provide data and other valuable services to our manufacturer customers, which includes our international presence in Switzerland where we lead our global manufacturer relations and commercialization strategy.", "We are organized based upon the products and services we provide to our customers.", "Our operations as of September 30, 2020 are comprised  of  the  Pharmaceutical  Distribution  Services  reportable  segment  and  other  operating  segments  that  are  not  significant  enough  to  require  separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation.", "In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments.", "\u2022 Optimize  and  Grow  Our  Global  Commercialization  Services  and  Animal  Health  Businesses.  Our  consulting  service  businesses  help  global", "In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time,", "We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes.", "We believe we have one of the lowest operating cost structures among all pharmaceutical distributors.", "Our robust distribution facility network includes a national distribution center in Columbus, OH, which offers pharmaceutical manufacturers a single shipping destination.", "World Courier is  a  leading  global  specialty  transportation  and  logistics  provider  for  the  biopharmaceutical  industry.  World  Courier  further  strengthens  our  service offerings  to  global  pharmaceutical  manufacturers  and  provides  an  established  platform  for  the  introduction  of  our  specialty  services  outside  North America.", "MWI also offers its customers a variety of value-added services, including its e- commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI.", "We continue to seek opportunities to expand our offerings in our Global Commercialization Services and Animal Health businesses.", "Pharmaceutical  Distribution  Services  also  has  support  professionals  focused  on  its  various  technologies  and  service  offerings.  Pharmaceutical  Distribution Services\u2019 sales teams also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their needs.", "Our other operating segments each have independent sales forces that specialize in their respective product and service offerings.", "In addition, we have an enterprise-wide marketing team that coordinates branding and all other marketing activities across the Company.", "We are typically the primary  source  of  supply  for  our  healthcare  provider  customers.  Our  manufacturer  customers  include  branded,  generic,  and  biotechnology  manufacturers  of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers.", "In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.", "The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations.", "We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal year ended September 30, 2020.", "The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers.", "We believe that our relationships with our suppliers are strong.", "The 10 largest suppliers in fiscal year ended September 30, 2020 accounted for approximately 46% of our purchases.", "As a result, the pharmaceutical distribution facilities in the United States all now operate under a single ERP system.", "We  have  a  diverse  customer  base  that  includes  institutional  and  retail  healthcare  providers  as  well  as  pharmaceutical  manufacturers.", "All of our other operating segments operate the majority of their businesses on their own common operating systems resulting in the ability to rapidly deploy new capabilities.", "We continue to make investments to enhance and upgrade the operating systems utilized by our other operating segments.", "pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems. are intended to strengthen customer relationships by helping customers to reduce operating costs, and by providing them a platform for a number of the basic and value-added services, including product demand data, inventory replenishment, single-source billing, third-party claims processing, real-time price and incentive updates, and price labels. make substantial investments to expand its electronic interface with its suppliers.", "The warehouse operating systems have improved Pharmaceutical Distribution Services\u2019 productivity and operating leverage.", "Pharmaceutical Distribution  Services  competes  with  both  McKesson  and  Cardinal,  as  well  as  national  generic  distributors  and  regional  distributors  within  pharmaceutical distribution.  In  addition,  we  compete  with  manufacturers  who  sell  directly  to  customers,  chain  drugstores  who  manage  their  own  warehousing,  specialty distributors, and packaging and healthcare technology companies.", "conduct  of  our  business  or  that  are  made  available  as  products  or  services  to  customers.  We  generally  seek  to  protect  such  intellectual  property  through  a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections. our medication and supply dispensing equipment, certain warehousing equipment, and some of our proprietary packaging solutions.", "Additionally, we are improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.", "We will continue  to invest in advanced  information  systems and automated  warehouse technology.  For example,  in an effort  to comply with future", "Pharmaceutical Distribution Services has made significant investments in its electronic ordering systems.", "A significant portion of our data center operations, which were previously outsourced to third-party providers, is now insourced.", "We  face  a  highly  competitive  global  environment  in  the  distribution  of pharmaceuticals  and  related  healthcare  services.  Our largest  competitors  are", "All of the principal trademarks and service marks used in the course of our business have been", "As of September 30, 2020, we had approximately 22,000 employees, of which approximately 21,000 were full-time employees.", "More than 56% of our workforce is comprised of women, 49% is comprised of individuals with ethnically diverse backgrounds, and 30% of our Board of Directors are women.", "Additionally, our Executive Management Committee is made up of 43% women.", "any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations.", "However, we believe we have adequate contingency plans in place to assure delivery of pharmaceuticals to our customers in the event of any such disruptions.", "We expect that the FDA, and eventually comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers.", "Approximately 2% of our employees are covered by collective bargaining agreements.", "We believe that our relationship with our employees is good.", "Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material.", "The reader should not consider this list to be a complete statement of all risks and uncertainties.", "Industry and Economic Risks Our results of operations could be adversely impacted by manufacturer pricing changes.", "Distribution Services reportable segment profit and our consolidated operating earnings.", "If such initiatives are passed or finalized and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.", "Competition and industry consolidation may erode our profit.", "recent years the healthcare industry has been subject to increasing consolidation, including among pharmaceutical manufacturers, retail pharmacies, and health insurers, which may create further competitive pressures on our pharmaceutical distribution business.", "If we do not compete successfully, it could have a material and adverse effect on our business and results of operations.", "The impact on us will be greater if consolidation among our customers, suppliers, and competitors gives the resulting enterprises greater bargaining power, which could lead to greater pressure on us to reduce prices for our products and services.", "The following discussion describes certain risk factors that we believe could affect our business and prospects.", "Declining economic conditions could adversely affect our results of operations and financial condition.", "If the economic conditions in the United States or in the countries where we do business deteriorate, our results of operations or financial condition could be adversely affected.", "Our top ten customers, including governmental agencies and GPOs, represented approximately 64% of revenue in the fiscal year ended September 30, 2020.", "Our operations and performance depend on economic conditions in the United States and other countries where we do business.", "Walgreens Boots Alliance Development GmbH (\"WBAD\") provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf.", "This reflected our expectation that partnering strategically with WBA would result in various benefits including, among other things, continued cost savings as a  result  of our generics  purchasing  services  arrangement  with WBAD, as well as the potential  for exploring  innovation  together  and sharing best practices.", "The processes and initiatives needed to achieve and maintain these benefits are complex, costly, and time-consuming.", "Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management time and attention.", "A disruption in our distribution or generic purchasing services arrangements with WBA could adversely affect our business and financial results.", "In addition, upon the expiration or termination of the distribution agreement or generics purchasing services arrangement, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.", "Moreover, if the economic benefits we are able to obtain through the generics purchasing services arrangement with WBA decline due to changes in market conditions or other changes impacting the fees and rebates that generic manufacturers make available through the arrangement, our margins and results of operations could also be adversely affected.", "Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate. assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated.", "We are the primary distributor of pharmaceutical products for WBA.", "If our operations are seriously disrupted for any reason deemed within our control,", "Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBA.", "As part of our strategy we seek to pursue acquisitions of and investments in other companies.", "Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio in order to determine whether an asset or business may no longer help us meet our objectives.", "When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives.", "We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above.", "At any particular time, our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition.", "Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability.", "Regulation of pharmaceutical  distribution  is  intended  to  prevent  diversion  and  the  introduction  of  counterfeit,  adulterated,  and/or  mislabeled  drugs  into  the  pharmaceutical distribution system.", "pedigree  requirements,  and  will  require  all  supply-chain  stakeholders  to  participate  in  an  electronic,  interoperable  prescription  drug  traceability  system  by November 2023.", "Acquisitions involve numerous risks and uncertainties and may be of businesses in which we lack operational or market experience.", "Our operations in jurisdictions outside of the United States are subject to various risks inherent in global operations.", "We have distribution centers and facilities located in the United States and throughout the world.", "Our business exposes us to risks that are inherent in the", "The healthcare industry in the United States is highly regulated at the federal and state levels.", "Our international operations may also be subject to local regulations containing record-keeping and other obligations related to our distribution operations in those locations.", "including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.", "distribution system may change their interpretation or approach to implementing or complying with those standards, in a manner that may adversely affect our business.", "Federal,  state  and  local  governmental  and  regulatory  agencies  are  conducting  investigations  of  us  and  others  in  the  supply  chain,  including  pharmaceutical manufacturers and other pharmaceutical wholesale distributors, regarding the distribution of opioid medications.", "In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the supply chain by state and local governmental entities and other plaintiffs for claims related to the Company\u2019s distribution of opioid medications.", "Litigation is costly, time-consuming, and disruptive to ordinary business operations.", "Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.", "We are a large corporation with operations in the United States and select global markets.", "We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business.", "more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations.", "customers  and  suppliers.  The  COVID-19  pandemic  is  adversely  affecting,  and  is  expected  to  continue  to  adversely  affect,  our  operations,  supply  chains  and distribution network, and we have experienced and expect to continue to experience unpredictable reductions in supply and demand for certain of our products and services.", "Further, it is possible that the manufacturers that produce the products that we distribute may experience delays or shutdowns due to COVID-19, such as from disruptions in their supply chains or in a suspension of production at their own facilities.", "Accordingly, we expect the continued spread of COVID-19 to adversely affect the supply of products and/or potentially disrupt our ability to deliver products to customers.", "resulted in our decision to temporarily close, and subsequently reopen, a small number of our distribution centers in accordance with our internal protocols.", "We have implemented measures designed to keep our employees safe and have protocols in place to address business continuity issues at our distribution centers and other locations, but a widespread or sustained outbreak of COVID-19 at one or more locations could disrupt our ability to service our customers.", "instance, demand for certain animal health products in our MWI business declined during the COVID-19 pandemic, and this reduced demand may continue as customers reduce or postpone purchases viewed as discretionary.", "We also face risks related to a downturn in our customers' respective businesses, including the operations of our retail pharmacy and health systems customers.", "enhancing and upgrading our information technology systems, may take longer than originally expected to complete as we focus on COVID-19-related issues.", "Additionally, a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "We also face risks related to our employees' health and the impact it may have on operations.", "Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.", "We continue to make substantial investments in data centers and information systems, including, but not limited to, the expanded implementation of our primary ERP system to integrate certain  of  our  key  business  areas.  Third-party  service  providers  are  also  responsible  for  managing  a  portion  of  our  information  systems.  To  the  extent  our information systems are not successfully implemented or fail, or to the extent there are data center interruptions, our business and results of operations may be adversely affected.", "Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.", "technologies, and the increased sophistication and activities of perpetrators of cyber attacks.", "A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, cause loss of customers or revenue, increase our costs, result in litigation and/or regulatory action, and/or cause other losses, any of which might have a materially adverse impact on our business operations and our financial position or results of operations.", "As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us.", "Although we believe that we have robust information security procedures, controls and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.", "adversely affecting our business,\u201d a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time.", "and other severe hazards or accidents in the United States or in other countries in which we operate or are located could adversely affect our operations and financial performance.", "Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure  of one or more  of distribution  centers  or outsourcing  facilities,  temporary  or long-term  disruption in the  supply of products,  delay in the  delivery  of products to our distribution centers, and/or disruption of our ability to deliver products to customers.", "Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.", "(including  Puerto  Rico)  and  select  global  markets.  We  lease  facilities  in  Chesterbrook,  Pennsylvania  and  in  Conshohocken,  Pennsylvania  for  our  corporate headquarters.", "Pharmaceutical Distribution Services has a robust distribution facility network in the United States.", "We consider all of our operating and office properties to be in satisfactory condition.", "The following is a list of our executive officers and their ages and positions as of November 15, 2020.", "biotech  manufacturers  improve  patient  access  to  products  and  enhance  patient  care.  We  deliver  innovative  programs  and  services  designed  to  increase  the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "We are organized based upon the products and services we provide to our customers.", "Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant  enough  to  require  separate  reportable  segment  disclosure  and,  therefore,  have  been  included  in  Other  for  the  purpose  of  our  reportable  segment presentation.", "We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and", "In connection with the mitigation and containment procedures recommended by the WHO and imposed by federal, state, and local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "\u2022 Revenue increased 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;", "Increased sales to Walgreens, our largest customer $2.8 Increased sales to specialty physician practices $2.8 Increased sales to other customers $4.1", "We currently expect our revenue growth percentage to be in the mid-single digits in fiscal 2021.", "Our future revenue growth will continue to be affected by", "Revenue increased by 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "A  number  of  our  contracts  with  customers,  including  group  purchasing  organizations,  are  typically  subject  to  expiration  each  year.  We  may  lose  a", "As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.10% in the current fiscal year decreased 3 basis points compared to the prior fiscal year primarily due to increased sales to our larger customers, which typically have lower gross profit margins.", "Our cost of goods sold includes a LIFO provision that is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "We incurred remediation costs in connection with the suspended production activities at PharMEDium.", "We also incurred shutdown costs in connection with permanently exiting the PharMEDium compounding business.", "primarily  due  to  an  increase  in  operating  costs  to  support  our  revenue  growth  and  costs  incurred  in  connection  with  permanently  exiting  the  PharMEDium compounding business, such as contract termination fees, offset in part by operational synergies realized from the integration of H.D.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Increased sales to Walgreens, our largest customer $5.6 Increased sales to specialty physician practices $3.0 Increased sales to other customers $1.7 Increased sales due to Profarma and H.D.", "Revenue increased by 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility had been suspended since December 2017.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.", "As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 4 basis points from the prior fiscal year primarily due to a lower contribution from our pharmaceutical compounding operations.", "We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends.", "Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly.", "We identify our reporting units based upon our management reporting structure, beginning with our operating segments.", "We aggregate two or more components within an operating segment that have similar economic characteristics.", "We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment.", "Our reporting units include Pharmaceutical Distribution Services, Profarma, ABCS, World Courier, and MWI.", "While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.", "Food and Drug Administration (\"FDA\") inspections of PharMEDium's compounding facilities, we voluntarily suspended production activities", "The decision to permanently exit the PharMEDium business was due to a number of factors including, but not limited  to,  ongoing  operational,  regulatory,  and  commercial  challenges,  such  as  PharMEDium's  decision  in  January  2020  to  suspend  production  at  the compounding  facility  in  New  Jersey  pending  facility  upgrades  related  to  the  air  handling  and  filtration  systems.  In  connection  with  the  decision  to  exit  the PharMEDium  business,  we  recorded  an  impairment  of  PharMEDium's  assets  of  $223.7  million  in  the  three  months  ended  March  31,  2020,  which  included impairments of the remaining finite-lived intangible assets and the majority of the remaining tangible assets.", "The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "The increase in inventories was due to an increase in business volume.", "We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance.", "Significant  capital  expenditures  in  fiscal  2020 included  investments  in various  technology  initiatives,  including  costs  related  to  enhancing  and  upgrading  our primary information technology operating systems.", "Significant capital expenditures in fiscal 2019 included costs associated with the construction of a new support facility and technology initiatives, including costs related to enhancing and upgrading our information technology systems.", "Significant capital expenditures in fiscal 2018 included technology initiatives, including costs related to enhancing and upgrading our information technology systems and costs associated with expanding distribution capacity.", "We acquired businesses to support our animal health business for $54.0 million and $70.0 million in the fiscal years ended September 30, 2019 and 2018,", "Among the factors that could cause actual results to differ materially from those projected, anticipated, or  implied  are  the  following:  unfavorable  trends  in  brand  and  generic  pharmaceutical  pricing,  including  in  rate  or  frequency  of  price  inflation  or  deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government  enforcement  initiatives  to  detect  and  prevent  suspicious  orders  of  controlled  substances  and  the  diversion  of  controlled  substances;  continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale,  purchase  and/or  dispensing  of  pharmaceutical  products  or  services,  and  associated  reserves  and  costs;  failure  to  comply  with  the  Corporate  Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse  resolution  of  any  contract  or  other  dispute  with  customers  or  suppliers;  changes  to  customer  or  supplier  payment  terms,  including  as  a  result  of  the COVID-19 impact on such payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative  initiatives  that  could  adversely  affect  the  Company\u2019s  tax  positions  and/or  the  Company\u2019s  tax  liabilities  or  adverse  resolution  of  challenges  to  the Company\u2019s  tax  positions;  managing  foreign  expansion,  including  non-compliance  with  the  U.S.  Foreign  Corrupt  Practices  Act,  anti-bribery  laws,  economic sanctions and import laws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data;  natural  disasters  or other unexpected  events that affect  the Company\u2019s operations;  the impairment  of goodwill or other intangible  assets (including  any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and  abroad;  and  other  economic,  business,  competitive,  legal,  tax,  regulatory  and/or  operational  factors  affecting  the  Company\u2019s  business  generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this Management's Discussion and Analysis of Financial Condition and Results of Operations, (ii) in Item 1A (Risk Factors), (iii) Item 1 (Business), (iv) elsewhere in this report, and (v) in other reports filed by the Company pursuant to the Securities Exchange Act.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of legal contingencies.", "The acquisition strengthens  the  Company's  core  business,  expands  and  enhances  its  strategic  scale  in  pharmaceutical  distribution,  and  expands  the  Company's  support  for independent community pharmacies.", "Smith has been integrated into the Pharmaceutical Distribution reportable segment.", "The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years.", "Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.", "decision to permanently exit the PharMEDium compounding business.", "Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith, and restructuring activities related to our consulting business.", "We  adopted  a  Code  of  Ethics  for  Designated  Senior  Officers  that  applies  to  our  Chief  Executive  Officer,  Chief  Financial  Officer,  and  Corporate", "AmerisourceBergen  is  one  of  the  largest  global  pharmaceutical  sourcing  and  distribution  services  companies,  helping  both  healthcare  providers  and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.", "We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers.", "Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services,  including  data  analytics,  outcomes  research,  reimbursement  and  pharmaceutical  consulting  services,  niche  premium  logistics  services,  inventory management, pharmacy automation, pharmacy management, and packaging solutions.", "such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases.", "We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry.", "In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business. next several years.", "We consider  the  increase  in  generic  usage  a  favorable  trend  because  generic  pharmaceuticals  have  historically  provided  us  with  a  greater  gross  profit  margin opportunity than brand-name products, although their lower prices reduce revenue growth.", "Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.", "The number of individuals age 65 and over in the United States is expected to exceed 63 million by 2024 and is the most rapidly", "spread  of  COVID-19.  In  connection  with  the  mitigation  and  containment  procedures  recommended  by  the  WHO  and  imposed  by  federal,  state,  and  local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "In our pharmaceutical  distribution  business, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers.", "We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.", "Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business, and we believe we are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:", "\u2022 Optimize and Grow Our Pharmaceutical Distribution and Strategic Global Sourcing Businesses.  We believe we are well positioned in size and market", "Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A.", "breadth to continue to grow our distribution businesses as we invest to improve our operating and capital efficiencies.", "Distribution, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value- added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.", "We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products.", "We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products.", "We are well positioned to service and support many of the new biotechnology therapies that are expected to be coming to market in the near future.", "We have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland.", "We  source  generics  globally,  offer  a  value-added  generic  formulary  program  to  our  healthcare  provider  customers,  and  monitor  our  customers' compliance with our generics program.", "We also provide data and other valuable services to our manufacturer customers, which includes our international presence in Switzerland where we lead our global manufacturer relations and commercialization strategy.", "We are organized based upon the products and services we provide to our customers.", "Our operations as of September 30, 2020 are comprised  of  the  Pharmaceutical  Distribution  Services  reportable  segment  and  other  operating  segments  that  are  not  significant  enough  to  require  separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation.", "In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments.", "\u2022 Optimize  and  Grow  Our  Global  Commercialization  Services  and  Animal  Health  Businesses.  Our  consulting  service  businesses  help  global", "In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time,", "We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes.", "We believe we have one of the lowest operating cost structures among all pharmaceutical distributors.", "Our robust distribution facility network includes a national distribution center in Columbus, OH, which offers pharmaceutical manufacturers a single shipping destination.", "World Courier is  a  leading  global  specialty  transportation  and  logistics  provider  for  the  biopharmaceutical  industry.  World  Courier  further  strengthens  our  service offerings  to  global  pharmaceutical  manufacturers  and  provides  an  established  platform  for  the  introduction  of  our  specialty  services  outside  North America.", "MWI also offers its customers a variety of value-added services, including its e- commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI.", "We continue to seek opportunities to expand our offerings in our Global Commercialization Services and Animal Health businesses.", "Pharmaceutical  Distribution  Services  also  has  support  professionals  focused  on  its  various  technologies  and  service  offerings.  Pharmaceutical  Distribution Services\u2019 sales teams also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their needs.", "Our other operating segments each have independent sales forces that specialize in their respective product and service offerings.", "In addition, we have an enterprise-wide marketing team that coordinates branding and all other marketing activities across the Company.", "We are typically the primary  source  of  supply  for  our  healthcare  provider  customers.  Our  manufacturer  customers  include  branded,  generic,  and  biotechnology  manufacturers  of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers.", "In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.", "The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations.", "We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal year ended September 30, 2020.", "The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers.", "We believe that our relationships with our suppliers are strong.", "The 10 largest suppliers in fiscal year ended September 30, 2020 accounted for approximately 46% of our purchases.", "As a result, the pharmaceutical distribution facilities in the United States all now operate under a single ERP system.", "We  have  a  diverse  customer  base  that  includes  institutional  and  retail  healthcare  providers  as  well  as  pharmaceutical  manufacturers.", "All of our other operating segments operate the majority of their businesses on their own common operating systems resulting in the ability to rapidly deploy new capabilities.", "We continue to make investments to enhance and upgrade the operating systems utilized by our other operating segments.", "pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems. are intended to strengthen customer relationships by helping customers to reduce operating costs, and by providing them a platform for a number of the basic and value-added services, including product demand data, inventory replenishment, single-source billing, third-party claims processing, real-time price and incentive updates, and price labels. make substantial investments to expand its electronic interface with its suppliers.", "The warehouse operating systems have improved Pharmaceutical Distribution Services\u2019 productivity and operating leverage.", "Pharmaceutical Distribution  Services  competes  with  both  McKesson  and  Cardinal,  as  well  as  national  generic  distributors  and  regional  distributors  within  pharmaceutical distribution.  In  addition,  we  compete  with  manufacturers  who  sell  directly  to  customers,  chain  drugstores  who  manage  their  own  warehousing,  specialty distributors, and packaging and healthcare technology companies.", "conduct  of  our  business  or  that  are  made  available  as  products  or  services  to  customers.  We  generally  seek  to  protect  such  intellectual  property  through  a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections. our medication and supply dispensing equipment, certain warehousing equipment, and some of our proprietary packaging solutions.", "Additionally, we are improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.", "We will continue  to invest in advanced  information  systems and automated  warehouse technology.  For example,  in an effort  to comply with future", "Pharmaceutical Distribution Services has made significant investments in its electronic ordering systems.", "A significant portion of our data center operations, which were previously outsourced to third-party providers, is now insourced.", "We  face  a  highly  competitive  global  environment  in  the  distribution  of pharmaceuticals  and  related  healthcare  services.  Our largest  competitors  are", "All of the principal trademarks and service marks used in the course of our business have been", "As of September 30, 2020, we had approximately 22,000 employees, of which approximately 21,000 were full-time employees.", "More than 56% of our workforce is comprised of women, 49% is comprised of individuals with ethnically diverse backgrounds, and 30% of our Board of Directors are women.", "Additionally, our Executive Management Committee is made up of 43% women.", "any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations.", "However, we believe we have adequate contingency plans in place to assure delivery of pharmaceuticals to our customers in the event of any such disruptions.", "We expect that the FDA, and eventually comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers.", "Approximately 2% of our employees are covered by collective bargaining agreements.", "We believe that our relationship with our employees is good.", "Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material.", "The reader should not consider this list to be a complete statement of all risks and uncertainties.", "Industry and Economic Risks Our results of operations could be adversely impacted by manufacturer pricing changes.", "Distribution Services reportable segment profit and our consolidated operating earnings.", "If such initiatives are passed or finalized and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.", "Competition and industry consolidation may erode our profit.", "recent years the healthcare industry has been subject to increasing consolidation, including among pharmaceutical manufacturers, retail pharmacies, and health insurers, which may create further competitive pressures on our pharmaceutical distribution business.", "If we do not compete successfully, it could have a material and adverse effect on our business and results of operations.", "The impact on us will be greater if consolidation among our customers, suppliers, and competitors gives the resulting enterprises greater bargaining power, which could lead to greater pressure on us to reduce prices for our products and services.", "The following discussion describes certain risk factors that we believe could affect our business and prospects.", "Declining economic conditions could adversely affect our results of operations and financial condition.", "If the economic conditions in the United States or in the countries where we do business deteriorate, our results of operations or financial condition could be adversely affected.", "Our top ten customers, including governmental agencies and GPOs, represented approximately 64% of revenue in the fiscal year ended September 30, 2020.", "Our operations and performance depend on economic conditions in the United States and other countries where we do business.", "Walgreens Boots Alliance Development GmbH (\"WBAD\") provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf.", "This reflected our expectation that partnering strategically with WBA would result in various benefits including, among other things, continued cost savings as a  result  of our generics  purchasing  services  arrangement  with WBAD, as well as the potential  for exploring  innovation  together  and sharing best practices.", "The processes and initiatives needed to achieve and maintain these benefits are complex, costly, and time-consuming.", "Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management time and attention.", "A disruption in our distribution or generic purchasing services arrangements with WBA could adversely affect our business and financial results.", "In addition, upon the expiration or termination of the distribution agreement or generics purchasing services arrangement, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.", "Moreover, if the economic benefits we are able to obtain through the generics purchasing services arrangement with WBA decline due to changes in market conditions or other changes impacting the fees and rebates that generic manufacturers make available through the arrangement, our margins and results of operations could also be adversely affected.", "Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate. assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated.", "We are the primary distributor of pharmaceutical products for WBA.", "If our operations are seriously disrupted for any reason deemed within our control,", "Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBA.", "As part of our strategy we seek to pursue acquisitions of and investments in other companies.", "Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio in order to determine whether an asset or business may no longer help us meet our objectives.", "When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives.", "We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above.", "At any particular time, our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition.", "Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability.", "Regulation of pharmaceutical  distribution  is  intended  to  prevent  diversion  and  the  introduction  of  counterfeit,  adulterated,  and/or  mislabeled  drugs  into  the  pharmaceutical distribution system.", "pedigree  requirements,  and  will  require  all  supply-chain  stakeholders  to  participate  in  an  electronic,  interoperable  prescription  drug  traceability  system  by November 2023.", "Acquisitions involve numerous risks and uncertainties and may be of businesses in which we lack operational or market experience.", "Our operations in jurisdictions outside of the United States are subject to various risks inherent in global operations.", "We have distribution centers and facilities located in the United States and throughout the world.", "Our business exposes us to risks that are inherent in the", "The healthcare industry in the United States is highly regulated at the federal and state levels.", "Our international operations may also be subject to local regulations containing record-keeping and other obligations related to our distribution operations in those locations.", "including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.", "distribution system may change their interpretation or approach to implementing or complying with those standards, in a manner that may adversely affect our business.", "Federal,  state  and  local  governmental  and  regulatory  agencies  are  conducting  investigations  of  us  and  others  in  the  supply  chain,  including  pharmaceutical manufacturers and other pharmaceutical wholesale distributors, regarding the distribution of opioid medications.", "In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the supply chain by state and local governmental entities and other plaintiffs for claims related to the Company\u2019s distribution of opioid medications.", "Litigation is costly, time-consuming, and disruptive to ordinary business operations.", "Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.", "We are a large corporation with operations in the United States and select global markets.", "We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business.", "more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations.", "customers  and  suppliers.  The  COVID-19  pandemic  is  adversely  affecting,  and  is  expected  to  continue  to  adversely  affect,  our  operations,  supply  chains  and distribution network, and we have experienced and expect to continue to experience unpredictable reductions in supply and demand for certain of our products and services.", "Further, it is possible that the manufacturers that produce the products that we distribute may experience delays or shutdowns due to COVID-19, such as from disruptions in their supply chains or in a suspension of production at their own facilities.", "Accordingly, we expect the continued spread of COVID-19 to adversely affect the supply of products and/or potentially disrupt our ability to deliver products to customers.", "resulted in our decision to temporarily close, and subsequently reopen, a small number of our distribution centers in accordance with our internal protocols.", "We have implemented measures designed to keep our employees safe and have protocols in place to address business continuity issues at our distribution centers and other locations, but a widespread or sustained outbreak of COVID-19 at one or more locations could disrupt our ability to service our customers.", "instance, demand for certain animal health products in our MWI business declined during the COVID-19 pandemic, and this reduced demand may continue as customers reduce or postpone purchases viewed as discretionary.", "We also face risks related to a downturn in our customers' respective businesses, including the operations of our retail pharmacy and health systems customers.", "enhancing and upgrading our information technology systems, may take longer than originally expected to complete as we focus on COVID-19-related issues.", "Additionally, a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "We also face risks related to our employees' health and the impact it may have on operations.", "Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.", "We continue to make substantial investments in data centers and information systems, including, but not limited to, the expanded implementation of our primary ERP system to integrate certain  of  our  key  business  areas.  Third-party  service  providers  are  also  responsible  for  managing  a  portion  of  our  information  systems.  To  the  extent  our information systems are not successfully implemented or fail, or to the extent there are data center interruptions, our business and results of operations may be adversely affected.", "Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.", "technologies, and the increased sophistication and activities of perpetrators of cyber attacks.", "A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, cause loss of customers or revenue, increase our costs, result in litigation and/or regulatory action, and/or cause other losses, any of which might have a materially adverse impact on our business operations and our financial position or results of operations.", "As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us.", "Although we believe that we have robust information security procedures, controls and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.", "adversely affecting our business,\u201d a large portion of our employees are working remotely.", "An extended period of remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business.", "Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time.", "and other severe hazards or accidents in the United States or in other countries in which we operate or are located could adversely affect our operations and financial performance.", "Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure  of one or more  of distribution  centers  or outsourcing  facilities,  temporary  or long-term  disruption in the  supply of products,  delay in the  delivery  of products to our distribution centers, and/or disruption of our ability to deliver products to customers.", "Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.", "(including  Puerto  Rico)  and  select  global  markets.  We  lease  facilities  in  Chesterbrook,  Pennsylvania  and  in  Conshohocken,  Pennsylvania  for  our  corporate headquarters.", "Pharmaceutical Distribution Services has a robust distribution facility network in the United States.", "We consider all of our operating and office properties to be in satisfactory condition.", "The following is a list of our executive officers and their ages and positions as of November 15, 2020.", "biotech  manufacturers  improve  patient  access  to  products  and  enhance  patient  care.  We  deliver  innovative  programs  and  services  designed  to  increase  the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.", "We are organized based upon the products and services we provide to our customers.", "Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant  enough  to  require  separate  reportable  segment  disclosure  and,  therefore,  have  been  included  in  Other  for  the  purpose  of  our  reportable  segment presentation.", "We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and", "In connection with the mitigation and containment procedures recommended by the WHO and imposed by federal, state, and local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations.", "\u2022 Revenue increased 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;", "Increased sales to Walgreens, our largest customer $2.8 Increased sales to specialty physician practices $2.8 Increased sales to other customers $4.1", "We currently expect our revenue growth percentage to be in the mid-single digits in fiscal 2021.", "Our future revenue growth will continue to be affected by", "Revenue increased by 5.7% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "A  number  of  our  contracts  with  customers,  including  group  purchasing  organizations,  are  typically  subject  to  expiration  each  year.  We  may  lose  a", "As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.10% in the current fiscal year decreased 3 basis points compared to the prior fiscal year primarily due to increased sales to our larger customers, which typically have lower gross profit margins.", "Our cost of goods sold includes a LIFO provision that is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "We incurred remediation costs in connection with the suspended production activities at PharMEDium.", "We also incurred shutdown costs in connection with permanently exiting the PharMEDium compounding business.", "primarily  due  to  an  increase  in  operating  costs  to  support  our  revenue  growth  and  costs  incurred  in  connection  with  permanently  exiting  the  PharMEDium compounding business, such as contract termination fees, offset in part by operational synergies realized from the integration of H.D.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Increased sales to Walgreens, our largest customer $5.6 Increased sales to specialty physician practices $3.0 Increased sales to other customers $1.7 Increased sales due to Profarma and H.D.", "Revenue increased by 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.", "Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility had been suspended since December 2017.", "PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.", "As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 4 basis points from the prior fiscal year primarily due to a lower contribution from our pharmaceutical compounding operations.", "We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends.", "Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly.", "We identify our reporting units based upon our management reporting structure, beginning with our operating segments.", "We aggregate two or more components within an operating segment that have similar economic characteristics.", "We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment.", "Our reporting units include Pharmaceutical Distribution Services, Profarma, ABCS, World Courier, and MWI.", "While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.", "Food and Drug Administration (\"FDA\") inspections of PharMEDium's compounding facilities, we voluntarily suspended production activities", "The decision to permanently exit the PharMEDium business was due to a number of factors including, but not limited  to,  ongoing  operational,  regulatory,  and  commercial  challenges,  such  as  PharMEDium's  decision  in  January  2020  to  suspend  production  at  the compounding  facility  in  New  Jersey  pending  facility  upgrades  related  to  the  air  handling  and  filtration  systems.  In  connection  with  the  decision  to  exit  the PharMEDium  business,  we  recorded  an  impairment  of  PharMEDium's  assets  of  $223.7  million  in  the  three  months  ended  March  31,  2020,  which  included impairments of the remaining finite-lived intangible assets and the majority of the remaining tangible assets.", "The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict.", "The increase in inventories was due to an increase in business volume.", "We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance.", "Significant  capital  expenditures  in  fiscal  2020 included  investments  in various  technology  initiatives,  including  costs  related  to  enhancing  and  upgrading  our primary information technology operating systems.", "Significant capital expenditures in fiscal 2019 included costs associated with the construction of a new support facility and technology initiatives, including costs related to enhancing and upgrading our information technology systems.", "Significant capital expenditures in fiscal 2018 included technology initiatives, including costs related to enhancing and upgrading our information technology systems and costs associated with expanding distribution capacity.", "We acquired businesses to support our animal health business for $54.0 million and $70.0 million in the fiscal years ended September 30, 2019 and 2018,", "Among the factors that could cause actual results to differ materially from those projected, anticipated, or  implied  are  the  following:  unfavorable  trends  in  brand  and  generic  pharmaceutical  pricing,  including  in  rate  or  frequency  of  price  inflation  or  deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government  enforcement  initiatives  to  detect  and  prevent  suspicious  orders  of  controlled  substances  and  the  diversion  of  controlled  substances;  continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale,  purchase  and/or  dispensing  of  pharmaceutical  products  or  services,  and  associated  reserves  and  costs;  failure  to  comply  with  the  Corporate  Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse  resolution  of  any  contract  or  other  dispute  with  customers  or  suppliers;  changes  to  customer  or  supplier  payment  terms,  including  as  a  result  of  the COVID-19 impact on such payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative  initiatives  that  could  adversely  affect  the  Company\u2019s  tax  positions  and/or  the  Company\u2019s  tax  liabilities  or  adverse  resolution  of  challenges  to  the Company\u2019s  tax  positions;  managing  foreign  expansion,  including  non-compliance  with  the  U.S.  Foreign  Corrupt  Practices  Act,  anti-bribery  laws,  economic sanctions and import laws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data;  natural  disasters  or other unexpected  events that affect  the Company\u2019s operations;  the impairment  of goodwill or other intangible  assets (including  any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and  abroad;  and  other  economic,  business,  competitive,  legal,  tax,  regulatory  and/or  operational  factors  affecting  the  Company\u2019s  business  generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this Management's Discussion and Analysis of Financial Condition and Results of Operations, (ii) in Item 1A (Risk Factors), (iii) Item 1 (Business), (iv) elsewhere in this report, and (v) in other reports filed by the Company pursuant to the Securities Exchange Act.", "We  tested  the  Company\u2019s  internal  controls  that  address  the  risks  of  material  misstatement  related  to  the  completeness, valuation, presentation and disclosure of legal contingencies.", "The acquisition strengthens  the  Company's  core  business,  expands  and  enhances  its  strategic  scale  in  pharmaceutical  distribution,  and  expands  the  Company's  support  for independent community pharmacies.", "Smith has been integrated into the Pharmaceutical Distribution reportable segment.", "The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years.", "Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.", "decision to permanently exit the PharMEDium compounding business.", "Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D.", "Smith, and restructuring activities related to our consulting business.", "We  adopted  a  Code  of  Ethics  for  Designated  Senior  Officers  that  applies  to  our  Chief  Executive  Officer,  Chief  Financial  Officer,  and  Corporate"]}